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                                                      Abstract 
 
Viruses have evolved to utilise host cell factors that promote viral replication and inactivate 
host cell factors that inhibit viral replication. For adenovirus, early region proteins modulate 
the functional activity of pro-viral and anti-viral host cell proteins in order to promote viral 
replication. In this regard, adenovirus early region proteins, E1B-55K, E4orf3 and E4orf6 
engage with the cellular Ubiquitin-Proteasome System, both independently and cooperatively 
to inactivate anti-viral host cell proteins. The principal aims of this thesis were to: investigate 
further how adenovirus E1B-55K, E4orf3 and E4orf6 proteins function in isolation to modulate 
host cell factors through engagement with the Ubiquitin-Proteasome System; and consider the 
role of the cellular chromatin remodelling complex, FACT in adenovirus infection. 
In order to study their functions in isolation we have developed, and characterized, clonal 
U2OS cell lines that express human Ad5 and Ad12 early region proteins in a tetracycline-
responsive manner. Using site-directed mutagenesis coupled with pharmacological inhibition 
of the proteasome and Cullin Ring Ligases we determined that Ad5 E4orf6 is subject to 
ubiquitylation on K95 and K171 and undergoes proteasome-dependent degradation in a Cullin 
Ring Ligase-dependent manner. Using quantitative mass spectrometry we also established that 
Ad12 E4orf6, but not Ad5 E4orf6, engages with Cullin Ring Ligases to promote the 
proteasome-mediated degradation of core histone proteins. In this regard, both adenovirus 5 
and adenovirus 12 were shown to promote the loss of core histones during infection but the 
mechanisms underlying this process require further investigation. Using a combination of 
immunoflouresence, GFP pull-down and RNA interference allied with Western blot analyses 
work presented here also established that FACT complex components, SPT16 and SSRP1 
associated with the RPA complex at viral replication centres during infection and that ablation 
III 
 
of FACT gene expression affected adenovirus early region gene product expression during 
infection.  
In consideration of previous published work and the data presented here, this study indicates 
that adenovirus utilises the Ubiquitin Proteasome System at multiple levels to regulate both 
host cell protein and adenovirus early region protein function during infection and suggests 
that cellular histones limit adenovirus replication.   Moreover, our data suggests that the histone 
chaperone protein complex, FACT has pro-viral activities during adenovirus infection. Taken 
together, our studies have identified potential new functions for adenovirus early region 
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Ephrin type-A receptor 2 
Facilitates Chromatin Transactions 
Foetal calf serum 
Gamma-tubulin ring complex 
Glutathione S-transferase 
Histone 2A family member 
Histone 2B family member 
Histone 3 
Histone 4 
H2A histone family member X 
H3 at lysine residue 9 
Hepatitis B virus 
Hydrogen chloride, 
Hepatitis C virus 
Human embryonic kidney cells 
Human Embryo Retinoblasts 
Hepatitis B 
Human herpes virus 8 
Human Immunodeficiency Viruses 
High Mobility Group Domain 
High-Performance Liquid Chromatography 
Human papillomavirus 
Horseradish Peroxidase 
Herpes simplex virus-1    
Human T-cell lymphotrophic virus 1 
Hydroxyurea 





Inverted terminal repeats 
Insulin receptor substrate 1 
Lysine 
Potassium chloride 
Kilo-Dalton   
Kaposi's sarcoma-associated herpesvirus 
latency-associated nuclear antigen 
Leukocyte common antigen-related 
Luria Broth 
Lysosomal Associated Membrane Protein-2 
Late-promoter 
Lysine 































































Mediator of DNA damage checkpoint protein 1 
Merkel cell polyoma virus 
Mediator Complex Subunit 23 
Carbobenzoxyl-L-leucyl-L-leucyl-L-leucine 
Major histocompatibility complex 
Molecular recognition features 
Messenger ribonucleic acids 
Mre11-Rad50-NBS1 
Meiotic recombination 11 
DNA mismatch repair protein 6 
Microtubule-organizing Center 
Sodium chloride 
National Center for Biotechnology Information 
Nuclear Export Signal 
Nuclear factor 1 
Non-homologous end joining 
Nuclear localization signal 
Nuclear retention signal 
N-terminal domain 
N-terminal region 
OGT Small Molecule Inhibitor 
Phosphate-Buffered Saline 
Polymerase Chain Reaction         





Retinal Pigment Epithelium 
Retinoblastoma protein 
Post Translational Modification 
Receptor type protein tyrosine phosphatase F 
RNA-binding protein 14 
RING-box Protein 1 
Ribonucleoprotein 
Replication Protein A 1 
Rous sarcoma virus 
SUMO-activating enzyme 
SUMO Conjugating Motif 
Site-directed mutagenesis 
Sodium Dodecyl Sulphate 
Serine    
Stable Isotope Labeling by/with Amino acids 
Small-Interfering RNA 
Structural Maintenance of Chromosomes 
SWI/SNF-related matrix-associated actin-dependent regulator of 
Chromatin Subfamily A-like Protein 1 
Specificity Protein 1 
Suppressor of Ty 16 
Substrate Recognition Subunit 
Structure Specific Recognition Protein 1 
SUMO-targeted ubiquitin ligase 
Simian Virus 40 
Tetraethylammonium bromide 
Triton Extraction Buffer 
Tris-buffered saline 
Transcription Factor IID 















































Transcriptional intermediary factor1β 
Transcriptional intermediary factor1γ 
Tumor Necrosis Factor 
Topoisomerase (DNA) II binding protein 1 
Topoisomerase 2-beta 
Terminal Protein 
TNF-Related Apoptosis Inducing Ligand 
Tripartite motif 
Transformation/transcription domain-associated protein 
Ubiquitin Proteasome System 
Osteosarcoma Epithelial Cells 
Ubiquitin 
Ubiquitin-conjugating enzyme 13 
Ubiquitin-Specific Protease 1 
Von Hippel-Lindau 
Viral Replication Centres 
Western blot 
World Health Organization 
Wild Type 




























1.1 Human Tumour Viruses 
The most recent data from the World Health Organization (WHO) suggests that upto 20% of 
all human cancers are attributable to infection, such that 2.1 million new cases of cancer in 
2012 were due to infection (WHO, 2012). Infection-induced cancers have been shown to be 
particularly common in poor and developing countries where pathogens such as human 
papilloma virus (HPV) and hepatitis B and C viruses and Heliobacter pylori bacteria are 
prevalent (Plummer, et al. 2016). Human tumour viruses possess either DNA or RNA genomes 
and, as such, are accordingly classified as either DNA viruses and RNA viruses. Given that the 
main focus of this thesis is adenovirus, a small DNA tumour virus that is implicated in cellular 
transformation and tumourigenesis, particularly in animal models, we will now consider a brief 
history of DNA viruses and their role in the pathogenesis of tumourigenesis before we consider 
adenovirus in more detail.  
1.1.1. DNA Tumour Viruses  
To date studies with Adenoviridae, Herpesviridae, Hepadanviridae, Papillomaviridae and 
Polyomaviridae have shown the capability of these DNA viruses to promote tumourigenesis in 
humans or other animals (Table 1.1; Javier and Butel, 2008). The role of human papilloma 
virus (HPV) in human cancer is now very well established. Early studies by Guiseppe Ciuffo 
in the first decade of the 20th century determined that the aetiology of warts was due to a 
transmissible agent, as a cell-free preparation from the wart could promote this proliferative, 
non-malignant disease in an uninfected individual ; this transmissable agent was subsequently 
identified as a distinct HPV type (reviewed by Bergonzini, et al. 2010). Subsequent to the 
studies by Ciuffo, a genuine mammalian papilloma tumour virus was identified, the Shope 
virus (named after the person who discovered it, Richard Edwin Shope), that infected the 
cutaneous epithelium of rabbits and induced a wart-like disease of the skin (Shope and Hurst, 
1933). It was only in the 1970’s when work from Harald zur Hausen established that HPV 
strains 11, 16 and 18 were the causative agents of cervical cancer; HPV infection is responsible 
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for almost all cases of human cervical cancer cases and is also responsible for other anogenital 
malignancies and head and neck cancers (Zur Hausen, 1976; Zur Hausen, 2009).  
It was not until 1962, however, that the first report of a human DNA tumour virus was 
published (Trentin, et al. 1962). John Trentin determined that human adenovirus 12 (Ad12), 
but not other adenovirus types, would induce sarcomas in the mediastinum, the chest wall and 
diaphragm when injected intrapulmonary into new-born hamsters. Further studies by Trentin 
and others determined that the ability of the Ad12, and not other human Ads to induce 
tumorigenesis was not only due to the expression of viral oncogenes (discussed below) but due 
to the virus’s ability to evade the immune system (reviewed by Gallimore and Turnell, 2001). 
Despite these early findings, adenovirus infection is not thought to play a significant role in 
human tumourigenesis, although studies from Thomas Lion’s group have determined that Ad 
groups B and D are found in a high proportion of different types of paediatric brain tumours, 
including glioblastomas, oligodendrogliomas and ependymomas (Kosulin, et al. 2007). 
Moreover, studies from Linda Gooding and David Ornelles have determined that persistent Ad 
infection of lymphoid tissue with group C viruses, correlates positively with children who later 
develop acute lymphoblastic leukaemia (ALL ; Gustafsson, et al. 2007). These studies taken 
alone suggest that adenovirus might also play a role in human tumourigenesis but clearly more 
work needs to be performed to establish a definitive role for human adenovirus types as 
causative agents of human cancer. Given the early findings by Trentin, however, adenovirus 
has become a very popular model to study the molecular basis of cellular transformation and 
oncogenesis and the cellular pathways that regulate these processes. A more deatiled 
consideration of the role of adenovirus gene products in cellular transformation and 
oncogeneicity is presented in section 1.2.5. In addition to adenovirus and HPV a number of 
DNA tumour viruses have been identified that play a role in human cancer (Table 1.1). 
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Neoplastic transformation of cells by DNA viruses, such as adenovirus, is a cumulative process 
that can occur long after the initial infection and requires other genetic changes in the cells 
where the cancer occurs that are independent of infection. Viral infection often results in the 
inactivation of cellular tumour suppressors, the inhibition of apoptosis, and cellular 
immortalization that aids tumourigenesis (Hanahan and Weinberg, 2000). Viral tumourigenesis 
is also often accompanied integration of the viral DNA into the cellular genome where the 
permanent expression of early viral oncogenes, or activation of cellular oncogenes deregulates 
cellular gene expression and signal transduction pathways that promote cell growth and inhibit 
cellular apoptosis. In this regard, a number of DNA tumour viruses target key cellular tumour 
suppressors such as p53 and the retinoblastoma gene product, pRB which are also often de-
regulated in cancers that are not caused by infection (Hanahan and Weinberg, 2000). Given the 
ability of viruses to de-regulate host cell signalling pathways, it is no surprise that researchers 
have utilized other tumour viruses, in addition to adenovirus, as experimental models to 
investigate the critical molecular events that occur during tumourigenesis (Berk, 2005). In this 
regard, the last 50 years of studying DNA tumour viruses has been extremely important towards 
understanding the molecular events that cause cancer and important cellular processes, such as 
cell cycle regulation, transcription and DNA replication (Javier and Butel, 2008). 
Before we consider the role of adenovirus gene products in cellular transformation and 
oncogenesis in more detail we will consider the classification and structure of adenoviruses 
and the role individual early region proteins play during infection and how they modulate host 




















1.1.2. Adenovirus Identification and Classification 
Adenoviruses belong to the adenoviridae family and are non-enveloped icosahedral DNA 
tumour viruses. They possess a linear double-stranded (ds) DNA genome and undergo a lytic 
cycle of replication. Adenoviruses were discovered in 1953 at the National Institutes of Health 
(Bethesda, Maryland) by researchers when they were trying to characterize viral agents isolated 
from the adenoid and tonsil tissue grown in cell culture; hence they were named adenoviruses 
“adeno” comes from the Greek word for gland (Rowe, et al. 1953). At the same time and in 
independent studies Hillman and Werner were investigating a flu-like virus in army recruits, 
whereby they isolated adenovirus form tracheal cells (Hillman and Werner, 1954). Since their 
discovery, this family of viruses have often been used as a model for studying different cellular 
processes such as viral entry and assembly, transcription and DNA replication, cell cycle 
control, cellular transformation and tumourigenesis and led to the seminal discovery of 
splicing, for which Phil Sharp and Richard Roberts received the Nobel prize (Berk and Sharp, 
1977; Chow, et al. 1977).  
 
Virus Family  
                
                  Virus and Disease  
Adenoviridae Adenoviruses (Ad): Tumours in rodents- potential role in human 
paediatric brain tumours and leukaemias. 
Papillomaviridae Human papillomavirus (HPV): Cervical Carcinoma, anogenital,  
head and neck and skin cancers.  
Hepadnaviridae Hepatitis B Virus (HBV): Hepatocellular Carcinoma 
Herpesviridae Epstein-Barr Virus (EBV): Burkitt's lymphoma, Nasopharyngeal 
carcinoma.  
Herpesviridae Kaposi’s sarcoma human virus (KSHV): Kaposi's sarcoma 
Polyomaviridae Merkel cell virus (MCV): Merkel Cell carcinoma 
Polyomaviridae Polyoma virus of the rhesus macaque (SV40): Tumours in rodents 




According to the Baltimore classification the adenoviridae family of adenoviruses are group 
one ds DNA viruses, which have subsequently been divided into five different genera 
according to the host species they infect: Aviadenoviridae, Atadenovirus, Mastadenoviridae, 
Siadenoviridae and Ichtadenovirus (Carstens, 2010). Viruses of Ichatadenoviruses and 
Avianadenoviruses infect fish and birds respectively, whilst Siadenoviruses and 
Atadenoviruses infect a number of different hosts such as birds, ruminants, amphibians and 
reptiles (Davison, et al. 2003). Mastadenoviruses infect mammalian hosts, of which there are 
over 100 known human serotypes divided into seven species (A to G) based on their antibody 
neutralization properties and ability to agglutinate erythrocytes of rat, monkey and human, 
which broadly corresponds with their ancestral relationship, sequence homology and 
oncogenic potential (Table 1.2; Russell, 2009). 
Adenovirus type 12 (Ad12) belongs to group A, which is considered to be highly oncogenic, 
unlike the group C viruses that includes the widely-studied adenovirus type 5 (Ad5) which has 
been shown to be non-oncogenic (Trentin, et al. 1962; Trentin, et al. 1968). As already 
discussed it is believed that adenoviruses are not major causative agents of cancer in humans; 
however human and rodent primary cells can be transformed by both oncogenic and non-
oncogenic viruses in tissue culture (McBride and Wiener, 1964; Russell, 2009). As outlined 
above adenoviruses infect a broad range of species, however, their ability to cause disease is 
largely controlled by the effective cellular defences of the infected host. Regardless of this, it 
is known that roughly a third of the known human Ad types are involved in respiratory, ocular 
and gastrointestinal diseases detected in children and immunocompromised individuals 
(Echavarría, 2008). Furthermore, serious health conditions such as hepatitis, hemorrhagic 
cystitis, pneumonia, colitis, pancreatitis, meningoencephalitis, and disseminated disease in 





Table 1. 2: Classification of Human Adenoviruses. The adenovirus types discovered to date 
are classified into groups A to G and as indicated. Their oncogenicity toward rodents and 
transformation activity in tissue culture is also indicted (http://hadvwg.gmu.edu/).   
 
1.1.3. Adenovirus structure and genome organization 
Adenovirus structure has been analysed by both electron microscopy and X-ray diffraction to 
a resolution of 3.5 Å which have contributed enormously to elucidating the virion’s 
architecture. Adenoviruses are quite large viruses with a molecular weight of approximately 
150 MDa and a diameter of between 70 and 100 nm. They are composed of two main parts, 
the outer capsid and the core. The non-enveloped capsid has an icosahedral arrangement 
consisting of 252 caspomeres with 240 surface facing features (homotrimeric hexons) and 12 
vertices (penton bases) from which long fibres with terminal knobs extend. Together, these 
structures form the outer capsid (Brenner and Horne, 1959; Horne, 1959; Valentine and Pereira, 
1965). Proteins such as IIIa, VI, VIII, and IX associate with the hexons and pentons, and 
participate to cement the virion capsid and provide structural support (Fig. 1.1 A; Saban, et al. 
2006). The adenovirus core comprises the adenovirus genome and core proteins. Adenoviruses 
 
         Group 
                
                              Types  
      
        Oncogenicity  
           in rodents 
 
Transformation in vitro 
A 12. 18. 31 High  Yes 
A (New) 61 Unknown  Unknown 
B (New) 66. 68. 76. 77. 78. 79 Unknown Unknown 
B1 3. 7. 16. 21. 50 Moderate  Yes 
B2 11. 14. 34. 35. 55 Moderate Yes 
C 1. 2.  5 .6. 89. Low or none Yes 
D 8. 9.  10.  13. 15. 17. 19. 20. 22. 30. 32. 33. 
36. 39. 42. 49. 51. 53. 54. 
Low or none Yes 
D (New) 56. 58. 59. 60. 62. 63. 64. 65. 67. 69. 70. 
71. 72. 73. 74. 75. 80. 81. 82. 83. 84. 85. 
86. 87. 88. 90. 91. 92. 93. 94. 95. 96. 97. 
98. 99. 100. 101. 102. 103.  
Unknown  Unknown 
E 4 Low or none Yes 
F 40. 41 None-reported  Yes 
G 52 None-reported  Unknown 
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have linear, dsDNA genomes, of between 26 and 45 kb in size, which rank them as medium-
sized among other DNA viruses. In this regard the Ad5 genome is 36kb in size whilst the Ad12 
genome is 34kb in size (Saha, et al. 2014). Adenovirus genomes are characterized by inverted 
terminal repeats (ITR) about 100-140 bp in size that cap each end of the genome and are 
concentrated in the virion core, where they are linked to the proteins V, VII, and X, and the 
terminal protein (TP), which associates covalently to the 5’ termini of each ITR and acts as a 
primer for DNA replication (Fig. 1.1A; Rauschhuber, 2011). The ITR possesses cis-acting 
elements and binding motifs for the cellular transcription factors SP1 and ATF that are required 
for the initiation of E1A transcription (Hatfield and Hearing, 1991).  
The Ad infectious cycle can be divided in two stages, early and late, which are separated by 
the commencement of DNA replication (Russell, 2000). As such, the Ad genome is organized 
into three regions; the early region which comprises six transcription units (E1A, E1B, E2A, 
E2B, E3, and E4), the intermediate region consists of two transcription units (IX and IVa2), 
and the late region which comprises only one transcription unit which is transcribed to produce 
five families of late mRNAs [L1-L5] (Fig. 1.1B; Täuber and Dobner, 2001). A detailed 
transcription map showing the major E1A and E1B transcripts are also depicted in Fig. 1.1B, 
whilst the major E4 transcripts are depicted in Fig. 1.1C. The major late promoter (MLP) is 
activated upon the onset of viral DNA replication by the intermediate gene products IX and 
IVa2, whilst the L4 products 22K, 33K enhance MLP activation to promote the early to late 
switch and the synthesis of the structural proteins (Russell, 2000). Indeed, L4-22K and L4-33K 
stimulate late gene expression from another late-promoter (L4P) located within the L4-100K 
open reading frame (Morris, et al. 2010), whilst E1A, E4orf3, and IVa2 also stimulate this 













Figure 1.1: Structural representation of the adenovirus virion and schematic 
representation of the adenovirus transcription map. (A) This picture depicts the viral capsid 
and shows the linear dsDNA adenovirus genome and the core viral proteins known to associate 
with the genome. Illustration taken from (Waye and Sing, 2010). (B) Schematic representation 
of the Ad5 transcription map. The figure shows the two main transcription units form the Ad 
genome following viral infection: the E1A, E1B, E2A, E2B, E3 and E4 early transcription unit 
(highlighted in yellow), including detail of E1A and E1B transcripts produced (highlighted in 
red); the Late transcription unit, comprising L1 to L5 are shown in blue. (C) The E4orfs are 
expressed from a single mRNA with a polyadenylation signal (polyA), to produce a primary 
transcript of 2800 nucleotides. The mRNA spliced gene products are shown as boxes, relative 
to their location in the Ad5 genome and are highlighted in red.  
 
1.1.4. Adenovirus cellular entry, chromatinization and viral DNA replication 
Adenovirus entry into the host cell follows sequential steps that requires virion attachment to 
the host cell, entry into the host cell by receptor-mediated endocytosis, endosomal escape from 
the host cell machinery and entry into the cytosol and the Dyenin-mediated transport delivery 
of the viral genetic material to the nucleus where viral DNA replication, viral gene expression, 
and viral assembly take place. A schematic summary of adenovirus life cycle is depicted in 
(Fig. 1.2; Luisoni and Greber, 2016). Studies have revealed that viral entry is dependent upon 
the viral capsid components, the fibre and the penton base (Wu and Nemerow, 2004). The fibre 
protein facilitates cellular internalization through its ability to associate with the coxsackie 
virus-adenovirus receptor (CAR) - the major cellular receptor for adenovirus (Hartlerode, et al. 
2015). Other cellular receptors also facilitate adenovirus binding to cells, including v3/5 




Indeed, association of the penton base protein to surface integrins triggers viral entry by 
clathrin-coated mediated endocytosis (Mathias, et al. 1998). Following internalization capsid 
dissociation and rearrangements occur in the acidified endosome which facilitates virus particle 
release into the cytoplasm, whereupon hexon associates with the Dynein transport apparatus to 
allow for transportation of the genetic material to the nucleus through nuclear pores to initiate 
viral transcription programmes that ultimately results in viral DNA replication, the synthesis 
and assembly of new virions, DNA packaging into new virions, cell lysis and virus release (Wu 
and Nemerow, 2004). 
Cellular DNA is packaged into the nucleosome that comprises 146bp of dsDNA wrapped 
around a histone octamer, comprising 2 sets each of Histone H2A-H2B and H3-H4 dimers. 
Incoming virus particles associate with the nuclear pore whereupon they associate with histone 
H1 for nuclear import, though histone H1 does not associate directly with viral DNA (Trotman, 
et al. 2001). It has been found that incoming adenovirus DNA is rapidly chromatinized by the 
cellular histone octamer in a 200bp repeat akin to normal nucleosome structure, in a manner 
that is independent of viral DNA replication (Daniell, et al. 1981). Chromatin 
Immunoprecipitation (ChIP) studies have established that the same molecule of viral DNA can 
be both protein VII and histone-associated suggesting that viral chromatin is distinct from 
cellular chromatin (Komatsu, et al. 2011). It has been determined that histone variant histone 
H3.3 is preferentially deposited on viral DNA by the chaperone protein HIRA, which normally 
coats actively transcribed DNA, whilst another histone H3.3 chaperone, Daxx is inactivated 
during Ad infection (Ross, et al. 2011; see section 1.2.2).  It has been suggested however, that 
most protein VII is removed from viral DNA prior to the activation of Ad transcription 
programmes that can occur on viral DNA associated with cellular histones which is regulated 
by histone acetylases such as CBP/p300 (Komatsu, et al. 2011; see section 1.2.1). Indeed ChIP 
analyses have shown that acetylated histones are associated with active early region promoters.  
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Ad DNA replication is a very efficient process. Within 40h of DNA replication initiation 
approximately one million copies of viral DNA are produced and approximately 10,000 new 
virions per cell assembled (Hoeben and Uil, 2013). To achieve this adenovirus employs a 
unique protein priming mechanism for replication to begin. This process requires three viral 
proteins encoded by the E2 early region: the TP precursor protein (pTP), Ad DNA polymerase 
(Ad Pol), and the DNA-binding protein (DBP). pTP serves as a primer for viral DNA 
replication initiation and has the capacity to bind to both ssDNA and dsDNA. Ad pol is a 
member of the -like DNA polymerases and utilises the pTP primer for replication initiation 
(Field, et al. 1984). Ad DBP localises at viral replication centres in the nucleus of the infected 
cell where it performs multiple activities during viral replication (Chang and Shenk, 1990), 
adenovirus utilises the cellular transcription factors nuclear factor 1 (NF1), nuclear factor 2 
(NF2), and octamer-binding protein 1 (Oct1; also known as NF3) to stimulate Ad DNA 
replication (Nagata, et al. 1982; Pruijn, et al. 1986; Mysiak, et al. 2004; Hoeben and Uil, 2013). 
Multiple associations between these viral and cellular proteins coordinate the formation of the 
pre-initiation complex formation (Hoeben and Uil, 2013). Ad replication occurs at viral 
replication centres (VRCs) in the nucleus of the infected cell, where both pro-viral and anti-
viral cellular factors accumulate to modulate viral replication.  
The Ad pol mediates the formation of deoxycytidine monophosphate (dCMP)/pTP complex by 
catalysing the covalent association between the β-OH group of a serine residue in pTP and the 
α-phosphoryl group of deoxycytidine monophosphate (dCMP). This complex is important as a 
primer for synthesis of the nascent strand (Liu, et al. 2003). The interaction between NF1 and 
Ad pol, as well as Oct1 to pTP is coordinated by DBP, which is also important in enhancing 
their affinity for viral DNA sequences (De Jong, et al. 2003). DBP also controls the unwinding 
of viral duplex DNA in an ATP-dependent manner and viral DNA elongation (De Jong, et al. 
1999). After replication, the viral protease cleaves pTP to produce its mature, smaller form TP 
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(Hoeben and Uil, 2013). TP remains covalently attached to the 5’ end of the genome during 
replication, although the reason for this is currently unknown, although it has been suggested 
to be involved in: facilitating unwinding of the DNA duplex; allowing for DNA-nuclear matrix 
association; protecting viral DNA from exonuclease activity (Dunsworth-Browne, et al. 1980; 
Stillman, et al. 1981; Schaack, et al. 1990). Indeed, protection from cellular exonucleases may 
be one strategy how adenovirus evades the cellular DNA damage response (DDR). Other 
strategies employed by adenoviruses to evade cellular antiviral DDR activities will be 
addressed later in this chapter (see section 1.4). Newly replicated Ad viral DNA is also coated 
with cellular histones though is ultimately packaged into new virions by protein VII.  
 
Figure 1.2: Summary of adenovirus life-cycle. Taken from (Waye and Sing, 2010). 
1.1.5. Viral Replication Centres  
Viral replication centres (VRCs) comprise the major regions of nascent viral transcription and 
post-transcriptional processing as well as viral DNA replication, viral particle assembly and 
packaging (Charman, et al. 2019). They serve as molecular hubs and serve to regulate host-cell 
interactions. As such, cellular proteins required for viral replication are actively recruited to 
VRCs by Ad early region proteins, particularly E1A, E1B-55K, E2A and E4orf6 (see section 
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1.2 for more details). Moreover, proteins that form the cellular defence to viral infection are 
targeted to VRCs, where they are often inactivated by interaction and sequestration by viral 
early proteins, or are targeted for degradation by cellular CRLs (see section 1.3.2.2.).  
The Replication A protein complex is recruited to VRCs following adenovirus infection and 
are often considered a surrogate marker for VRCs. As cellular proteins recruited to VRCs often 
possess either pro-viral or anti-viral activities our laboratory attempted to identify proteins that 
are recruited to VRCs through interaction with the RPA complex (Qashqari, PhD thesis, 
University of Birmingham, 2017). By analysing proteins that associated specifically with GFP-
RPA1 during both Ad5 and Ad12 infection our laboratory identified a number of cellular 
proteins that were potentially recruited to VRCs during infection. Of those proteins identified, 
the FACT chaperone complex, comprising SPT16 and SSRP1, Pur and Pur transcriptional 
regulators and the RNA-binding protein, RBM14 were all suggested to be recruited to VRCs. 
1.1.5.1. The FACT Complex 
The FACT (Facilitates Chromatin Transcription) chaperone complex serves to regulate the 
assembly/disassembly of nucleosomes that comprise chromatin, as compact chromatin creates 
a barrier for critical cellular processes such as transcription, replication and DNA damage 
responses (Fig.1.3). As such, the FACT complex temporarily modulates chromatin architecture 
so that these processes can be completed. Specifically, FACT promotes the dissociation of the 
histone H2A-H2B dimer from the nucleosome to allow for processes such as transcriptional 
regulation, but also has the capacity to mediate nucleosome reconstitution (reviewed by 
Belotserkovskaya, et al. 2004). As FACT is recruited to VRCs during adenovirus infection, it 
is likely that complex possesses either pro- or anti- viral activities during infection, though its 




Figure 1.3: Model of FACT action in nucleosome/hexasome assembly. a: FACT associates 
with H2A–H2B dimer; b1: FACT chaperones H2A–H2B onto (H3–H4)2 tetrasome; (B2): free 
DNA end competes FACT off H2A–H2B; c: hexasome is formed. Taken from: (Wang, et al. 
2018). 
 
The FACT complex is a heterodimer of two proteins: Structure-Specific Recognition Protein1 
(SSRP1) and Suppressor of Ty (SPT16; Fig. 1.4; Winkler and Luger, 2011; Formosa, 2012; 
Garcia, et al. 2013). Both proteins have been shown to be involved in nucleosome remodelling, 
cell cycle regulation and the DNA damage response (Belotserkovskaya, et al. 2003; Dinant, et 
al. 2013). FACT has also been shown to be overexpressed in different types of cancers. 
Although, FACT proteins do not function directly as oncogene products they have been shown 
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to cooperate with other oncogenes and serve to enhance tumourigenicity; FACT is both a 
potential cancer biomarker and a target for cancer therapeutics There are very few studies that 
have identified roles for FACT in viral replication, although FACT has reported to be involved 
in supressing HIV-1 transcription and enhancing viral latency (Huang, et al. 2015).   
 
Figure 1.4: Domain structure of FACT proteins. The FACT heterodimeric is composed of 
Spt16 (cyan) and SSRP1 (dark green) subunits. SPT16 protein for all eukaryotic has multible 
domains: N-terminal domain (NTD), Middle - domain (MD), dimerization domain (DD) and  
C-terminal domain (CTD). SSRP1 has the following domains N-terminal domain (NTD), 
dimerization domain (DD) Middle - domain (MD), intrinsically disordered domain (IDD), high 
mobility group domain (HMG) and C–terminal domain (CTD). Taken from: (Winkler and 
Luger, 2011).  
 
 
1.2. Adenovirus Early region proteins 
This section will consider mainly the function of the early region proteins, 12S and 13S E1A, 
E1B-19K and E1B-55K, as well as the E4orf’s that arise from differential splicing of the E1A, 
E1B and E4 transcription units, respectively (Fig. 1.1B and C). Specific attention will be given 
to the E1B-55K, E4orf3 and E4orf6 proteins that are the major focus of this thesis. As such the 
roles of these proteins both during infection, and in cooperation with E1A during cellular 
transformation will be considered. For convenience a table highlighting the major biological 





Table 1. 3: Description of early region gene product function. The Table indicates functions 
of E1A, E1B, E2, E3 and E4 proteins. 
 
 
1.2.1. Adenovirus E1A proteins 
Adenovirus early region 1A (Ad E1A) is located within the first 11.2% of the Ad genome on 
the left side and is transcribed from the top strand. Its molecular weight is found to vary from 
35 to 48 kDa, which is dependent upon the E1A species expressed and also post-translational 
modification-PTM (Gallimore and Turnell, 2001). Although E1A is not a DNA-binding 
protein, E1A functions primarily as a transcriptional regulator that promotes cell cycle 
progression and viral replication, and has the capacity to induce oncogenic transformation due 
its association with various proteins through distinct conserved region (CR) domains in the 
E1A protein, or a less well conserved N-terminal region (NTR; Subramanian, et al. 2013). By 
binding to and radically changing the activity of many cellular proteins, AdE1A promotes a 
productive adenovirus infection and, in certain circumstances, Ad-induced transformation 
(Gallimore and Turnell, 2001). In this regard E1A possesses the ability to transform both 
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primary human and rodent cells in cooperation with Ad E1B, or activated ras (Byrd, et al. 
1982; Ruley, 1983). Indeed, in the absence of cooperating oncogenes E1A induces p53-
dependent apoptosis (Lowe, et al. 1993).  
Ad E1A is the first protein to be expressed following adenovirus infection and is expressed as 
two major mRNA products, 12S and 13S, which give rise to proteins of 243 and 289 amino 
acids, respectively for Ad2 and Ad5 and 235 and 266 amino acids for Ad12 (Boulanger and 
Blair, 1991). Both isoforms possess three highly conserved regions CR1, CR2, and CR4 with 
the larger 13S gene product possessing an additional domain, CR3 (Fig. 1.5; Avvakumov, et 
al. 2002;  Avvakumov, et al. 2004). 13S E1A is generally regarded as a transcriptional activator 
whereas the 12S E1A gene product is regarded as a transcriptional repressor. Three other splice 
variants, 9S, 10S and 11S E1A gene products are also produced during the late stages of 
infection. Their function is not well understood, although the 9S E1A gene product does retain 
some functions of the larger 12S and 13S gene products (Miller, et al. 2012). 
The CR3 region of Ad E1A is a transcriptional activator and drives the expression of the other 
early region genes. As such it associates with the cellular transcriptional machinery and viral 
early promoters through protein-protein interactions. CR3 can also modulate cellular 
transcription programmes through interaction with cellular promoters. The CR3 transactivation 
domain is composed of two regions, a zinc finger region (residues 147-177, in Ad5 E1A) that 
associates with a number of transcriptional regulators and a carboxyl region (residues 183-188, 
in Ad5 E1A) that targets E1A to promoters (Webster and Ricciardi, 1991). The CR3 zinc finger 
region associates with TBP, the MED23 component of the Mediator complex as well as 19S, 
20S and 26S proteasomes, and histone acetylases, CBP/p300 and P/CAF to stimulate 
transcription (Berk, 2005; Rasti, et al. 2006). One of E1A’s primary functions is to re-
programme cellular gene expression in order to induce S-phase in the infected cell and to create 
an environment permissive for viral DNA replication. As such, E1A function is dependent 
19 
 
upon short motif/molecular recognition features (MoRFs) that direct E1As interaction with 
numerous cellular proteins (Fig. 1.5). For instance, it has been established that the NTR, CR1 
and CR2 domains of E1A are required to induce S-phase entry. CR1 and CR2 of E1A bind to 
the tumour suppressor protein, pRB, and related proteins p107 and p130, to activate E2F-
dependent transcription, whilst the NTR and CR1 bind independently to CBP/p300 to modulate 
cellular histone acetylation (Egan, et al. 1988; Whyte, et al. 1988; Howe, et al. 1990; Eckner, 
et al. 1994). It has been established that E1A can, during infection, redistribute CBP/p300 to 
specific genomic loci to modulate histone H3 K18 acetylation; E1A interaction with p300/CBP 
enhances the acetylation of pRB at K873/K874 which associates with repressive chromatin-
modifying enzymes to repress transcription of genes that would otherwise inhibit viral 
replication (Ferrari, et al. 2008; Horwitz, et al. 2008; Ferrari, et al. 2014). The roles of these 
E1A-binding proteins in cellular transformation will be considered later (see section 1.2.5.1). 
 
 
Figure 1.5: E1A functional domains and binding proteins. The conserved regions (CR) of 
the 12S and 13S E1A are shown as orange circles. Key E1A binding proteins are listed as are 
the biological functions of specific E1A domains. Adapted from: (Berk, 2005). 
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1.2.1.1.The ubiquitin-like protein SUMO and its regulation by E1A 
SUMO is a small ubiquitin-like modifier that covalently attaches to lysine residues of target 
substrates to regulate enzymic activity, protein stability, protein-protein interactions and 
cellular localization that affects multiple biological activities including transcription, cell cycle 
and the DDR (Wilkinson and Henley, 2010). In mammalian cells there are five SUMO genes, 
SUMO-1 to SUMO-5; SUMO-1, SUMO-2, and SUMO-3, are the most extensively studied 
SUMO species. SUMO-2 shares 97% amino acid similarity with SUMO-3 (often known as 
SUMO-2/3) and 50% homology with SUMO-1. SUMO is an 11 kDa protein that exists as 
inactive precursor and so requires first to be cleaved by a SENP (SUMO-specific protease) at 
its C-terminus, which allows SUMO to be covalently attached through its C-terminal glycine 
residue to a catalytic cysteine in the heterodimeric E1 SUMO-activating enzyme SAE1/SAE2 
in an ATP-dependent manner. SUMO is then transferred to a catalytic cysteine residue in the 
E2 SUMO-conjugating enzyme, Ubc9 before being conjugated to a lysine residue in target 
substrate in the absence or presence of a SUMO E3 ligase.  
It was established in 1996 through a yeast two-hybrid screen that the CR2 region of E1A 
interacted with Ubc9 (see Fig. 1.8 A; Hateboer, et al. 1996). Given its association with CR2 it 
was postulated that E1A interaction with Ubc9 was important for the cellular functions of E1A. 
It was later established that an E1A MoRF comprising the sequence EVIDLT in CR2 bound to 
the NTR of Ubc9, the same region of Ubc9 that binds to SUMO in a non-covalent manner. It 
was therefore postulated that E1A affected Ubc9-mediated polySUMOylation of substrate 
proteins. It was established however that E1A expression did not affect global 
polySUMOylation and that E1A interaction with Ubc9 was not required for E1A-mediated 
transformation. Despite this the E1A-Ubc9 interaction was shown to modulate promyelocytic 
leukemia body reorganization by E1A and pseudohyphal growth in yeast (Yousef, et al. 2010). 
Studies from another laboratory indicated that E1A expression inhibited pRB SUMOylation at 
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K720, a modification that was suggested to modulate pRB-mediated repression of E2F-
dependent transcription (Ledl, et al. 2005). To date, pRb is the only known protein whose 
SUMOylation is regulated by E1A. In consideration of the activities of the E1B-55K (section 
1.2.2) and E4orf3 (section 1.2.4.1) gene products, adenovirus modulates the SUMO pathway 
at multiple levels during infection. 
1.2.2. Adenovirus E1B proteins  
The adenovirus early region 1B (E1B) gene is differentially spliced to give five gene products 
for Ad2/5: E1B-84R, E1B-93R, E1B-156R (E1B-19K), E1B-176R and E1B-496R (E1B-55K) 
that all participate in promoting viral DNA replication and, moreover, participate in promoting 
cellular transformation. E1B-55K and E1B-19K are the most widely studied E1B gene products 
that serve to inhibit the pro-apoptotic effects of p53 during both infection and cellular 
transformation (Berk, 2005; Sieber and Dobner, 2007). The function of the other E1B 
polypeptides is not known. 
E1B-19K is a homologue of the cellular anti-apoptotic protein, BCL-2 and binds to the pro-
apoptotic proteins, BAX and BAK to prevent the assembly of BAK/BAX oligomers that would 
otherwise promote mitochondrial outer membrane permeabilization and activation of the 
intrinsic pathway of apoptosis (Sundararajan, et al. 2001; White, 2001). Indeed, BAK and BAX 
are nuclear-encoded proteins that in response to pro-apoptotic signals permeabilize the 
mitochondrial outer membrane that leads to the release of cytochrome c and Smac/DIABOLO 
and the activation of caspase-9 and caspase-3 (White, 2001; Cuconati, et al. 2003), E1B-19K 




Figure 1.6: Mitochondrial apoptosis pathway inhibition by E1B-19K. Adenovirus infection 
leads to the E1A-induced proteasomal degradation of BAK-binding protein, MCL-1. This 
serves to release BAK that would otherwise associate with BAX to stimulate apoptosis. E1B-
19K expression inhibits this pro-apoptotic pathway by sequestering BAX and BAK and 
preventing mitochondrial outer membrane permeabilization (Berk, 2005). 
 
E1B-55K protein expression is fundamental for a productive adenoviral infection and 
oncogenic transformation and plays a role host-cell shut-off, viral mRNA export and the 
inhibition of p53 (Hidalgo, et al. 2019). The Ad5 E1B-55K polypeptide encompass a highly 
conserved cysteine and histidine C2H2 zinc finger around amino acids 350-370 and a 
conserved hydrophobic core between amino acids 215-345 that encodes a ribonucleoprotein 
(RNP) motif implicated in the non-sequence-specific interaction with RNA in vitro and with 
viral RNA in vivo (Tejera, et al. 2019). Other recognized conserved sequences in E1B-55K 
include a nuclear export signal (NES), a nuclear localization signal (NLS), and a number of C-
terminal amino acids that are modified by PTM, particularly phosphorylation at serine 490, 
491 and threonine 495 though the significance of these modifications is not known  (Hidalgo, 
et al. 2019; Fig. 1.7).  
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Ad5 E1B-55K inhibits p53-dependent apoptosis during infection and transformation. It binds 
directly to p53 and inhibits the activation of pro-apoptotic p53-dependent transcription 
programmes (Sarnow, et al. 1984; Yew and Berk, 1992). E1B-55K and p53 associate in 
cytoplasmic compartments known as aggresomes (Zantema, et al. 1985; Yew and Berk, 1992). 
It has been reported that E1B-55K is SUMOylated at lysine 104 (Fig. 1.7; Endter, et al. 2001). 
The SUMOylation consensus motif sequence V/IKRE (ψ-K-x-E), has been shown to be 
conserved within many E1B-55K proteins, but not Ad12 E1B-55K. Moreover, it has been 
shown that Ad5 E1B-55K, but not Ad12 E1B-55K, is a SUMO E3-ligase that can undergo 
auto-SUMOylation. In this regard SUMO 1, 2 and 3 can covalently attach to E1B-55K lysine 
104 at its consensus SUMOylation motif (Endter, et al. 2001; Wimmer, et al. 2013). It also 
possesses the ability to SUMOylate p53, which serves to inhibit p53 activity (Fig. 1.8 B; Muller 
and Dobner, 2008). E1B-55K SUMOylation is also important in the regulation of E1B-55K 
nuclear export and the degradation of the cellular antiviral protein, Daxx (Wimmer, et al. 2013).  
E1B-55K cooperates during infection with other early region proteins, E4orf3 and E4orf6 to 
regulate processes such as host cell shut-off and, in the absence of infection, cellular 
transformation (Nevels, et al. 1997; Nevels, et al. 1999; Nevels, et al. 2001). For instance, it 
cooperates with E4orf6 to target many antiviral factors, such as p53, for ubiquitin-mediated 
proteolysis (Querido, et al. 2001). In this regard, E1B-55K serves predominantly as a substrate 
adaptor (Blanchette, et al. 2004), whereas the E4orf6 protein recruits a cellular E3 ubiquitin 
ligase to E1B-55K to promote the polyubiquitylation of the E1B-55K-associated substrate 
(Schreiner, et al. 2012). A growing numbers of target proteins including components of the 
MRN complex, Rad50 (Harada, et al. 2002), and meiotic recombination 11 (Mre11), DNA 
ligase IV (Baker, et al. 2007), p53 (Querido, et al. 2001) the Bloom helicase (Orazio, et al. 
2011) and ATRX (Schreiner, et al. 2013) are all substrates for the Ad ubiquitin ligase (see 
section 1.3.1. for more details). 
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The intracellular distribution pattern of E1B-55K in Ad-infected cells varies during the viral 
replication cycle and in Ad-transformed cells. Early during infection, E1B-55K localizes 
diffusely in the nucleus and in perinuclear spots in transformed 293 cells (Liu, et al. 2005). The 
nuclear accumulation of E1B-55K is linked to the expression of E4orf3 protein and its 
reorganization of PML-nuclear bodies (PML-NB; Leppard and Everett, 1999); alternatively 
E1B-55K can associate with the nuclear matrix, independently of E4orf3 (Lethbridge, et al. 
2003). Later during infection, E1B-55K localizes to the periphery of virus replication centres 
with E4orf6 (Ornelles and Shenk, 1991), where the SUMOylation of E1B-55K has been 
reported to play a role in its nuclear localization (Kindsmüller, et al. 2007). Indeed, E1B-55K 
is a substrate for the E4orf3 SUMO E3-ligase; SUMOylation of E1B-55K recruits E1B-55K to 
nuclear inclusion bodies (Sohn and Hearing, 2019).  
 
Figure 1.7: Schematic representation of E1B-55K structural features. The domain 
architecture of E1B-55K is shown, including an N-terminal NES region and SUMO 
Conjugating Motif (SCM) at Lysine 104. Also shown is the central region (residues 147–384), 
which possesses a ribonucleoprotein (RNP) motif and a C2H2 zinc finger. Also shown is the 
C-terminal NLS and region that is subject to phosphorylation (Serine 490, Serine 491, and 
Threonine 495; Hidalgo, et al. 2019). 
 
1.2.3. Adenovirus E3 region   
The E3 region is involved in host immune evasion and promoting viral virulence and 
persistence. The E3 region is not a major consideration of this thesis and will only be 
considered briefly here. AdE3 proteins E3-6.7K, E3-14.7K and E3-10.4K/14.5K (also known 
as the receptor internalization and degradation protein complex (RID/RID) all protect Ad-
infected cells from cytolysis by ligands, such as TNF, Fas and TRAIL that activate the TNF 
receptor family of proteins (Gooding, et al. 1991). Indeed, the RID complex promotes the 
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internalization and degradation of the TRAIL receptor 1 to block Fas and TRAIL-dependent 
cytolysis, whilst AdE3-6.7K cooperates with RID to target TRAIL receptor 2 for degradation 
(Benedict, et al. 2001; Lichtenstein, et al. 2004). The Ad2/5E3-19K protein also plays a role in 
immune evasion through its ability to bind to the heavy chain of the class I major 
histocompatibility complex (MHC1; Pääbo, et al. 1983). The consequence of this is to retain 
MHC1 molecules in the endoplasmic reticulum so that CD8+ lymphocytes do not target Ad5-
infected cells for clearance (Cox, et al. 1990). 
1.2.4. Adenovirus E4 region  
The E4 transcription unit generates a primary transcript of 2800 nucleotides that is transcribed 
from the bottom strand on the right hand side of the Ad genome (Täuber and Dobner, 2001). 
Alternative splicing of this transcript generates approximately 18 different mRNAs which 
encode for seven orfs: orf1, orf2, orf3, orf3/4, orf4, orf6 and orf6/7 (Fig. 1.1C; Täuber and 
Dobner, 2001; Thomas, et al. 2001). E4 proteins exert their biological activities through 
interaction with host cell proteins that function in cell growth and cell survival processes. As 
such E4 proteins regulate viral DNA replication, viral mRNA transport, host cell shut-off of 
protein synthesis, transcriptional control and modulation of antiviral pathways, including the 
DDR (Halbert, et al. 1985; Weiden and Ginsberg, 1994; Täuber and Dobner, 2001). Given that 
proteins of the E4 region often cooperate functionally it is perhaps not surprising that the 
deletion of entire E4 region significantly hinders viral DNA replication, accumulation of late 
viral proteins and the shut-off of host protein synthesis, whilst the individual deletion of E4orfs 
has a more modest affect upon these activities (Halbert, et al. 1985; Falgout and Ketner, 1987). 
E4orf1 and E4orf2 have ill-defined functions during the late phase of viral infection, though 
E4orf1 from Ad9 is highly oncogenic and enhances mammary tumours formation in rats 
(Thomas, et al. 2001). E4orf4 is not important for efficient viral infection. In fact, it has a 
negative effect upon viral replication, particularly on the E1A-dependent transactivation of E2 
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and E4 viral promoters (Kleinberger, 2015). It is known however to interact with protein 
phosphatase 2A regulatory B-subunits to induce p53-independent apoptosis and as such is a 
potential cancer therapeutic agent (Kleinberger and Shenk, 1993). E4orf4 has also been shown 
to inhibit Ataxia-Telangectasia Mutated (ATM) and ATM and Rad3-related (ATR) activities 
in response to viral infection or treatment with DNA damaging drugs (Brestovistsky, et al, 
2016). E4orf4 also associates with DNA-PK to modulate its activity during infection 
(Nebenzahl-Sharon, et al. 2019). Not a lot is known about the E4ORF6/7 protein, though it is 
known to activate E2F-dependent transcription (Kleinberger, 2015). 
This region of viral genome also encodes two other proteins, E4orf3 and E4orf6, which 
together with E1B-55K cooperate to perform many functions during infection such as to inhibit 
Ad viral genome concatenation, although they also function individually during infection 
(Dobner and Kzhyshkowska, 2001). E4orf3 and E4orf6 proteins also participate in Ad-
mediated ‘hit and run’ mediated transformation (Nevels, et al. 1999; Nevels, et al. 2001). The 
properties of E4orf3 and E4orf6 will be addressed in more detail below.   
1.2.4.1.Adenovirus E4orf3 
E4orf3 is an 11kDa, 116 amino acid protein that serves primarily to inactivate the host cell 
antiviral response to infection. As such, it reorganizes PML nuclear bodies into nuclear track-
like structures (Doucas, et al. 1996), where it also sequesters the TIF1 tumour suppressor 
proteins TRIM24 (TIF1α) and TRIM33 (TIF1γ) and the MRE11/RAD50/NBS1 (MRN) DNA 
repair complex. It also targets TIF1γ, at least, for proteasomal-mediated degradation (Yondola 
and Hearing, 2007; Forrester, et al. 2012). Immunofluorescent microscopy studies have 
revealed that E4orf3 forms a network of track-like structures throughout the nucleus of the 
infected cell where they physically separate cellular chromatin from viral replication centres 
(Doucas, et al. 1996). It has been determined by crystallography that the E4orf3 protein exists 
as a dimer that self-assembles to give extensive linear and branched oligomeric chains that 
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form a polymeric structure, which forms multivalent binding sites that increase avidity for 
partner proteins (Ou, et al. 2012). E4orf3 has also been shown to function epigenetically, and 
silence p53 transactivation by inducing Histone H3K9me3 heterochromatin formation at p53 
target promoters (Soria, et al. 2010). 
More recent studies have determined that E4orf3 is a SUMO E3-ligase that drives the 
SUMO2/3 polySUMOylation and SUMO-targeted ubiquitin ligase (STUbL)-mediated 
proteasomal degradation of TFII-I and TIF1γ (Fig. 1.8 C; Sohn, et al. 2015; Bridges, et al. 
2016). As such, targets for E4orf3-directed SUMOylation are recognised by STUbLs that 
subsequently target them for ubiquitin-mediated degradation. It also possesses the ability to 
promote the SUMOylation and reorganization to nuclear tracks of MRN components, MRE11 
and NBS-1(Sohn and Hearing, 2012). As described earlier it also serves to SUMOylate E1B-
55K and promote its retention in the nucleus (Sohn and Hearing, 2019). 
 
Figure 1.8: Relationship between adenovirus early region proteins and the SUMO 
pathway. (A) E1A inhibits the SUMOylation of pRB by binding to SUMO E2 enzyme Ubc9. 
(B) E1B-55K is SUMOylated and serves an E3 ligase for p53 and Sp100A. (C) E4orf3 is also 
a SUMO ligase and regulates the SUMOylation of Nbs, Mre11, TIF1γ and TFII-I. Adapted 
from: (Sohn and Hearing, 2016).  S = SUMO moiety; Ub = ubiquitin moiety.  STUbL = SUMO-






1.2.4.2. Adenovirus E4orf6  
The 34kDa product of the adenovirus early region 4 (E4) open reading frame 6, E4orf6, is a 
multifunctional protein that regulates viral late gene expression, viral mRNA export, p53 
function and the host DDR pathway. In this regard it interacts with multiple viral and host cell 
proteins in both infected and transformed cells. Indeed, E4orf6 physically associates with E1B-
55K and that this complex has the capacity to shuttle between the nucleus and cytoplasm 
(Dobbelstein, et al. 1997), such that E4orf6 is responsible for E1B-55K localization during 
infection and, in cooperation with E1B-55K, the export of viral mRNA from the nucleus to the 
cytoplasm (Dobbelstein, et al. 1997). E4orf6 also cooperates with E1B-55K to drive the 
ubiquitin-mediated degradation of cellular substrates for degradation during infection. This 
will be discussed in detail in section 1.3.2. Mutagenesis studies have revealed that E4orf6 
possesses a putative nuclear localization signal (NLS) within the NTR, and an amphipathic 
arginine rich α-helical nuclear retention signal (NRS), within the CTR. The N-terminal NLS is 
important in re-directing E1B-55K to the nucleus during infection (Fig. 1.9A; Goodrum, et al. 
1996; Orlando and Ornelles, 1999) whilst E1B-55K association with E4orf6 has been shown 
to mask the NRS and allow for the nuclear export of both proteins (Fig. 1.9A; Dobbelstein, et 
al. 1997). E4orf6 also possesses a functional nuclear export site (NES), similar to rev and rex 
retroviral proteins, which play a role in nuclear-cytoplasmic shuttling of the E1B-55K-E4orf6 
complex (Dobbelstein, et al. 1997; Dobbelstein, et al. 1997),  which is important in promoting 












Figure 1.9: Nuclear export signals and localization signals present in Ad5 E4orf6. (A) 
Schematic model of the 294 residue wild -type Ad5 E4orf6 protein, indicating the position and 
the putative amino acids sequences for nuclear localization (NLS), nuclear export signal (NES) 
and nuclear retention (NRS). (B) An NES motif sequence MVLTREELVILR (amino acids 83-
94), is important in directing nuclear-cytoplasmic shuttling of the E1B-55K-E4orf6 complex. 
Mutation from L90A or I91A impairs nuclear-cytoplasmic shuttling. The Arginine-rich NRS 
promotes nuclear retention, unless mutated from R248E or inhibited by E1B-55K association 
Adapted from: (Dobbelstein, et al. 1997). 
 
Analysis of the E4orf6 amino acid sequence from multiple Ad types has revealed several 
conserved cysteine and histidine residues (Fig. 1.10). Zinc binding assays indicate Ad5 E4orf6 
is a zinc-binding protein, though the role of the cysteine and histidine residues in zinc binding 
has not been established (Boyer and Ketner, 2000). Mutagenesis studies have revealed however 







E4orf6 to associate with E1B-55K association and re-localize E1B-55K to the nucleus,  and 
associate with p53 and promote p53 degradation (Boyer and Ketner, 2000).  
In addition to the well-established role of E1B-55K in inhibiting p53 activity, Ad5 E4orf6 is 
also known to inhibit p53 transcriptional activity independently of E1B-55K following 
infection with mutant viruses that lack E1B-55K, and in Ad E4orf6-transfected cells (Dobner, 
et al. 1996). As stated earlier functional p53 would be detrimental to Ad replication, unless 
otherwise inactivated by early region proteins (Debbas and White, 1993; Lowe and Ruley, 
1993). Ad5 E4orf6 has been shown to bind specifically to the CTR of p53 between amino acids 
318 to 360 and antagonize p53-mediated transcriptional activity (Dobner, et al. 1996). This 
region of the p53 protein is known to be required for p53 tetramerisation and DNA-binding, 
however Ad5 E4orf6 was shown not affect p53 oligomerisation or p53 binding to DNA. 
Instead, E4orf6 was shown to inhibit the ability of the transcription factor (TFIID) component, 
TAFII31 to associate with the N-terminal transactivation domain of p53 (Dobner, et al. 1996). 
It has been suggested that Ad5 E4orf6 association with the CTR of p53 might induce a 
conformational change in p53 that alters the function of the NTR. Consistent with this view 
previous studies have suggested that CTR modifications of p53 do affect p53 DNA-binding 












Figure 1.10: Multiple sequence alignment of E4orf6 from several adenovirus types. The 
sequences selected here are representative of subgroups C (Ad5), A (Ad12), D (Ad9), F 
(Ad40), B1 (Ad50), B2 (Ad14), E (Ad4), F (Ad40) and G (Ad52). A highly conserved, 
cysteine-rich motif within E4orf6 was obvious along the entire length of E4orf6. CLUSTAL 
W was used to perform the multiple alignment. 
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1.2.5. Role of early region proteins in cellular transformation 
1.2.5.1. The role of E1A and E1B in cellular transformation 
As stated in section 1.1.1. John Trentin and colleagues determined, over 50 years ago, that 
Ad12 was oncogenic in new born rodents. Further work demonstrated that the E1 region from 
a number of different Ad types could transform primary human embryonic retinoblast (HER) 
cells, and baby rat kidney (BRK) cells and rat embryo fibroblasts to give immortal transformed 
cell lines that resembled the neoplastic state. These studies made an immense contribution 
towards our understanding of the molecular processes that underlie adenovirus-induced 
oncogenic transformation (Endter and Dobner, 2004). As described earlier, E1A is a 
transcription regulator that promotes cell-cycle progression into S-phase, but that in the absence 
of cooperating oncogenes promotes cellular apoptosis.  
The ability of E1A to drive oncogenic transformation is dependent upon its ability to bind pRB 
and CBP/p300 as mutants unable to bind these proteins (e.g. LXCXE and RG2 mutants, 
respectively) are transformation defective (Egan, et al. 1988; Jelsma, et al. 1989; Rasti, et al. 
2005). The NTR of E1A also associates with chromatin remodellers, TRRAP and p400, to 
promote E1A-induced cellular transformation (Deleu, et al. 2001; Fuchs, et al. 2001). CR4, at 
the C-terminal region of E1A, interacts with the C-terminal binding protein (CtBP) 
transcriptional repressor, HAN11 proteins and the dual-specificity tyrosine-regulated kinase 
1A (DYRK1A) in order to modulate cellular transformation (Schaeper, et al. 1995; Turnell, et 
al. 2000).  
Initially, it was shown that transformation of mammalian cells could be induced by introducing 
to the cells, DNA fragments that contained the Ad5 E1 region (Gallimore, et al. 1974; Graham, 
et al. 1974). Indeed, it was subsequently reported that complete cellular transformation of 
rodent cells required both E1B transcription units, E1B-55K and E1B-19K in addition to E1A 
(Gallimore, et al. 1985).  Other studies with BRK cells also determined that transformation 
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required the entire Ad E1 region, suggesting the importance of both E1B-19K and E1B-55K 
(Bernards, et al. 1986). Likewise, the transformation of HER cells only occurred with an entire 
Ad E1 region (Whittaker, et al. 1984; Gallimore, et al. 1986). The role of the E1B proteins in 
cellular transformation is mainly ascribed to their ability to inhibit p53 activity and prevent 
cellular apoptosis (Debbas and White, 1993). E1B-19K disrupts both p53- dependent and 
independent apoptotic pathways by possessing bcl-2 activities (White, 1996), whilst E1B-55K 
inhibits p53 directly through association (Sarnow, et al. 1982) and is able to inhibit p53 
activities in BRK cells expressing E1A (Yew, et al. 1994; Sabbatini, et al. 1995).  
1.2.5.2.The role of E4orf3 and E4orf6 in cellular transformation and the concept of hit 
and run transformation 
In addition to the known roles of E1A and E1B oncogenes in the cellular transformation of 
primary cells in culture, the roles of the E4 proteins, E4orf3 and E4orf6 in Ad-mediated cellular 
transformation have also been investigated in detail (Bernards, et al. 1984; Zalmanzon, 1987). 
The first indication that proteins from the E4 region might participate in transformation comes 
from the observation of the presence of E4 gene products in virus-transformed cells (Flint, et 
al. 1976; Flint and Sharp, 1976). The detection of E4 products in serum from hamsters with 
Ad12 tumours (Brackmann, et al. 1980; Downey, et al. 1983), and ultimately, that co-
expression of E1 and E4 early regions from the highly oncogenic Ad12, transformed 
completely rat cells in culture (Shiroki, et al. 1984).  
Studies investigating the individual contribution of E4 gene products in cellular transformation 
has demonstrated that two of the Ad5 E4 region gene products, E4orf3 and E4orf6 have 
transforming and oncogenic potential (Moore, et al. 1996; Nevels, et al. 1999). Both E4 
proteins promote enhanced focus formation in primary BRK cells in cooperation with either 
E1A alone or Ad E1 in its entirety. Indeed, transformed BRK cells, that express either E4orf6 
or E4orf3 in the presence of E1A and E1B, exhibit more advanced oncogenic transformation, 
compared to cells expressing only E1A and E1B (Moore, et al. 1996; Nevels, et al. 1999). The 
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ability of E4orf6 to promote foci formation and morphological transformation is dependent 
upon the C-terminal cysteine-histidine rich region of the protein, whilst accelerated tumour 
growth in nude mice is dependent upon both the NTR and CTR of the protein (Nevels, et al. 
2000). Studies with E4orf3 have indicated that its oncogenic potential does not correlate with 
p53 inactivation, but is rather based upon its ability to associate with E1B-55K and reorganise 
PML bodies and associated cellular proteins into nuclear tracks. It has been suggested that 
reorganisation of PML bodies during transformation might trigger cellular signalling pathways 
that promote dysregulated cell proliferation and neoplastic growth (Nevels, et al. 1999). 
The oncogenic and potential of E4orf3 and E4orf6 is linked to their overlapping activities 
during lytic infection and their capability to modulate the cellular activity of proteins through 
cooperative interactions with E1B-55K. For instance, these two E4 proteins have been reported 
to interact with E1B-55K and facilitate the nuclear accumulation of E1B-55K Leppard and 
(Everett, 1999;  Nevels, et al. 1999). Such activities are believed to increase the oncogenic 
activities of E1/E4orf3 or E1/E4orf6-transformed rat cells (Nevels, et al. 1999). 
It is now well established that adenovirus E1A, E1B synergistically cooperate with E4 gene 
products to mediate the full neoplastic transformation of both primary human and rodent cells 
(Moore, et al. 1996; Nevels, et al. 1999; Shenk, 2001). It has been determined that E1A/E1B 
transformation results in cell lines that continue to express these viral gene products (Graham, 
et al. 1977; Hutton, et al. 2000). This is consistent with the conventional concept of viral 
oncogenesis which claims that viral oncogene expression persists in the transformed cells and 
the corresponding tumours such that the expression of viral oncogene products maintains the 
transformed phenotype (Weiss and Javier, 1997). There is another concept in viral oncology 
known as hit-and-run transformation, whereby viral oncogenes initiate cellular transformation- 
the hit, whilst maintenance of the transformed state is not dependent upon the expression of 
viral oncogenes and is accompanied by the run of viral genes, whereby other genetic changes 
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in the transformed cell maintain the transformed phenotype (Skinner, 1976). Interestingly, 
although both E4orf3 and E4orf6 can cooperate with E1A in the transformation of primary rat 
cells, the majority of transformed cells lacked detectable viral DNA, mRNA or protein (Nevels, 
et al. 2001). This is in opposition to the conventional concepts of oncogenesis induced by 
viruses and is consistent with the hit-and-run model of transformation. In this situation it has 
been suggested that E4orf3 and E4orf6 have increased mutagenic potential which introduces 
oncogenic mutations in cellular genes and increases genomic instability (Nevels, et al. 2001). 
In addition to these findings Ad5 E1A is also known to induce chromosomal aberrations 
(Caporossi and Bacchetti, 1990). Taken together, these studies are suggestive that adenovirus 
could contribute towards human oncogenesis through hit-and-run transformation, though 
ultimately this will be difficult to establish. 
1.2.5.3.The role of E1A and Ras in cellular transformation 
Apoptosis is an important biological process that protects hosts against possible malignant 
formation (Williams, 1991). The adenovirus E1B genes, E1B-55K and E1B-19K inhibit 
cellular apoptosis during adenovirus E1-mediated cellular transformation (White, 1993). 
Activation of the Ras oncoprotein, predominantly through point mutation at exons 12, 13 or 
61, is linked to the formation of many different types of human cancers (Bos, 1988; Bos, 1989). 
Despite its oncogenic activity, paradoxically in primary cells, activated Ras promotes growth 
arrest, which is considered as a defence strategy against oncogenic transformation (Serrano, et 
al. 1997; Spyridopoulos, et al. 2002). Consistent with the model of multiple genetic hits being 
required for oncogenesis it is not surprising that transformation by Ras requires further genetic 
alterations such as Rb inactivation (Peeper, et al. 2001) and loss of p53 functionality (Shvarts, 
et al. 2002). E1A expression has been shown to render primary human fibroblasts resistant to 
Ras senescence and promote oncogenic transformation (Serrano, et al. 1997). Indeed, several 
studies have demonstrated that activated ras genes can like, E1B-55K and E1B-19K, promote 
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E1A-dependent transformation by suppressing E1A-induced apoptosis though the mechanism 
by which this occurs is not well understood (Jochemsen, et al. 1986; Byrd, et al. 1988; Lin, et 
al. 199). Interestingly, E1A/Ras transformation is inhibited by the interaction of the CR4 region 
of E1A with DYRK1A and HAN11 as E1A deletion mutants unable to bind DYRK1A and 
HAN11 enhanced E1A/ras transformation which is presumably modulated through E1A’s 
known ability to bind cellular tumour suppressors pRB, CBP/p300 and p400 (Boyd, et al. 
1993).  
1.3. The Ubiquitin-Proteasome System 
One of the most abundant PTMs in cells is ubiquitylation in which a ubiquitin polypeptide, 
comprising 76 amino acids, is covalently attached through its C-terminal glycine residues to a 
lysine residue on a target protein through a coordinated multiple enzymatic cascade (Fig. 1.11). 
This process often leads to proteasomal degradation of the substrate, hence the ubiquitin-
proteasome system (UPS). Initially, ubiquitin is activated by an E1 ubiquitin activating enzyme 
that forms a high energy thioester bond with an active site cysteine residue. The ubiquitin is 
then transferred to an E2 ubiquitin conjugating enzyme, again through a high energy thioester 
bond with cysteine. Finally, the ubiquitin transfer to the target substrate is catalysed by an E3 
ubiquitin ligase enzyme (Dye and Schulman, 2007; Kulathu and Komander, 2012; Yau and 





Figure 1.11: Diagram detailing the Ubiquitin-Proteasome System. Ubiquitylation of 
protein substrates is an ATP-dependent process that requires the action of three enzymes E1, 
E2, E3 (see text for details). K11 and K48 polyubiquitin linkages target substrates for 
proteasomal degradation. Adapted from: (Sarikas, et al. 2011). 
 
The attachment of a ubiquitin molecule to a target lysine residue can be diverse. For instance, 
it could be attached on one or multiple lysine residues, to form either a mono- or multi-mono 
ubiquitylated protein. Repeated rounds of ubiquitylation on one lysine residue is termed 
polyubiquitylation. Polyubiquitin chain can be formed through the attachment of the C-
terminal glycine residue to a Lys residue on another ubiquitin molecule (i.e. Lys6, Lys11, 
Lys27, Lys29, Lys33, Lys48 and Lys63), or through the ubiquitin amino terminal Met1 residue 
(Fig 1.12; Kulathu and Komander, 2012). Ubiquitin polymers formed using the same linkage 
type are known as homotypic ubiquitin conjugates, whilst heterotypic chains are formed using 
mixed linkages and can be branched (Fig. 1.12; Ikeda and Dikic, 2008). Polyubiquitylation 
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through Lys11 and Lys48 typically drive proteasomal degradation, whilst polyubiquitylation 
on other residues (e.g. Lys 63) are important in lysosomal targeting, DDR, and other non-
degradative processes such as protein interactions, functionality or location, as does mono-
ubiquitylation (Kulathu and Komander, 2012; Yau and Rape, 2016). As outlined above the 
versatility of ubiquitin rises from the distinct cellular functionality assigned to each of the 
linkages that comprise the ubiquitin polymers, though the cellular roles for Lys6, Lys27. Lys29 
and Lys33 remain elusive (Kulathu and Komander, 2012).   
 
  
Figure 1.12: Ubiquitin and ubiquitin linkages. Multiple Lys residues present within 
ubiquitin that can be used to generate polyubiquitin linkages (Kulathu and Komander, 2012). 
Figure also shows the diversity of ubiquitylation modifications (i.e. mono-, multi-mono- or 
polyubiquitin chains). Ubiquitin polymers are coloured according to linkage-type. 
Polyubiquitin chains containing the same type of linkage are called homotypic chains, whereas, 
different linkages are termed heterotypic chains and can be branched or non-branched. Adapted 






1.3.1. Cullin–Ring Ubiquitin Ligases (CRLs) 
Cullin–RING Ligases (CRLs) comprise the largest known class of ubiquitin ligases. CRLs are 
involved in diverse cellular activities including cell cycle regulation, cell signalling pathways, 
DDR as well as development (Petroski and Deshaies, 2005). CRLs are multicomponent 
complexes that comprise a Cullin, which is often curved in shape with a rigid N-terminal stalk, 
that serves as a scaffold to recruit other components of the ubiquitin ligase complex (Zheng, et 
al. 2002). The adaptor protein serves to recruit the substrate recognition subunit (SRS) to the 
Cullin complex, whilst the large family of SRS recruit substrates specifically to the CRL for 
ubiquitylation (Fig. 1.13). The zinc-binding (RING-H2-DOMAIN) proteins, referred to as 
ROC1/RBX1/HRT1 or ROC2/RBX2/HRT2 are E3 ubiquitin ligases that recruit the appropriate 
ubiquitin-conjugating enzyme (E2) and performs the transfer of ubiquitin to the substrate 
(Zheng, et al. 2002).  
 
Figure 1.13: Architecture of Cullin-RING E3 ubiquitin ligase (CRL) complexes. In 
mammalian cells there are nine members of the Cullin family (CUL1 to CUL7, PARC and 
APC2). Cullin proteins in CRLs recruit a substrate-recognition subunit, through an adaptor 
protein, and also associate with the RING finger ligase component. (A) General CRL 
composition. (B) Specific composition of the CRLs assigned to Cullins 1 to 7 and PARC.  






In Human cells there are seven different cullins, (CUL1, 2, 3, 4A, 4B, 5 and 7), the p53 
cytoplasmic anchor protein (PARC) and the APC2 subunit of the Anaphase-Promoting 
Complex/Cyclosome (APC/C; Petroski and Deshaies, 2005). CRLs are activated by the 
covalent binding of NEDD8 to a conserved lysine near a Cullin’s C-terminus and are 
inactivated by CAND1 (cullin-associated and neddylation-dissociated) inhibitor (Petroski and 
Deshaies, 2005). NEDDylation is a process of covalent attachment of a ubiquitin-like molecule 
NEDD8 (neuronal precursor cell-expressed developmentally down-regulated protein 8) to a 
lysine residue of target substrate (Kamitani, et al. 1997). This process is controlling by 
successive enzymatic cascade. Briefly, NEDD8 is activated by the activating enzyme (NAE) 
and is then transferred to the NEDD8-conjugating enzyme, UBE2M (also known as UBC12), 
whence it is finally transferred to a lysine residue in its target protein by a substrate specific-
E3 ligase, such as RBX1/2 or DCN1 (Fig. 1.14 A; Walden, et al. 2003; Zhou, et al. 2018). 
Overall, NEDDylation of target proteins may affect their stability, localization and function. 
The cullin subunits of Cullin-RING ligases (CRLs) are the best-characterized targets of 
NEDDylation. Conjugation of NEDD8 at the C-terminus of a Cullin promotes the dissociation 
of the CRL negative regulator, CAND1 and activates the Cullin complex (Zhao, et al. 2014). 
It has been reported that the Rbx1 component of a CRL is essential in NEDDylation and any 
mutation within RING finger motif of Rbx1 abolishes NEDDylation in vitro (Kamura, et al. 
1999). DeNEDDylation by COP9 Signalosome (CSN) isopeptidese activity inactivates CRL 
activity, whilst CAND1 association with the Cullin N-terminus blocks the NEDD8 conjugation 
site and the recruitment of the adapter to the Cullin (Bosu and Kipreos, 2008). It has been 
reported that the small molecule, MLN4924 is a potent inhibitor of the NAE, such that 
MLN4924 is covalently attached to NEDD8 by the NAE to form an NEDD8-MLN4924 moiety 
that resembles NEDD8 adenylate, which is an intermediate in the NAE reaction. The NEDD8-
MLN4924 adduct is a stable entity that blocks the NAE active site and limits the activation of 
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Cullin-containing CRLs. MLN4924 therefore, effectively inhibits Cullin neddylation and 
inactivates CRLs, causing the accumulation of various CRL substrates (Fig.1.14 B; Soucy, et 
al. 2009; Brownell, et al. 2010).  
 
Figure 1. 14: MLN4924 as an inhibitor of Cullin-RING ubiquitin ligases (CRLs).  (A) Role 
of NAE and Ubc12 in the activation of NEDD8 (N8). (B) Role of MLN4924 as a potent and 
selective inhibitor of NAE and CRLs. 
 
1.3.2. Regulation of the ubiquitin-proteasome system by E1B-55K and E4orf6 proteins 
In order to promote a productive infection viruses such as adenovirus exploit the cellular 
ubiquitylation machinery. Viruses have been shown to manipulate the ubiquitylation of specific 
target proteins by: encoding viral E3 ligases; integration into cellular ubiquitin ligase 
complexes to modulate E3 activity and specificity; manipulation of existing cellular E3 ligase 
enzymic activity to modulate E3 activity and specificity (Dybas, et al. 2018).  
1.3.2.1. Utilization of Cullin Ring Ligases by E1B-55K and E4orf6 proteins during 
infection to promote p53 degradation 
The p53 tumour suppressor protein was initially identified over 40 years ago as an SV40 large 
T antigen-binding protein (DeLeo, et al. 1979; Kress, et al. 1979;  Lane and Crawford, 1979; 
Linzer and Levine, 1979). Since that time, it has been appreciated that p53 can induce cell cycle 




radiation, U.V. radiation or viral infection (Vogelstein, et al. 2000; Surget, et al. 2014). As such 
p53 acts as a potent antiviral and adenoviruses, like other viruses, have evolved to inhibit p53 
during infection. Early studies determined that E1B-55K and E4orf6 independently associated 
with p53 in Ad-transformed cells to inhibit its transcriptional activity and affect its cellular 
localization, whilst in Ad-infected cells it was established that E1B-55K and E4orf6 cooperated 
to reduce p53 levels by reducing the protein half-life (Steegenga, et al. 1998; Cathomen and 
Weitzman, 2000). Phil Branton’s lab then reported that the ability of E1B-55K and E4orf6 to 
reduce the protein levels of p53 was due to E1B-55K and E4orf6’s ability to engage with 
cellular CRLs to target p53 for proteasomal degradation (Querido, et al. 2001). It was 
established that E1B-55K acted as the receptor for p53, whilst E4orf6 recruited CRL5, 
containing Cullin 5, to E1B-55K-p53 complexes to promote its polyubiquitylation and 
degradation by the proteasome (Fig. 1.15; Querido, et al. 2001).  
 
Figure 1.15: Schematic model of Cullin-RING E3 ligases and their utilization by E1B-55K 





CRLs are major targets for E1B-55K and E4orf6 (Querido, et al. 2001; Harada, et al. 2002). 
Indeed, mass spectrometric studies with Ad5-infected cells identified all components of CRLs 
including the Cullin 5 and Elongin B and C proteins, and the Rbx1 ubiquitin ligase as E4orf6-
interacting proteins (Querido, et al. 2001; Harada, et al. 2002). It was later established that Ad5 
E4orf6 possessed three BC boxes which enabled the assembly of the cellular proteins Cul5, 
Elongins B and C, and RBX1 with E4orf6 prior to its association with E1B-55K, which 
functions as the major substrate recognition protein (Blanchette, et al. 2004; Cheng, et al. 
2007). E4orf6 was shown to be crucial in the formation of ligase complex, as an E4orf6 BC-
box mutant that prevents the formation of this complex was unable to promote p53 degradation 
(Blanchette, et al. 2008). Our laboratory then reported that Ad12 used a similar mechanism to 
promote the degradation of p53 in Ad12-infected cells, but in this instance used CRL2, rather 
than CRL5 (Blackford, et al. 2010). Further work by the Branton lab determined that E1B-55K 
and E4orf6 from all Ad groups associated with CRLs, such that most Ads utilize CRL5, whilst 
Ad groups A, F, and G utilize CRL2 (Blackford, et al. 2010; Cheng, et al. 2011). Ad5 E4orf6 
possesses a Cul5 box and Ad12 E4orf6, a Cul2 box which determines CRL specificity (Fig 
1.16; Gilson, et al. 2016).  
 
Figure 1.16: Schematic representation of BC boxes and CUL boxes in Ad5 and Ad12 
E4orf6. The relative positions of the Elongin B and C –interaction motifs (BC boxes) and 





1.3.2.2. Adenovirus utilisation of CRLs to promote viral replication and inhibit DDR and 
other antiviral pathways 
It has become apparent that, in addition to p53, E4orf6 and E1B-55K cooperate during infection 
to target a growing number of cellular proteins for degradation by CRL E3 ubiquitin ligases. A 
number of the proteins targeted for degradation by adenovirus function in the DDR pathway 
(see section 1.4 for a brief description of the DDR). The reason for this becomes apparent when 
it is considered that the Ad consists of linear dsDNA that would be seen by the host cell as a 
double-strand break, whilst replicated Ad DNA exists as ssDNA intermediates which would 
be seen by the host cell as erroneous cellular DNA replication. For instance, it has been 
determined that Mre11 is targeted for degradation during infection, whereby adenovirus 
prevents viral genome concatenation (i.e. the end-to-end joining of Ad genomes resulting in 
circular dsDNA) that, otherwise occurs following infection of cells with E4-deleted viruses 
where Mre11 expression persists; Mre11 degradation effectively inhibits the ATM-mediated 
repair of double-stranded DNA breaks in Ad-infected cells (Stracker, et al. 2002). Similarly, 
adenovirus promotes the E1B-55K/E4orf6 degradation of DNA ligase IV in order to inhibit 
DNA-PK-dependent non-homologous end-joining (NHEJ) and viral genome concatenation 
(Baker, et al. 2007). In this regard, E4orf6 also associates with DNA-PK independently and 
inhibits DNA PK-dependent V(D)J-recombination, in order to prevent viral genome 
concatenation (Boyer, et al. 1999). 
Adenovirus 12 is also known to inhibit the ATR pathway, selectively through its ability to 
promote the degradation of ATR activator protein, TOPBP1, in a CRL2 dependent mechanism 
that requires Ad12 E4orf6, but not Ad12 E1B-55K, such that Ad12 E4orf6 acts as both the 
substrate adaptor as well as to recruit CRL2 to the substrate (Blackford, et al. 2010). Moreover, 
this study was the first to demonstrate that Cullin-2 is NEDDylated (i.e. activated) in response 
to Ad12 infection, and that Cullin-5 is NEDDylated in response to Ad5 infection. More 
recently, it has been established that both Ad5 and Ad12 E1B-55K/E4orf6 engage with cellular 
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CRLs to target the ATR substrate, SMARCAL1 for degradation in order to modulate cellular 
DNA replication (Nazeer, et al. 2019).  
As indicated earlier E1B-55K and E4orf6 cooperate to promote viral mRNA export to the 
cytoplasm during infection. Mutational studies have determined the importance of  both the 
nuclear export signal (NES) within E4orf6 in this process and E1B-55K/E4orf6 ability to 
associate with cellular CRLs, though the cellular substrate that is targeted for degradation in 
order to enhance viral mRNA transport to the cytoplasm has yet to be identified (Weigel and 
Dobbelstein, 2000). Consistent with this view the expression of a dominant-negative Cullin 5 
protein abolishes the ability of E1B-55K/E4orf6 to promote the nuclear export of viral mRNAs 
(Woo and Berk, 2007).  
Other studies have identified other cellular proteins that are targeted for degradation during 
infection that might help facilitate viral release and spread. It was determined that integrin 3 
was degraded by CRL5 in an E1B-55K and E4orf6 dependent manner during Ad5 infection 
(Dallaire, et al. 2009), whilst ALCAM, EPHA2, PTPRF proteins that also function in cellular 
adhesion were substrates for CRL and E1B-55K/E4orf6 (and E1B-55K/E4orf3) dependent 
degradation in Ad5-infected cells (Fu, et al. 2017). Finally Ad5 E1B-55K, like Ad12 E4orf6, 
has been shown to engage with CRLs independently and target the Daxx (death-domain-
associated protein), for degradation during Ad5 infection (Schreiner, et al. 2010). Taken 
together, these studies highlight the importance of Ad modulation of cellular CRLs during 
infection to promote viral replication.  
1.3.2.3. Regulation of CRLs by other viruses 
Upto 20% of all ubiquitylated cellular proteins are attributed to CRL activity (Soucy, et al. 
2009). Modulation of CRL activity is widely exploited by a number of DNA and RNA viruses 
to alter the host cell environment in order to allow for efficient virus replication (Fig. 1.17; 
Barry and Früh, 2006). For instance, human papillomavirus (HPV), a causative agent of several 
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mucosal cancers including cervical cancer, targets CRL2 through its transforming protein, E7 
which through its association with Elongin C recruits the pRB protein for CRL2-dependnet 
degradation. E7-mediated pRB degradation allows for the activation of E2F-dependent 
transcription and cell cycle progression past the restriction point (Fig. 1.17 C; Huh, et al. 2007).  
KSHV is the aetiological agent of Kaposi’s sarcoma.  The KSHV latency-associated nuclear 
antigen (LANA) protein, like Ad5 E4orf6, possesses an Elongin B/C box and a Cullin 5 box, 
whereby it recruits CRL5 to promote the ubiquitin-mediated degradation of p53 and the VHL 
tumour suppressor proteins (Cai, et al. 2006). Moreover, it has been determined that the 
NEDDylation inhibitor MLN4924 reactivates KSHV lytic gene expression and as such, 
identifies CRLs as novel KSHV therapeutic targets (Hughes, et al. 2015). The HIV-1 virion 
infectivity factor, Vif, similarly associates with CRL5 and Elongin’s B and C to promote the 
degradation of APOBEC3G during infection to protect HIV-1 DNA from G to A 
hypermutation (Kobayashi, et al. 2005). SV40 on the other hand interacts with CRL7 to inhibit 
its E3 ligase activity towards IRS1 (insulin receptor substrate 1) which allows for the activation 











Figure 1.17: Regulation of host Cullin RING ligases by different viruses. (A) CRL complex 
assembled by the HIV-1 Vif protein (B) CRL complex assembled by the SV40 LT protein. (C) 
CRL complex assembled by the HPV E7 protein (D) CRL complex assembled by the KSHV 
LANA protein. Adapted from: (Barry and Früh, 2006). 
 
1.4 . The cellular DNA damage response 
The DDR is a surveillance mechanism that ensures genomic stability in the presence of 
genotoxic agents such as ionizing radiation and virus infection and ensures the proper 
transmission of genetic information from generation to generation (Ciccia and Elledge, 2010; 
Turnell and Grand, 2012; Maréchal and Zou, 2013; Yoshiyama, et al. 2013). The DDR is 
orchestrated by three phosphoinositide 3-kinase (PI3K)-related protein kinases ATM and 
DNA-PK, and ATR which respond to double-strand, and single-strand breaks, respectively 





requires different cellular factors: DNA damage sensors/mediators, signal transducers and 
effectors that serve to detect and correct damaged DNA, whilst modulating cell cycle 
progression; in situations where the extent of DNA damage is too great apoptosis is induced 
(Fig. 1.18). Given the relationship between adenovirus and DDR pathways (section 1.3.2.2) it 
is worthwhile to give a brief overview of cellular DDR pathways. 
 
Figure 1.18: Role of PI3K-related protein kinases in DDR signalling pathways. See text 
for details. Taken from: (Turnell and Grand, 2012). 
 
1.4.1. The ATM pathway 
ATM is the gene that when inactivated gives rise to the autosomal recessive syndrome, Ataxia-
Telangiectesia (A-T), which is characterized by defects in cerebellar degeneration, 
immunodeficiency and cancer susceptibility. In undamaged cells, ATM exists as an inactive 
dimer, but in response to DNA damage ATM becomes auto-phosphorylated on S1981 leading 
to its activation, its association with MDC1 and recruitment to the DNA double-strand break 
sites (So, et al. 2009). Recruitment of the MRN (Mre11- Rad50-NBS1) complex enhances 
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ATM activation. Collectively, ATM mediated phosphorylation of Chk2, p53, H2AX, 
TIF1/KAP1, BRCA1, 53BP1 and NBS1 at the DNA double-strand break ensures that cell 
cycle checkpoints are activated and DNA double-strand breaks are repaired by homologous 
recombination (Sancar, et al. 2004; Turnell and Grand, 2012). As discussed earlier adenovirus 
inhibits the ATM pathway by promoting the targeted degradation of Mre11 (section 1.3.2.2). 
1.4.2. The ATR pathway 
ATR is an essential gene in proliferating cells; hypomorphic mutations in ATR gives rise to 
the human autosomal recessive disorder, Seckel syndrome, which is characterised by 
microcephaly and mental, and growth, retardation (Sancar, et al. 2004; Byun, et al. 2005). ATR 
acts to correct ssDNA damage often as the result of DNA replication errors. In response to 
DNA damage ATR and its partner protein, ATR-interacting protein (ATRIP), are recruited to 
DNA damage sites via the replication protein A (RPA) complex which coats ssDNA (Zou, et 
al. 2003). ATR is activated by TopBP1 which results in the activation of the CHK1 kinase, 
through ATR-dependent phosphorylation on serine residues 317 and 345 which allows for 
checkpoint activation (Liu, et al. 2000; Zhao and Piwnica-Worms, 2001). ATR-dependent 
regulation of proteins such as SMARCAL1 allows for the replication re-start after fork collapse 
(Cortez, 2015). As detailed earlier, adenovirus inhibits ATR signalling during infection by 
promoting the degradation of TopBP1 and SMARCAL1 (see section 1.3.2.2.). 
1.4.3. The DNA-dependent protein kinase pathway 
The DNA-activated protein kinase (DNA-PK) is a nuclear serine/threonine protein kinase that 
is involved in modulating NHEJ. It is composed of catalytic subunit (DNA-PKcs / 470KDa) 
and two additional regulatory subunits Ku70 and Ku86 (Smith, et al. 1999). Following DNA 
damage Ku associates with the broken DNA end and recruits DNA-PKcs (Cary, et al. 1997; 
Gell and Jackson, 1999). DNA-PKcs in turn tether the DNA ends and bridge them together to 
allow for their re-ligation.  DNA-PK then stimulates the recruitment and activation of DNA 
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ligase IV - XRCC4 complexes that are required for the re-joining step (Fig. 1.18; Hsu, et al. 
2002). As detailed earlier, adenovirus inhibits DNA-PK signalling during infection by 
promoting the degradation of DNA ligase IV (see section 1.3.2.2.). 
1.4.4. Regulation of the DDR by other viruses  
It is apparent that a number of viruses, including the DNA tumour viruses discussed earlier 
(section 1.1.1.) all modulate DDR pathways during infection to promote viral replication 
(Pancholi, et al. 2017). Some viruses negatively regulate DDR pathways, while others utilize 
or exploit DDR pathways, and some viruses can selectively utilize or repress DDR pathways 
for viral growth and/or oncogenesis (Pancholi, et al. 2017). Like adenovirus, most other viruses 
often engage with the UPS to regulate DDR pathways (Dybas, et al. 2018). For instance HPV 
negatively regulates the DDR effector protein, p53 through E6 association with the E3-
ubiquitin ligase, E6-AP. Interestingly however, HPV utilises the DDR machinery directly. E7 
associates with, and activates, ATM in order to promote the phosphorylation of Chk2, BRCA1 
and Nbs1 to stimulate viral genome replication (Moody and Laimins, 2009). It has been 
proposed that the rapid replication of the 8Kb HPV genome creates aberrant DNA structures 
that need to be resolved by the DDR machinery which requires its activation (Bristol, et al. 
2017). Moreover, HPV replication proteins E1 and E2 localize at sites of viral DNA replication 
with phosphorylated, activated forms of ATM, H2AX and p53, as well as with viral genomes 
and the MRN component NBS1 (Nishiyama, et al. 2011). These data suggest that the ATM 
pathway is crucial in facilitating HPV genome replication.  HPV16 E2 also interacts with the 
ATR activator TopBP1 at centrosomes during mitosis, suggesting that DDR pathways also be 
utilized by HPV to modulate genome segregation during mitosis (Donaldson, et al, 2007). 
Given these few examples, it is clear that an understanding of the relationship between viruses 
and DDR pathways is important in understanding how viruses subvert host cell pathways in 




1.5. Project Aims   
In recent years it has become increasingly clear that viruses such as adenovirus promote viral 
replication and cellular transformation through their ability to modulate host cell PTMs and 
cell signalling pathways. As such, adenoviruses have evolved complex mechanisms to regulate 
and exploit these cellular pathways to maximise viral production. Indeed, E1B-55K, E4orf3 
and E4orf6 early region proteins cooperate functionally to regulate host cell UPS and SUMO 
pathways in order to promote viral replication and cellular transformation. It is becoming more 
apparent however that these proteins also function separately during cellular infection and 
cellular transformation. It is also not clear how many functions of E1B-55K, E4orf3 and E4orf6 
are conserved between different Ad types given that Ad12 E4orf6 can promote TopBP1 
degradation, whilst Ad5 E4orf6 cannot.  
Given these observations the aims of my project were to: 
 
• Generate and characterize Tet-On inducible cell lines that express Ad5 and Ad12 E1B-
55K, E4orf3 and E4orf6 proteins in isolation. 
• Investigate the function of both Ad5 and Ad12 E4orf3 proteins in the SUMO pathway 
in an attempt to identify new cellular proteins that are substrates for E4orf3-targeted 
SUMOylation.  
• Investigate the post-translational modification status of Ad5 E4orf6 
• Investigate the function of both Ad5 and Ad12 E4orf6 proteins in the UPS in an attempt 
to identify new cellular proteins that are substrates for E4orf6-targeted ubiquitylation 
Given that E1B-55K, E4orf3 and E4orf6 accumulate at VRCs and nuclear tracks here is also 
considerable interest in the relationship between the UPS and SUMO pathways and these 
virally-induced structures. Indeed, our laboratory had determined that the FACT complex 
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which functions as a chromatin regulator was recruited to VRCs during Ad infection. Another 
aim of my project was therefore to: 
• Determine the role of the FACT complex during adenovirus infection.  
 




































2.1. Tissue Culture 
2.1.1. Cell culture 
A derivative of the human osteosarcoma U2OS cell line has been used throughout this study. 
The U2OS- FRT-TREX cell line expresses the TET repressor and contains a single Flp 
recombination site to allow for the integration of an exogenous gene that is under the control 
of the CMV immediate early promoter (Life Technologies). This cell line was used to generate 
cells that expressed Ad5 or Ad12 E1B-55K, E4orf3, and E4orf6 in a TET-dependent manner 
(see 2.1.5). Human A549 small cell lung carcinoma cells (CCL-185) and U2OS osteosarcoma 
cells (HTB-96), which both possess normal, wild-type [w.t.] p53 alleles (Lehman, et al. 1991; 
Landers, et al. 1997) were obtained from the American Type Culture Collection (ATCC) and 
typically used for adenovirus infection. As p53 is the main target for adenovirus during 
infection it was important to use cells whose p53 status was known. Ad5 E1-transformed 
human embryonic kidney (HEK) 293 cells and Ad12 E1-transformed human embryo 
retinoblast (HER) 3 cells were used to propagate adenovirus 5 and adenovirus 12, respectively. 
GFP-U2OS and GFP-RPA1-U2OS cells, derived from human U2OS osteosarcoma cells and 
engineered to express GFP-tagged proteins, were provided by Dr. Andrew Blackford (The 
University of Oxford; Galanty, et al. 2012). All cell lines used were adherent, epithelial in 
nature and permissive for adenovirus infection. Cells were grown in HEPES-buffered 
Dulbecco Modified Eagle Medium (DMEM; Sigma-Aldrich) enriched with 8% (v/v) foetal 
calf serum (FCS; Sigma-Aldrich) and 2mM L-glutamine (Sigma-Aldrich). The growth medium 
for U2OS-FRT-TREX cell lines was supplemented with 200µg/ml Hygromycin (Gibco) whilst 
the medium for GFP-U2OS cells was supplemented with 500µg/ml G418 (Gibco). All tissue 
culture reagents were bought pre-sterilized and stored at 4°C. Prior to use reagents were 
warmed to 37°C in a water bath. 
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2.1.2. Maintenance and passage of cell lines             
Cell lines were grown in monolayer and passaged by removing the existing medium from the 
cells followed by washing with pre-warmed phosphate-buffered saline (PBS; Oxoid). Cells 
were then detached from the plate by the addition of 1ml of trypsin (Tryple E; Life 
Technologies) and the incubation of cells for approximately 5 min at 37°C in a humidified 
atmosphere containing 5% (v/v) CO2 (CO2 AIR Jacketed incubators by NUAIRE 
AUTOFLOW). A Nikon Eclipse TS 100 Microscope was used to confirm the detachment of 
cells from the plastic. Growth medium containing FCS was then added to the cells to inactivate 
the trypsin. Cells were then pelleted by centrifugation at 1500 rpm for 5 min. The pellet was 
resuspended in fresh medium then re-plated at the required density, using a haemocytometer 
to measure cell number, and incubated in the CO2 incubator until required. All techniques were 
performed under sterile conditions using a Mars Safety Class 2 hood (SCANLAF).  
 
2.1.3. Cryopreservation of cell lines and cell recovery 
To store cell-lines for a long time, cells were trypsinized and resuspended in HEPES-buffered 
Dulbecco Modified Eagle Medium containing 8% (v/v) FCS, 2mM L-glutamine and 10% (v/v) 
dimethyl-sulphoxide (DMSO HybriMax; Sigma-Aldrich) at a density of 5 x106 cells/ml. Cells 
were cooled to -80°C at a controlled rate of 1°C/min in isopropanol using a Mr Frosty then 
transferred to the liquid nitrogen tanks for storage at -180°C.  When cells were recovered from 
liquid nitrogen, they were thawed rapidly in water bath at 37°C. The cells were immediately 
pelleted by transferring to a tube containing 10 ml of fresh culture medium then centrifuged at 
1500 rpm for 5 min. After that the cells were washed once more with fresh medium then re-





Human, Ad5 (VR-5) and Ad12 (Huie; VR-863) types were from the ATCC. Ad5 was 
propagated on Ad5 E1-transformed HEK293 cells, whilst Ad12 was propagated on Ad12 E1-
transformed E1 HER3 cells. The FLAG-tagged E4orf3 Ad12 virus was made in collaboration 
with Thomas Dobner’s laboratory (HPI, Hamburg, Germany). This virus is a mutant Ad12 
virus that expresses FLAG-tagged E4orf3 that retains normal expression of other viral gene 
products. Stock titres of Ad5 and Ad12 viruses were determined by plaque assay on Ad5 E1-
transformed HER911 and Ad12 E1-transformed HER3 cells, as appropriate. All adenovirus-
transformed cells were grown in DMEM-HEPES containing 8% (v/v) FCS. For infection, sub-
confluent monolayers of A549 or U2OS cells were washed twice with 5 ml of pre- warmed 
serum-free, HEPES-buffered DMEM containing 2mM L-glutamine. Cells were then infected 
with the virus at a multiplicity of infection (m.o.i.) of 10 plaque forming units (p.f.u)/cell, 
unless otherwise stated, and then incubated in an incubator with a humidified atmosphere 
containing 5% CO2. Dishes were agitated every 10 min for 2 h at 37°C to ensure that cells were 
covered with medium. After infection the medium containing the virus was replaced with 
HEPES-buffered DMEM containing 8% (v/v) FCS and 2mM L-glutamine until required.     
 
2.1.5. Generation of U2OS FRT TREX cell lines  
Prior to transfection the FRT-U2OS TREX cells were grown to 90% confluence on a 10cm 
dish. For transfection, 1.5g of the pcDNA5-FRT plasmid containing the adenovirus gene of 
interest was mixed with 13.5g of the pOG44 plasmid, which expresses the Flp recombinase 
required for exogenous gene integration, in 200l reduced-serum containing medium (Opti-
MEM, Life Technologies) in a sterile Eppendorf. Secondly, 15l of the Lipofectamine 2000 
transfection reagent was added to a separate Eppendorf containing 200l Opti-MEM medium. 
After 5 min incubation, the transfection regent was mixed with the pcDNA5-FRT/pOG44 
mixture and incubated for an additional 45 min at room temperature to produce Lipofectamine-
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plasmid complexes. The cells were then washed with 5ml Opti-MEM and incubated in 5ml of 
Opti-MEM. The DNA: Lipofectamine transfection complex was then added to the cells in a 
dropwise manner, after which cells were incubated in CO2 incubator at 37°C for 6 h. Following 
incubation the plate’s media was changed and fresh DMEM supplemented with 8% (v/v) FCS 
and 2mM glutamine was added. Two days post-transfection cells were split 1 in 4 onto 10cm 
dishes. 72 h post-transfection cells were incubated with media containing 200μg/ml 
Hygromycin B (Life Technologies) for selection of positive cell clones that had integrated the 
adenovirus gene of interest. Cells were fed every three days until individual colonies could be 
isolated under a light microscope at low magnification. Selected cells were isolated and 
expanded after which time they were incubated with 0.1μg/ml Doxycycline (Duchefa Farma) 
to assess expression of the particular adenovirus gene product. 
 
2.1.6. Transfection of siRNA   
In order to knockdown endogenous SSRP1 and SPT16 genes small-interfering RNA (siRNA) 
oligonucleotides (silencer select and validated siRNA) were purchased from Life 
Technologies/Ambion (Table 2.1). Four h prior to transfection, A549 were plated at a 
confluency of 30%-40% (5x105 cells per 6cm dish). For transfection the appropriate siRNA 
was incubated in 200l of Opti-MEM medium, whilst 10l of transfection reagent, RNAiMax 
(Life Technologies) was incubated in a separate tube with 200l of Opti-MEM. After 5 min 
the siRNA and the RNAiMax solutions were mixed and incubated at room temperature for 30 
min to produce RNAiMax-siRNA complexes. Cells were then washed twice with Opti-MEM 
and incubated in 2.5ml of Opti-MEM. The RNAiMax-siRNA complexes were then added to 
the cells (siRNA final concentration, 30nM) and incubated at 37°C in humidified atmosphere 
containing 5% CO2, for 6 h. After incubation the transfection mix was removed, and the cells 
were incubated in fresh medium at 37°C in 5% (v/v) CO2.  48 h post-RNAi treatment 
adenovirus infection was performed.  
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2.1.7. Transient DNA transfection 
Target cells were grown to approximately 90% confluence on 6 cm dishes. The transfection 
mixture was prepared by adding 4 μg of plasmid DNA to 200μl of Opti-MEM and incubating 
for 5 min at room temperature. Similarly, 10μl of Lipofectamine 2000 was added to 200μl of 
Opti-MEM and left for 5 min. After this incubation time the plasmid DNA mixture and the 
transfection reagent were combined and mixed gently and incubated for 30 min at room 
temperature. Cells were then washed twice with Opti-MEM then incubated in 2.5ml of Opti-
MEM to which the plasmid DNA-Lipofectamine mix was added in a drop-wise manner. After 
6 h incubation at 37°C in 5% (v/v) CO2 the existing media was replaced with fresh DMEM 
supplemented with 8% (v/v) FCS and 2mM glutamine.  Cells were then incubated at 37°C, 
before being harvested at the appropriate times.   
 
2.1.8 Treatment of cells with Ultra-Violet irradiation or drugs 
Prior to ultra-violet (UV) irradiation, the existing medium was removed and stored in a sterile 
tube. Cells were then either mock-irradiated or irradiated at a dose of 25 J/m2 from a 254 nm 
UV light source, after which the culture medium was replaced. Where indicated, target cells 
were treated with a specific drug (Table 2.2). MLN-4924 is a cell-permeable NEDD8-
Activating Enzyme inhibitor used to inhibit Cullin Ring Ligase activation in vivo (Soucy, et al. 
2009). Salinosporsmide A is a non-competitive, cell-permeable inhibitor of the 26S proteasome 
(Feling, et al. 2003). Lactacystin is also a non-competitive, cell-permeable inhibitor of the 26S 
proteasome (Fenteany, et al. 1995). MG132 is a competitive, cell permeable inhibitor of the 
Target               siRNA Sequence                                                                  Supplier
Control (si Luciferase) 5’- CGUACGCGGAAUACUUCGAdTdT -3’ Ambion  
SPT16 5’- GGUUUGGGAUGGGAAUUGAdTdT -3’ Ambion 
SSRP1 5’- GGACUUAAACUGCUUACAAdTdT -3’ Ambion 
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26S proteasome (Sesta, et al. 2020). Hydroxyurea induces DNA replication stress by inhibiting 
ribonucleoside diphosphate reductase and depleting the cellular pool of dNTPs (Koç, et al. 
2004).  
 
Table2.2: Drugs used in the current study.  
 
2.2. Protein Biochemistry 
2.2.1. Preparation of whole cell lysates  
The existing medium was removed from the cells which were then washed twice with ice-cold 
PBS and then incubated with lysis buffer containing 9M urea, 50mM Tris-HCl (pH 7.4), and 
0.15M β-mercaptoethanol (UTB) at room temperature for 5 min. Then cells were detached 
using a cell scraper and transferred into a 1.5ml Eppendorf. Cell lysates were then sonicated 
for 20 sec (setting 4), using a Misonix microsin ultrasonic cell disruptor, to cleave DNA. 
Insoluble cell debris was precipitated by centrifugation at 15,000 rpm for 20 min at 4°C in a 
chilled centrifuge (Eppendorf) and then either stored at -80 °C prior to use or prepared for 
protein quantification. 
 
2.2.2. Protein concentration quantification 
The Bradford assay was used to determine the protein concentration of lysates (Bio-Rad).       
Bovine serum albumin (BSA) was used to generate a standard curve from 0-30 µg/ml. 
Typically, 4µl of whole cell lysate or known amounts of BSA were incubated with 1ml of 
Drug  Working concentration                 Supplier  
MLN-4924   3µM Cayman 
Salinosporsmide A ( Marizomib) 1µM Sigma-Aldrich 




Hydroxyurea (HU) 1mM ACROS 
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Bradford reagent (diluted 1 in 4 with dH20). The absorbance of the solution at a wavelength of 
595nm was determined using a Cecil CE9200 spectrophotometer. Protein concentrations were 
calculated from the BSA standard curve.    
 
2.2.3. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Typically, 50 µg protein samples were separated based on their relative molecular weight by 
SDS-PAGE. They were first incubated with an equal volume of sample buffer (6M Urea, 
33.3mM Tris pH 7.4, 3.33% (w/v) Sodium Dodecyl Sulphate (SDS) and 0.1% (w/v) 
Bromophenol Blue) and boiled at 95ºC for 5 min prior to their separation by SDS-PAGE using 
8% (w/v) or 10% (w/v) polyacrylamide gels (made from a 40% (w/v) acrylamide/Bis-
acrylamide (37.5:1) stock solution [Severn Biotech]), containing 0.1M Tris, 0.1M Bicine, 0.1% 
(w/v) SDS,  0.3% (v/v) TEMED and 0.06% (w/v) ammonium persulphate. Gels were run in 
the presence of running buffer (0.1M Tris, 0.1M Bicine and 0.1% (w/v) SDS) at constant 
amperes until the desired separation had been achieved.   
 
2.2.4. Western blotting  
After SDS-PAGE proteins were transferred onto Bio-Trace nitrocellulose membranes (PALL). 
According to the proteins being analysed membranes were cut to size and soaked in transfer 
buffer (24mM Tris, 193mM Glycine, 20% (v/v) methanol), The gel was then laid upon the top 
of pre-wetted nitrocellulose membrane and then sandwiched between two pieces of Whatman 
3MM blotting filter paper pre-soaked in transfer buffer and two blotting sponges, before being 
closed in a plastic cassette and placed into a Transfer tank filled with transfer buffer. 
Electrophoretic transfer was performed at 280 mA for 6 h, or 180 mA overnight at room 
temperature such that the protein was transferred on to the nitrocellulose membrane towards 
the anode. Following the transfer, and in order to block non-specific protein binding, 
nitrocellulose-immobilized proteins were incubated in Tris-buffered saline (TBST; 20mM 
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Tris-HCl pH 7.5, 150mM NaCl, 0.1% (v/v) Tween-80), containing either 5% (w/v) dried milk 
powder (Melford laboratories), or 2.5 % (w/v) BSA (Melford Laboratories) for 45 min 
depending on the antibody to be used. Membranes were then washed in TBST buffer then 
incubated with the appropriate primary antibody (Table 2.3), diluted in TBST-milk or TBST-
BSA overnight at 4°C with agitation on a rocker. The following day, the membranes were 
washed with TBST buffer for 15 min prior to incubation with the appropriate Horseradish 
Peroxidase (HRP) -conjugated secondary antibody (Dako) diluted in TBST-milk or TBST-
BSA for 3 h at room temperature (Table 2.4). Following incubation with the secondary 
antibody the membrane was washed three times in TBST for 15 min per wash. To visualize the 
protein of interest, the membranes were covered in enhanced chemiluminescent HRP substrate 
(ECL, MILLIPORE) reagents for 1 min and then exposed to Blue-Sensitive X-Ray film (Wolf 
laboratories) in the Dark Room for the appropriate time. X-ray films were then developed using 
a Compact X4 developer (X-ograph Imaging System).  Films were scanned and saved as TIFF 
files for editing with Adobe Photoshop and Figure preparation in PowerPoint. As ECL 
detection of proteins is at best a semi-quantitative method due to the quick ‘saturation’ of 
protein levels and the short linear range upon which most densitometric methods rely, for most 
purposes we did not measure protein levels densitometrically and relied on visual inspection 
of blots to recognise large changes in protein abundance. We do concede however, that this 
approach might not identify subtle changes in protein levels, and as such for validation of our 
results it would be prudent to use a LI-COR imaging system or a similar, more rigorous, 
quantitative ECL method for determination of protein levels. In situations where we stained 
proteins with coomassie we did utilise densitometric methods to quantify protein levels. 






        Table2.3: Antibodies used for Western blotting during this project.  
 
 




Antigen Antibody Dilution Blocking Species Supplier 
Ad12 E1A M13 1:2000 Milk Mouse In-house 
Ad12 E1B55K XPH9 1:3000 Milk Mouse In-house 
Ad5 E1A M73 1:2000 Milk Mouse Ed Harlow 
Ad5 E1B55K 2A6 1:2000 Milk Mouse Arnold Levine 
Ad5 E4orf3 6A11 1:100 Milk Mouse Thomas Dobner 
Ad5 E4orf6 RSA1 1:200 Milk Mouse Thomas Dobner 
Ad5 E2A B-8 1:200 Milk Mouse Thomas Dobner 
EPHA2 EPHA2 1:2000 Milk Mouse Abcam 
β-actin AC-74 1:50000 Milk Mouse Sigma-Aldrich 
p53 DO-1 1:20 Milk Mouse David Lane 
p53 FL-393 1:2000 Milk Rabbit Santa Cruz 
PURB PURB 1:1000 Milk Rabbit Proteintech 
SMARCAL1 H-124 1:10000 BSA Mouse Santa Cruz 
SPT16 H-300 1:2000 Milk Rabbit Santa Cruz 
SSRP1 D-7 1:2000 BSA Mouse Santa Cruz 
TOPBP1 611875 1:2000 Milk Mouse BD Biosciences 
TopIIα G-9 1:2000 Milk Mouse Santa Cruz 
TopIIβ A-12 1:2000 Milk Mouse Santa Cruz 
Flag-tag Anti-Flag M2 1:3000 Milk Mouse Sigma 
TIF1γ 197 1:3000 Milk Rabbit In-house 
HA-tag 12CAS 1:2000 Milk Mouse Sigma-Aldrich 
pRB RB1 1:500 Milk Mouse Fitzgerald Industries 
RPA32 Ab-2 1:2000 Milk      Mouse Calbiochem 
RBM14 69 1:10.000 BSA Rabbit Sigma-Aldrich 
Ku -70 E-5 1:2000 Milk Mouse Santa Cruz 
Ku-86 B-1 1:2000 Milk Mouse Santa Cruz 
Histone H3 Ab1791 1:50000 Milk Rabbit Abcam 
Histone H2A Ab18255 1:3000 Milk Rabbit Abcam 
GST Ab-1 1:2000 Milk Rabbit Oncogene 
GFP  B-2 1:2000 Milk Mouse   Santa Cruz 
Ubiquitin anti-Ubiquitin 1:2000 Milk Rabbit Cell Signalling 
Timeless anti-Tim 1:2000 Milk 
Rabbit 
(Yoshizawa-Sugata 
and Masai 2007) 
LAR 7/LAR 1:2000 Milk Mouse BD Biosciences 
Antibody                                                    Dilution      Supplier 
Polyclonal Goat anti-mouse immunoglobulins/HRP                                                            1:3000
 
Dako/Agilent (P0447) 
Polyclonal Goat anti-rabbit immunoglobulins/HRP       1:3000   Dako/Agilent (P0448) 
Goat anti-Rat IgG – H+L HRP Conjugated                 1:3000         Bethyl, A110-10 SP 




Cells for immunoprecipitation (IP) were washed twice with ice-cold PBS then solubilized in 1 
ml NETN buffer (1% (v/v) Nonidet P-40, 1mM Ethylene Diamine Tetra Acetic Acid (EDTA), 
50mM Tris–HCl (pH 7.5) and 150mM sodium chloride containing 25mM sodium fluoride and 
25mM β-glycerophosphate). Cell lysates were prepared using a Wheaton dounce homogenizer 
and tight pestle; cells were homogenized twice on ice, with 10 strokes each time. Homogenised 
cells were then centrifuged at 16000 rpm for 30 min at 4°C.  The supernatant was removed 
from cell debris and lipid layer using a Terumo® Agani™ needle (25G x 1”) and transferred 
to a fresh Eppendorf. Protein concentrations were determined by Bradford assay (section 2.2.2) 
and equal amounts of protein were used for each immunoprecipitation reaction. Typically 5µg 
of immunoprecipitating antibody or normal IgG control antibody was added to the supernatant 
and incubated overnight at 4°C with rotation. Immune complexes were then isolated from the 
mixture using 20μl packed of Protein G-Sepharose beads (Sigma-Aldrich) by incubation for an 
additional 3 h at 4 °C by rotation. Immunoprecipitated complexes were then washed five times 
in cold NETN buffer containing 250mM NaCl. After the last wash a needle (25G x 1”) was 
used to remove all of the buffer. Finally, beads were resuspended in SDS-PAGE sample buffer, 
boiled for 5 min at 95ºC and separated by SDS-PAGE using 50µg of whole cell lysates as 
indicators of protein input (section 2.2.3).   
2.2.6. Chromatin Isolation  
This procedure was performed as described (Wysocka, et al. 2001). Typically, existing media 
was discarded and cells washed twice with ice-cold PBS. Cells were then scraped in ice-cold 
PBS and precipitated by centrifuged at 1000 x g for 2 min at 4°C. Cell pellets were then 
incubated in buffer A for 8 min on ice (Table 2.5), after which pellets were subjected to 
centrifugation (1300 x g, 4°C, 5 min). The resulting supernatant was collected and centrifuged 
at 20,000 x g, 4°C, for 30 min to isolate the soluble, cytoplasmic fraction. The resulting pellet 




membrane. The nuclear lysate was then centrifuged at 1700 x g, 4°C for 15 min to isolate the 
Nucleoplasm Fraction (supernatant) and the Chromatin Fraction (pellet). Then to elute 
chromatin-binding proteins, the chromatin fraction (pellet) was washed with a 0.5M salt 
solution (Table 2.5) and centrifuged at 1700 x g, 4°C for 15 min to obtain the chromatin-
binding proteins (supernatant), whilst the pellet was resuspended in solubilisation buffer 
(Table 2.5) followed by sonication for 20 sec (setting 4), and centrifugation at 1700 x g, 4°C 
for 20 min to collect the Chromatin Fraction (supernatant). 
 
Table 2.5: Buffers Used in Chromatin Isolation  










HEPES (pH 7.9) 10 mM 
KCl 10 mM 
MgCl2 1.5 mM 
Sucrose 0.34 M 
Glycerol 10% (v/v) 
DTT 1 mM 





EDTA 3 mM 
EGTA 0.2 mM 
DTT 1 mM 
 
              Lysis Buffer (UTB)   
Urea 9 M 
Tris-HCl (pH 7.4) 50 mM 
β-mercaptoethanol 0.15 M 
                NaCl salt solution     NaCl 0.5M 
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2.2.7. Acid extraction of histones 
Cells were washed twice with warmed PBS then detached from the tissue culture plate by 
applying 1 ml of trypsin (Tryple E; Life Technologies). Following incubation for 5 min at 37°C 
in a humidified atmosphere containing 5% (v/v) CO2, medium containing 8% (v/v) FCS was 
added to the cells to inactivate the trypsin. The cells were then pelleted by centrifugation at 
1500 rpm for 5 min. The cell pellet containing approximately 1x107 cells/ml was then 
resuspended in 1 ml of ice-cold Triton Extraction Buffer (TEB; 0.5% (v/v) Triton X-100, 1 x 
PBS, 2mM PMSF) and incubated on ice for 10 min, after which the lysate was centrifuged at 
2000 rpm for 5 min at 4°C. The resulting cell pellet was resuspended in half of the original 
volume of TEB and re-centrifuged at 2000 rpm for 5 min at 4°C. The cell pellet was then 
resuspended in 0.4M HCl (25µl per 1x106 cells), then incubated on ice for a minimum of 3 h. 
The supernatant which contained the core histone proteins was collected by centrifugation at 
2000 rpm for 10 min at 4°C. Isolated histones were separated by SDS-PAGE then stained with 
Coomassie Blue. 
 
2.2.8. Purification of GST Fusion Proteins 
Full-length Ad12 and Ad5 E4orf6 were cloned into pGEX 4T-1 (GE healthcare) which contains 
an N-terminal Glutathione–S-Transferase (GST) tag and verified by DNA sequencing (section 
2.3.4). Ad5/12 E4orf6-pGEX 4T-1 constructs were then used to transform BL21 Codon plus 
(RIPL) competent cells (Agilent) and plated onto LB-agar plates containing 100g/ml 
ampicillin (section 2.3.1) for selection. Individually isolated bacterial colonies were grown in 
20ml LB, supplemented with 100ug/ml ampicillin and incubated in the orbital shaker at 220 
rpm overnight at 37ºC. The following day, the cultures were transferred to 500ml LB 
supplemented with 100ug/ml ampicillin and incubated in the orbital shaker at 250 rpm at 37ºC 
for approximately 3 h as the optical density at 600nm was approx. 0.5-0.6. The temperature of 
the orbital shaker was then reduced to 30ºC, 200rpm for 30 min. After that, GST fusion-protein 
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expression was induced by the addition of 0.5mM IPTG (Isopropyl-β-D-thio-galactoside; 
Sigma-Aldrich) and incubated for an additional 3 h at 30ºC, 200rpm. The cell pellet was then 
centrifuged at 5000 rpm for 10 min 4ºC and the supernatant discarded. The pellet was lysed 
and resuspended in 28ml of GST lysis buffer (1.0% Triton X-100, 1 x PBS, 1mM EDTA 
(pH=8.0). The bacterial lysate was then sonicated on ice (5Khz output) for 1 min, three times 
with 1 min break in between each cycle, and centrifuged for 15 min at 16,000rpm at 4ºC 
(twice). The supernatant was then collected and incubated with 1ml of packed glutathione 
agarose beads (Sigma-Aldrich), resuspended in GST lysis buffer overnight at 4ºC, by rotation 
at 12rpm. The beads were then centrifuged at 3000rpm for 2 min and washed with 50ml of 
GST lysis buffer twice and twice with 50ml of GST wash buffer (1 x PBS, 1mM EDTA 
(pH=8.0)). For elution the GST-bound beads were incubated with 2 ml of GSH elution buffer 
(25mM reduced glutathione in 50mM Tris, pH 8.0), and incubated at 4ºC, 12rpm for 2 h. The 
eluted GST proteins were then dialysed using dialysis tubing with 12,000-14,000 molecular 
weight cut-off, using 5L dialysis buffer (25mM Tris pH 7.4, 10% (v/v) glycerol, 0.15M sodium 
chloride and 1mM dithiothreitol (DTT) at 4ºC. The next day, the dialysis tubing was incubated 
in 2 changes of 2L of fresh dialysis buffer at 4ºC and left throughout the day. The protein 
concentration was then measured by Bradford assay and stored at -80 ºC until required.   
 
2.2.9. GST-pull downs   
Following the generation of GST-Ad12 E4orf6 and GST-Ad5 E4orf6, pull-down assays were 
performed by either: incubating 10µg of GST, GST-Ad12 Eorf6 or GST-Ad5 Eorf6 in the 
absence or presence 10g of core Histones (Histone from calf thymus type II A; Sigma) in 
50mM Tris pH 7.4, 0.15M NaCl at 4°C for 16 h by rotation; or by incubating 10µg of GST, 
GST-Ad12 Eorf6 or GST-Ad5 Eorf6 in the presence of 2mg of RPE-1 lysate prepared in NETN 
at 4°C for 16 h by rotation. Twenty l glutathione beads were then added to the GST-histone 
mixture and incubated for 3h at 4°C by rotation.  GST proteins and any associated histones 
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were then eluted from the glutathione beads by the addition of 30l of 25mM glutathione in 
50mM Tris pH 8.0 and incubated on ice for 1h with agitation every 5 min. The supernatant was 
then collected and SDS sample buffer were added and heated for 5min at 95°C. Eluted proteins 
were then subjected to SDS-PAGE (see section 2.2.3), transferred to nitrocellulose and stained 
with ponceau-S (0.1% ponceau-S in 3% (w/v) trichloroacetic acid) and washed extensively 
with dH2O to visualise precipitated proteins, particularly from the GST-pull down using 
purified histones. GST-pull downs from RPE-1 lysates were then subjected to WB analyses for 
Histones H2A and H3, as well as GST. 
 
2.2.10. GFP-pull down   
GFP-U2OS and GFP-RPA1-U2OS cells were grown on 10 cm dishes. Cells were washed twice 
with cold PBS, solubilised with 1 ml NETN and homogenized using a Wheaton dounce 
homogenizer using a tight pestle, twice on ice, with 10 strokes each time. Homogenised cells 
were then centrifuged at 16000 rpm for 30 min at 4°C and protein concentrations determined 
by Bradford assay. 20 µl GFP-sepharose beads (GFP Trap- ChromoTek) were added to each 
sample and incubated for 3 h at 4°C with rotation. GFP Trap beads were washed five times in 
cold NETN containing 250 mM NaCl. The beads were then resuspended in SDS sample buffer, 
boiled for 5 min at 95ºC and separated by SDS-PAGE (section 2.2.3). 
 
2.2.11. Coomassie staining of polyacrylamide gels  
Polyacrylamide gels were stained at room temperature overnight in colloidal coomassie 
solution (0.08% (v/v) Coomassie Brilliant Blue G250 (Fisher Scientific), 1.6% (v/v) 
orthophosphoric acid (Fisher Scientific), 8% (w/v) Ammonium Sulphate (Sigma-Aldrich) and 




2.2.12. FASP (Filter-Aided Sample Preparation) tryptic digestion of nuclear lysates   
Cells were trypsinized and pelleted at 1,000g, 4°C for 5 min.  Cells were then washed with cold 
PBS (x2) and pelleted. The pellets were then resuspended in 5ml of ice-cold hypotonic buffer 
(10mM HEPES pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.5mM DTT) and allowed to swell on ice 
for 5 min. To disrupt the plasma membrane and obtain intact, pure nuclei, cells were subjected 
to Dounce homogenization using 20 strokes with a tight pestle on ice. Intact nuclei were 
visualised using an inverted phase-contrast microscope (Nikon eclipse TS100) and pelleted at 
1,000g, 4°C for 5min. Nuclei were washed twice more in hypotonic buffer and collected by 
centrifugation. Nuclei were then solubilised in 9M Urea and 100mM Tetraethylammonium 
bromide (TEAB; Sigma), then normalized by protein concentration. Cysteine residues were 
then reduced following incubation with 50mM DTT (in 10% (v/v) acetonitrile and 100mM 
TEAB) for 1h at 55°C and then carboxymethylated following the incubation with 100mM 
iodoacetamide, 10% (v/v) acetonitrile and 100mM TEAB, for 30 min in the dark. Denatured 
lysates were then filtered through a 0.5ml Amicon 92 Ultra 10 kDa centrifugal filter 
(Millipore), washed five times with 100mM TEAB and subjected to digestion with Sequence-
Grade Modified Trypsin (Promega) in 100mM TEAB at 37°C for 16 h. The peptides were then 
centrifuged and the filtrate collected. The filter was then washed twice with 100mM TEAB to 
obtain tryptic peptides.   
 
2.2.13. Dimethyl-labelling of tryptic peptides obtained from nuclear lysates  
To measure quantitatively the effect of Ad12 E4orf6 expression on the cellular proteome 
nuclear lysates from Ad12 E4orf6 U2OS cells (+/- 0.1g/ml Dox) were isolated 24h post-
treatment. Tryptic peptides were then isolated by FASP as described above (section 2.2.12). 
Following their isolation tryptic peptides from the nuclear lysates of U2OS cells that were 
induced to express Ad12E4orf6 were incubated with 1/10th volume 10.73% (w/v) heavy 
formaldehyde ([2H]-CH2O); Isotec) and those from non-induced cells were incubated with 
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1/10th volume 10.73% (w/v) light formaldehyde (CH2O; Sigma), both for 1 min with constant 
mixing. The sample was then centrifuged, and 1/10th volume 1.5M sodium cyanoborohydride 
was added for 30sec with constant mixing, followed by centrifugation and incubation for 1h 
on a shaker at 600rpm. To quench the reaction 1/10th volume 10.73% (w/v) sodium hydroxide 
and 1/10th volume Formic acid were added. Equimolar heavy and light peptides were then 
mixed and purified through a 2.1×150 mm Acclaim Mixed-Mode WAX-1 C18 reverse-
phase/anion exchange chromatography column (using a Dionex HPLC (high performance 
liquid chromatography) system, Camberley, UK) into 20 fractions using a gradient of 0–40% 
B over 40 min (A: 20mM ammonium formate pH 6.5, 3% (v/v) acetonitrile, B: 2mM 
ammonium formate pH 3.0, 80% (v/v) acetonitrile) at a flow rate of 250μl/min. Isolated 
fractions were dried by vacuum centrifugation until required for mass spectrometry.  
 
2.2.14. Mass spectrometric analysis of tryptic peptides 
Dried tryptic peptide mixtures isolated above that had been labelled with both heavy and light 
formaldehyde were resuspended in 20μl 1% (v/v) acetonitrile/1% (v/v) formic acid, of which 
10μl was analysed by LC-MS/MS using a 90 min 0–40% acetonitrile gradient in 0.1% formic 
acid (75 μm × 50 cm C18 Pepmap column, Dionex) and an Impact TOF mass spectrometer 
(Bruker Daltonics, Bremen, Germany). Peptides were identified using MASCOT 2.3 to search 
SWISSPROT (human and randomised version thereof).  Mass tolerances for parent and 
fragment ions were 20 p.p.m. and 0.05 Da, respectively and the minimum peptide Mowse score 
was 20. Modifications considered were carboxymethylation (fixed) and methionine oxidation 
(+/-). Quantitation of LC-MS ms/ms data from identified peptides was performed using 
WARP-LC (Bruker) and ProteinScape 2.1 (Bruker Daltonics), whereupon the ratios of Heavy 
to Light peptides were calculated to give a quantitative readout of the effect of Ad12 E4orf6 
expression on the absolute levels of nuclear proteins from U2OS cells. Protein identifications 
were filtered using both a 1% false discovery threshold and a requirement for two or more 
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peptides. All MS and HPLC solutions were made up in HPLC (High-Performance Liquid 
Chromatography)-grade H2O (Chromanorm, VWR). 
2.3. Molecular and Cell Biology  
2.3.1. Preparation of media for growth of bacteria    
Luria broth (LB) was made with 1.0% (w/v) Bacto-tryptone (Difco), 0.5% (w/v) Bacto-yeast 
extract (Difco) and 1.0% (w/v) sodium chloride (pH 7.2) in de-ionized water. LB-agar was 
made by the addition of Bacto-agar (Difco) to LB to a final concentration of 1.5% (w/v). LB 
and LB-agar were then sterilized by autoclaving at 121°C and 15 psi for 30 min. Prior to use, 
LB-agar was melted then incubated at about 50°C before the appropriate antibiotic was added 
to the solution and the medium was poured onto sterile petri dishes. Finally, LB-agar plates 
were left to cool and set inside a fume hood prior to storage at 4°C.  
 
2.3.2. Transformation of Bacteria 
Introduction of exogenous genetic plasmid material to competent bacteria is known as 
transformation. Plasmid DNA containing the gene of interest was introduced to competent 
bacteria typically for isolation of appropriate clones, clone amplification and purification of 
plasmid DNA (section 2.3.3), or protein expression (section 2.2.9). Prior to transformation, 
competent bacteria were allowed to thaw on ice after taking them from -80ºC storage (Table 
2.6). After thawing was complete, 100ng of plasmid DNA was mixed with 20μl of bacteria and 
incubated on ice for 30 min to allow for plasmid DNA to associate with the bacterial cell 
membrane. Following this incubation plasmid/bacteria mixtures are heat-shocked at 42°C for 
1 min to allow plasmid DNA to enter the bacteria, after which mixtures are placed back on ice 
for 5 min. Transformed bacteria were then incubated in 400 µl of SOC outgrowth medium 
(NEB) for 1h in an orbital shaker at 37°C and 200rpm.  Bacterial cultures were then spread 
with a disposable hockey spreader onto LB agar plates in the presence of 100µg/ml ampicillin, 
or 50µg/ml of kanamycin, according to the antibiotic resistance gene in the plasmid. Plates 
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were then dried, inverted and incubated at 37ºC for 16h to allow for antibiotic-resistant clones 
to grow. Individual colonies were picked and dispersed in 5ml LB broth containing antibiotic 
and incubated at 37ºC overnight with agitation. For long term storage, 500µl of a mixture of 
50% (v/v) sterile glycerol and 500 µl bacterial suspension were mixed together and frozen at -
80ºC. 







2.3.3. Mini-prep and Maxi-prep plasmid DNA purification  
Plasmid DNA was purified using a technique based on the alkaline-SDS lysis method which 
was first developed and described by Birnboim and Doly in 1979. The lysis solution utilized 
contains SDS, which disrupts the bacterial cell membrane and denatures the majority of the 
cellular proteins. It also contains sodium hydroxide which breaks the hydrogen bonds between 
the DNA bases to generate single-stranded plasmid and genomic DNA. Neutralising the 
alkalinity of the mixture by the addition of potassium acetate selectively renatures the small 
plasmid DNA to its double-stranded soluble form. However, the large genomic DNA and other 
lysed proteins on treatment, is precipitated as insoluble clots which are separated from the 
plasmid DNA solution by centrifugation. We have used this method for both small-scale 
purification (miniprep) of plasmid DNA, as initial screens for positive bacterial clones, and 
large-scale purification (maxiprep) of plasmid DNA to purify high yield of DNA be used for 
downstream applications such as transfection.      
Bacteria                                     Supplier  
DH5α subcloning efficiency                     Life Technologies 
 
 
                    
               
                  




   
 
Max Efficiency Stab2                              Invitrogen 
           
 
BL21-CodonPlus (DE3)-RIPL             Stratagene 
NEB Stable (C30401) High Efficiency   NEB  
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For minipreps, single colonies were incubated overnight in 5ml of LB supplemented with the 
appropriate antibiotic, from which plasmid DNA was purified by using the GenElute™ 
Plasmid Miniprep Kit (Sigma-Aldrich). As stated in the kit instructions, bacterial cells were 
pelleted by centrifugation at 6000 rpm for 5 min then resuspended in 200µl of pre-chilled 
resuspension buffer. Then, 200µl of the lysis solution was added, mixed by gentle inversion 
and incubated for 5 min. After this time 350µl of the neutralisation solution was added to 
terminate the lysis reaction. The samples were then centrifuged at 13000 rpm for 10 min to 
separate the insoluble precipitate from the solution. The clear solution was transferred to a 
silica column and centrifuged again for 1 min. The flow through was discarded and 750µl of 
wash solution was added to remove any contaminants. The plasmid DNA was eluted by adding 
50µl of nuclease-free water (Ambion),and followed by Sanger sequencing step to identify 
positive clones (section 2.3.4).           
For large scale plasmid purification, a positive clone was incubated with 5 ml LB supplemented 
with the appropriate antibiotic and incubated for between 6 and 8 h in an orbital shaker shaking 
at 200 rpm at 37°C. The bacterial culture was transferred to a flask containing 200ml LB 
supplemented with antibiotic. The bacterial culture was then incubated overnight at 37 °C with 
shaking at 200 rpm. In line with the Plasmid Maxi kit (NucleoBond® Xtra Maxi, 
MACHEREY-NAGEL) instructions, the bacterial culture was pelleted by centrifugation at 
5000 rpm for 10 min at 4°C and then resuspended in 12ml of resuspension buffer. The cells 
were then lysed in 12ml of lysis buffer which changed the colour of the solution to blue due to 
the presence of Lyseblue reagent. The solution was mixed gently for approximately 5 min until 
the blue colour was evenly distributed. Next 12 ml of neutralisation buffer was added to the 
samples and mixed until the blue indicator disappeared. The mixture was then transferred to a 
DNA-binding column that had been pre-washed with 25 ml of binding buffer and allowed to 
flow through by gravity. After that, 15 ml of binding buffer was added to the binding column 
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followed by 2 x 15ml wash buffer. The plasmid DNA was then eluted by adding 15ml elution 
buffer, which was precipitated by the addition of 10.5ml isopropanol and pelleted by 
centrifugation at 15.000 rpm at 4°C for 30 min. The supernatant was then decanted carefully, 
and the pellet washed twice with 70% (v/v) ethanol to remove salts. The DNA samples were 
then air- dried by leaving them with lid open in the hood for 10 min then, depending on the 
size of the pellet, resuspended in 50-400μl of nuclease-free water and left for 10 min to 
rehydrate. To assess the plasmid quantity and purity, the concentration was determined by the 
NanoDrop and the 260nm/280nm absorbance ratios measured had to be within the acceptable 
range to allow the use of samples in future applications. Typically, purified DNA had a 260/280 
ratio of approximately 1.8. 
 
2.3.4. Sanger DNA Sequencing  
The sequence reaction was performed in a total volume of 20μl using 200ng of plasmid DNA 
template, 10ng/μl of  sequencing primer (Table 2.7), 1μl Big Dye™ terminator V3.1 (Thermo 
Fisher), 4μl of 5 x sequencing buffer and 9μl of nuclease-free water. The sequencing reaction 
was performed by PCR using the following conditions: 96°C for 10 sec, 50°C for 5 sec, and 
60°C for 4 min, for 25 thermal-cycles. After PCR the plasmid DNA was precipitated upon the 
addition of 80μl of a mixture of 63.5μl 100% (v/v) ethanol, 3μl 3M sodium acetate and 14μl 
nuclease-free water. The solutions were incubated at room temperature for 30 min and DNA 
pelleted by centrifugation at 13000 rpm for 20 min. The supernatant was removed and the DNA 
pellet washed with 2 x 100μl 70% (v/v) ethanol. After a final centrifugation step for (13000 
rpm for 15 min) the supernatant was discarded and the pellet was air dried at 90°C for 1 minute. 
The samples were resuspended in 11 μl Hi-Di, heated for 5 min at 95°C, quickly quenched on 
ice, and briefly centrifuged before loading for analysis by a  3500xl Genetic Analyzer (Applied 
Biosystems) for sequencing. The sequence results were uploaded into Chromas and were 
analysed utilizing the NCBI BLAST program obtained online at http://www.ncbi/nlm/nih.org 
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2.3.5. PCR  
PCR was performed in a total volume of 50μl with 10μl of 5x reaction buffer, 500nM of 
forward and reverse primers (Table 2.8; restriction sites shown in red), 10-50ng of DNA 
template, 200μM dNTP mix, 1 Unit of HotStart Q5 Polymerase (New England BioLabs), made 
up to 50μl by the addition of nuclease-free water. PCR was performed using a 2720 Thermal 
cycler PCR machine (Applied Biosystems) using the following protocol: 98°C -30 sec, 24-35 
cycles at 98°C for 10 sec, 50-72°C for 30 sec, 72°C for 30 sec per kb; final extension at 72°C 
for 2 min. The DNA products obtained were separated by agarose gel electrophoresis and 
purified using a Qiagen gel extraction kit (section 2.3.6).  
                Gene       Forward Primer sequence 
 
Ad12 E1B55K Seq1  
 
5'AACTGTATATTGGCAGGAGTTGCAG-3'    
 
 
Ad12 E1B55K Seq2   
       
5'- AATACCTGTTCTTGTCTTGCATGGT-3'                                                  
                                             
 
Ad12 E1B55K Seq3   
 
 5'- ATAACATGTTTATGCGCTGTACCAT-3'  
 
 
Ad5 E1B55K Seq1 
                               
5'-GGCTACAGAGGAGGCTAGGAATCTC-3'                                                              
 
 
Ad5 E1B55K Seq2 
 
5'-CCTGGCCAATACCAACCTTATCCT-3'                                                              
 
 
Ad5 E1B55K Seq3   
 
5'-TGCTGACCTGCTCGGACGGCAACT-3'                                                              
 
pcDNA5 Seq Forward 
 
5'-CGCAAATGGGCGGTAGGCGTG-3'                                                              
 
pcDNA Seq Reverse 
 












Table 2.8: Primers used for cloning.  
 
2.3.6. Agarose gel electrophoresis  
Gel electrophoresis was performed using 0.8% (w/v) agarose (electrostatic grade, Life science) 
dissolved in 60ml of Tris-Borate-EDTA buffer (TBE; 100mM Tris, 100mM boric acid, 2mM 
EDTA pH 8.3). 1μl of 10mg/ml ethidium bromide (Sigma-Aldrich), or 1.5μl of SyberSafe (Life 
Technologies) was added prior to pouring to visualise DNA. PCR products were mixed 6 x 
loading buffer (30% v/v glycerol, 0.25% w/v bromophenol blue and 0.25% w/v xylene cyanol 
FF) before being loaded onto the gel. A 1kb ladder (Life Technologies) was used to monitor 
DNA size. Gels were run at a constant voltage of 60V in 1 x TBE for the required time. When 
SyberSafe was used the DNA bands were visualized when exposed to blue light (Safe Imager- 
Invitrogen) and then extracted by the Qiagen QIAquick gel extraction kit (Qiagen). As such, 
the gel was solubilised in 600l of QG buffer at 55°C for 10 min, after which, 200l of 
isopropanol was added to the solution. After mixing the solution was transferred to a QIAquick 
column and centrifuged for 1min at 13000 rpm. The flow through was discarded and the 
column was washed with 500l of QG buffer followed by another round of centrifugation as 
detailed above. The column was then washed with PE buffer and dried by two rounds of 









































centrifugation. The DNA was eluted into a clean tube by centrifugation at 13000 rpm for 5 min 
with 50l of nuclease-free water. When ethidium bromide was used to stain agarose gels DNA 
bands were observed under ultraviolet light (Gene Flash; Syngene Bioimaging). 
    
2.3.7. DNA cloning  
In order to subclone the gene of interest amplified by PCR into the cloning vector, both plasmid 
DNA and the gene of interest were digested by incubating them with the appropriate restriction 
enzymes (NEB) according to the manufacturer’s instructions. Digested DNA was then purified 
by electrophoresis as described above (section 2.3.6). After extraction and purification of DNA, 
plasmid DNA and insert DNA were ligated at molar ratios of between 1:5 and 1:10. Ligation 
reactions were performed in a final volume of 30μl using 3µl 10 x ligation buffer (NEB) and 
1µl T7 DNA ligase (NEB)  Ligation mixtures were then incubated in the cold room in a water 
bath at 16°C overnight. The reaction was stopped by heating the sample at 65°C for 15 min. 
Ligation mixtures were then used for the transformation of competent bacteria as described in 
section 2.3.2 to identify positive clones by sequencing (section 2.3.4).    
 
2.3.8. Site-directed mutagenesis  
Site-directed mutagenesis (SDM) was used to introduce specific DNA mutations into the gene 
of interest using the Q5 Site-Directed Mutagenesis Kit (NEB). The first step of the SDM 
procedure was to amplify the gene by PCR to incorporate the appropriate mutation. This was 
achieved using the following protocol (98°C 30sec; 98°C for 10sec, 65°C for 15sec, 72 °C for 
4 min- 25 thermal cycles; final extension 72°C for 2 min).  Following the PCR reaction, 1µl of 
the PCR product was incubated in a KLD reaction mixture containing KLD reaction buffer, 
KLD enzyme mix (Kinase, Ligase and DpnI enzymes; NEB) and nuclease-free water, which 
was incubated for 5 min at room temperature. After this time the KLD mixture was then 
incubated the appropriate bacterial strain for transformation (section 2.3.2), mini-prep 
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purification (section 2.3.3) and DNA sequencing for validation (section 2.3.4). 
Oligonucleotides used were designed using the NEBaseChanger tool and obtained from Sigma-
Aldrich (Table 2.9; mutated residues shown in red).  
Table 2.9: Mutagenic primers used in this study.                                                            
 
2.3.9. Immunofluorescence 
Cells were grown on glass, 12-well multispot microscope glass slides (Hendley-Essex) at 
densities of 2 x 104 cells/well. Following the appropriate treatment (e.g. viral infection of A549 
cells or Dox-induction of FRT-U2OS cells) slides were washed twice in warmed PBS followed 
by fixation for 8 min in 4% (w/v) paraformaldehyde in PBS. Cells were then permeabilized in 
ice-cold acetone for 10 min. Cells were then blocked in HINGS buffer (20% v/v HINGS (heat 
inactivated normal goat serum), 0.2% w/v BSA in PBS) for 45 min at room temperature. After 
a further wash in PBS, cells were incubated with the appropriate primary antibody diluted in 
HINGS buffer and incubated at 37°C for 2 h. After this time cells were washed twice in PBS 
for 15 min each before being incubated with the appropriate fluorescent secondary antibody 
(either α-mouse Alexa Fluor 488 or 594 and/or α-rabbit Alexa Fluor 488 or 594, Life 
Technologies) diluted in HINGS buffer and incubated at 37°C for 2 h. Cells were washed again 
three times in PBS and mounted in Vectashield mounting medium (Vector Laboratories) 
containing 4’,6-diamidino-2-phenylindole (DAPI), and protected with 20-70 mm glass 
coverslips (Menzel-Gläser). Immunofluorescent staining of cells was viewed using a Nikon Y-
FL epi-fluorescence microscope or a Zeiss LSM780 confocal microscope. TIFF images were 
Mutagenic   Primers                  Forward primers     
                                                             
           Reverse  primer                    
 
Ad5 E4orf6  KR1 
 
 
 5- AATCCTGAGGAGGTGTATGCACG-3 
 
 
5-ACAAGCTCCTCCCGCGTT-3                                                                                            
 
 
Ad5 E4orf6 KR2 
 
 
5- AACATGCCAAAGGGAGGTAATGTTATG-3                                                                                                                                                 
 
 




generated following data acquisition using either NIS-Elements or Zen software, and edited 
using Adobe Photoshop. 
 
2.3.10. Metaphase spreads 
Cells were treated with 0.2 μg/ml colcemid (Sigma) for 4 hr prior to harvesting by 
trypsinisation. Cells were then subjected to hypotonic shock by incubation in hypotonic 
solution (10.7 mM KCl, 14.3% (v/v) foetal calf serum) for 20 min at 37°C. Cells were then 
fixed three times in a methanol: acetic acid (3:1 (v/v)) solution. Fixed cells were dropped onto 
acetic acid cleaned microscope slides, stained for 15 min in Giemsa-modified (Sigma) solution 
(5% v/v in H2O) and washed twice in H2O for 5 min to remove residual stain. Metaphases were 
viewed under a Zeiss Axioscop light-microscope at 100x magnification and images captured 
using Axiovision software. The number of chromatid breaks, gaps and exchanges from at least 








































Generation and  characterization of TET-
inducible U2OS cell lines to investigate  
the function of adenovirus  




3.1. Introduction  
Adenovirus early region proteins have been studied at the molecular level since the discovery 
that Ad12 induces tumours in new-born hamsters and Ad2/5 and Ad12 promote the 
transformation of both human cells and rodent cells in tissue culture (reviewed by Gallimore 
and Turnell, 2001). Indeed, the generation of Ad2/5 and Ad12 mutant viruses and the use of 
mammalian expression plasmids has established that early region proteins are essential for both 
viral replication and cellular transformation. The role of the adenovirus E1A proteins are very 
well understood, during infection E1A serves to activate early region gene expression and 
promote entry into S-phase, the latter process being important in E1A’s ability to promote 
cellular transformation (see Introduction, section 1.2.1). E1B-19K serves to inhibit premature 
cellular apoptosis during infection, a function which similarly facilitates cellular 
transformation (see Introduction, section 1.2.2). E1B-55K, E4orf3 and E4orf6 cooperate to 
regulate host-cell shut-off during infection by inhibiting host cell mRNA transport and 
translation and inactivating antiviral pathways activated in the host cell (see Introduction, 
sections 1.2.2, 1.2.4.1 and 1.2.4.2). One such host cell response that is activated during 
infection in response to the synthesis of linear dsDNA that resemble cellular DNA breaks is 
the DDR (see Introduction, sections 1.4.1, 1.4.2, 1.4.3, and 1.4.4).  In this regard, E1B-55K, 
E4orf3 and E4orf6 engage with the cellular UPS to inactivate DDR pathways during infection 
to inhibit cell cycle checkpoint control and cellular apoptosis. As such E1B-55K-E4orf6 
complexes utilize cellular CRL ubiquitin ligases during infection (Querido, et al. 2001; Harada, 
et al. 2002). E1B-55K also forms complexes with E4orf3 during infection, as does E4orf6 but 
the significance of these interactions is largely unknown. The inactivation of DDR pathways 
by E1B-55K, E4orf3 and E4orf6 is key in their ability to promote cellular transformation 
(Nevels, et al. 2001). The individual and combined functions of E1B-55K, E4orf3 and E4orf6 
have been studied in both adenovirus-infected and adenovirus-transformed cells. For instance, 
Ad5 E1B-55K associates with p53 in cellular structures known as aggresomes and inactivates 
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its transcriptional activities (Zantema, et al. 1985). Ad12 E1B-55K also inhibits p53 
transactivation, though it binds less avidly to p53 than Ad5 E1B-55K and does not localise to 
aggresomes but resides both in the nucleus and cytoplasmic flecks; Ad12 E1B-55K associates 
with p53 in the nucleus (Liu, et al. 2000). Moreover, Ad5 E1B-55K is a SUMO E3 ligase that 
can self-SUMOylate or SUMOylate p53, which is required for maximal p53 inhibition; Ad12 
E1B-55K does not possess these activities (Muller and Dobner, 2008). Interestingly, mutant 
virus, mammalian expression plasmid, and adenovirus vector expression studies have indicated 
that Ad5 E1B-55K has other cellular activities that do not require E4orf3 and/or E4orf6. As 
such, Ad5 E1B-55K induces the degradation of the death-associated protein, Daxx by engaging 
with the cellular CRL5 ubiquitin-ligase (Schreiner, et al. 2010).  
Similarly, adenovirus E4orf3 also possesses individual activities during infection that do not 
require E1B-55K and/or E4orf6. Indeed, it has been shown that Ad5 E4orf3 disrupts both ATM 
and ATR pathways by causing the misslocalization of DDR protein, MRE11 into PML 
(promyelocytic leukemia protein)-containing nuclear track-like structures in Ad5-infected cells 
(Araujo, et al. 2005; Vink, et al. 2015), whilst Ad12 E4orf3 lacks this ability (Carson, et al. 
2009). Data from our laboratory has determined that the transcriptional repressor, TIF1γ is 
recruited to nuclear tracks by both Ad5 and Ad12 E4orf3 during infection, prior to its 
degradation by the UPS (Forrester, et al. 2012). Later, Ad5 E4orf3 was, (like Ad5 E1B-55K) 
determined to be a SUMO E3 ligase, which promoted the SUMOylation of TIF1γ and 
subsequent SUMO-targeted ubiquitylation and degradation of TIF1γ (Sohn and Hearing, 
2016). E4orf3 also functions independently to inhibit p53 transcriptional activity by silencing 
epigenetically the activation of p53 responsive promoters (Soria, et al. 2010). 
 
Like E1B-55K, Ad5 E4orf6 blocks p53 transcriptional activity through its ability to associate 
directly with the C-terminal regulatory domain of p53 (Dobner, et al. 1996). Interestingly, work 
82 
 
from our laboratory has determined that Ad12 E4orf6, but not Ad5 E4orf6, is required to inhibit 
ATR activation by associating with, and stimulating the CRL2 ubiquitin ligase-dependent 
degradation of the ATR activator, TopBP1 during infection (Blackford, et al. 2010).  
 
To date, the study of E1B-55K, E4orf3 and E4orf6 function has been instrumental in 
establishing the molecular basis of viral replication and cellular transformation. Based on the 
work described above and that detailed in the introduction it is clear however, that, not only do 
these proteins have the capacity to function independently of one another but that these proteins 
utilize multiple strategies to achieve the same goal e.g. the inactivation of p53 activity through 
direct association, mislocalization of the p53 protein or epigenetic silencing (see introduction 
for more detail). Moreover, it is also clear that early region protein activities are not always 
conserved between different adenovirus types e.g. the mislocalization of p53 to aggresomes, 
or the degradation of TopBP1. Most studies in this area, however, tend to focus on the function 
of the Ad5 E1B-55K, E4orf3 and E4orf6 proteins and not the Ad12 equivalent proteins, such 
that we understand much less about the function of the Ad12 E1B-55K, E4orf3 and E4orf6 
proteins. Given that the focus of my thesis is to further our understanding of how Ad5, and 
particularly, Ad12 E1B-55K, E4orf3 and E4orf6 proteins function at the molecular level in the 
host cell, in isolation, we reasoned that it would be extremely valuable to make a library of 
TET-inducible cell lines that expressed individually either Ad5 or Ad12 E1B-55K, E4orf3 or 
E4orf6 proteins, that we could use to study their cellular activities in the absence of other viral 
proteins, or virus particles that is not achievable using mutant adenoviruses or adenovirus 
vectors. We reasoned that this approach would also allow us to study the function of these 
proteins at consistent levels in whole populations of cells that is not achievable by transient 
transfection. This chapter describes the generation and characterization of such TET-inducible 
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FRT-U2OS cell lines that express either Ad5 or Ad12 E1B-55K, E4orf3 or E4orf6 proteins, in 
isolation. 
3.2. Results 
3.2.1. Use of the Flp-In T-Rex System to generate U2OS-FRT-inducible cell lines 
In order to study the function of adenovirus early region proteins in isolation and in a systematic 
manner we decided to use the Flp-In T-Rex system developed by Invitrogen. In this system the 
gene of interest is cloned into the pcDNA5/FRT/TO plasmid whose expression is under the 
control of a tetracycline operator. This plasmid is then transfected along with another plasmid 
expressing a Flp recombinase gene (pOG44) into a cell line (U2OS) that expresses a 
tetracycline repressor for TET-responsive expression and possesses an engineered, single 
recombination site in its genome to allow for the gene of interest to be inserted in the cell 
genome. Therefore, to understand the complex relationship between adenovirus early region 
proteins and cellular signalling pathways that enhance or repress viral replication we generated 
Flp-In T-Rex U2OS-FRT- cell lines that express either Ad5 or Ad12 E1B-55K, E4orf3 and 
E4orf6 oncoproteins individually.  
3.2.2. Generation of Ad5 and Ad12 E1B-55K Flp-In T-Rex U2OS-FRT-inducible cell 
lines 
To generate Ad5 and Ad12 E1B-55K Flp-In T-Rex U2OS-FRT-inducible cell lines we 
synthesized w.t. Ad5 and Ad12 E1B-55K genes with appropriate restriction sites by PCR 
(section 2.3.5) and cloned them into the pcDNA5- FRT TO vector (see section 2.1.5). After 
transformation of bacteria and mini-preparation of plasmid DNA we performed DNA 
sequencing and used Chromas and the NCBI BLAST program to validate the sequence 
integrity of the clones isolated (sections 2.3.2- 2.3.4). Sequencing revealed that we had 
successfully isolated w.t. Ad5 and Ad12 E1B-55K pcDNA5-FRT TO clones that possessed a 
BamHI site prior to the ATG and XhoI site after the stop codon [Fig.3.1 A, B, C, and D 
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respectively]. Sequencing also revealed that the entire genes were w.t. and in-frame (data not 
shown). 
   
 
Figure 3.1: Chromatograms demonstrating sequence integrity of Ad5 and A12 E1B-55K 
pcDNA5-FRT TO clones at 5’ and 3’ ends. (A) Illustrates the 5` end of the Ad5 sequence 
showing the BamHI cloning site and the start codon (ATG); (B) Illustrates the 3` end of the 
Ad5 sequence showing the stop codon (TGA) and the XhoI cloning site. (C) Illustrates the 5` 
end of the Ad12 sequence showing the BamHI cloning site and the start codon (ATG); (D) 
Illustrates the 3` end of the Ad12 sequence showing the stop codon (TGA) and the XhoI cloning 
site. 
Ad5 E1B-55K Ad5 E1B-55K 
Ad12 E1B-55K Ad12 E1B-55K 





3.2.2.1. Generation and characterization of Ad5 E1B-55K and Ad12 E1B-55K Flp-In T-
Rex U2OS inducible cell lines  
Once we had verified the validity of our Ad5 and Ad12 E1B-55K pcDNA5-FRT TO clones, 
we next generated the Ad5/12 E1B-55K TET-inducible U2OS cell lines, as described [see 
Materials and Methods, section 2.1.5]. To test for Ad5 E1B-55K expression cells were induced 
to express the viral gene by the addition of Doxycycline, harvested 24 h post-induction and 
then subjected to SDS-PAGE and Western blot [WB] analysis. WB analysis revealed that the 
Ad5 E1B-55K was expressed in a Dox-dependent manner in most of the cell lines isolated but 
that some of the cell lines also expressed varying levels of Ad5 E1B-55K in control cells not 
treated with Dox [panel ii, Fig. 3.2 Ai, Aii]. Consistent with previous studies, higher molecular 
forms of Ad5 E1B-55K were detectable, which have previously been identified as 
SUMOylated Ad5 E1B-55K [panel ii, Fig. 3.2 Ai, Aii; (Endter, et al. 2001)]. It has also been 
reported previously that Ad5 E1B-55K expression increases p53 protein levels through the 
inactivation of Mdm2 and protein stabilization (Li, et al. 2011). As such that there was also an 
increase in the levels of p53 in response to Ad5 E1B-55K expression in most of the cell lines 
tested [panel i, Fig. 3.2 Ai, Aii]. 
Ad12 E1B-55K cells were similarly harvested 24 h post-induction and subjected to SDS-PAGE 
and WB analysis, which revealed that the Ad12 E1B-55K was also expressed in a Dox-
dependent manner in most of the cell lines tested [panel ii, Fig. 3.2 Bi, Bii]. Consistent with 
previous studies that determined that Ad12 E1B-55K was not modified by SUMOylation there 
were no modified forms of Ad12 E1B-55K detected by WB [panel ii, Fig. 3.2 Bi, Bii, Biii; 
(Endter, et al. 2001)]. Like the Ad5 E1B-55K cell lines, the induction of Ad12 E1B-55K often 
resulted in the expected stabilization of p53 [panel i, Fig. 3.2 Bi, Bii, Biii; (Li, et al. 2011)]. 
Taken together, these data indicate that we have successfully generated Flp-In T-Rex U2OS 
cell lines that express E1B-55K in a Dox-dependent manner. Given these results, it was 
important to investigate the function of E1B-55K in these cell lines in more detail to determine 
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whether they are a useful cell model to study E1B-55K function. To this end, we chose a few 
different cell lines from both Ad5 and Ad12 that showed good induction of E1B-55K in the 
presence of Dox, and E1B-55K induced p53 stabilization to study E1B-55K function in more 
detail. For simplicity, in the experiments shown results are presented from Ad5 E1B-55K cell 
line #10 and Ad12 E1B-55K cell line #14 although these results are representative of all cell 











Figure 3.2: Validation of Ad5 and Ad12 E1B-55K Flp-In T-Rex U2OS cell lines. The 
expression of Ad5 and Ad12 E1B-55K in Flp-In T-Rex U2OS-FRT cell lines was induced with 
0.1μg/ml doxycycline. 24h post-induction cells were harvested and subjected to SDS-PAGE 
and WB analysis with the appropriate antibodies. # represents clone number.  The data shown 
is representative of 3 independent induction experiments. 
 
3.2.2.2. Characterization of Ad5 and Ad12 E1B-55K cell lines: E1B-55K association 
with p53 
It is generally accepted that both Ad5 and Ad12 E1B-55K function to repress p53 
transcriptional activity, which is based on their ability to associate with p53 in vitro and in vivo 
(Yew, et al. 1994).  Therefore, to test the functionality of Ad5 and Ad12 E1B-55K in the Flp-
88 
 
In T-Rex U2OS cell lines it was deemed important to establish that Ad5/Ad12 E1B-55K 
interact with p53. To investigate this, co-immunoprecipitation assays were performed [section 
2.2.5]. Thus, following induction of E1B-55K expression by Dox, Ad5 E1B-55K was 
immunoprecipitated from the corresponding Flp-In T-Rex U2OS cell lines using the 2A6 mAb 
[Fig. 3.3A], whilst Ad12 E1B-55K was immunoprecipitated from the corresponding Flp-In T-
Rex U2OS cell lines using the XPH9  mAb [Fig. 3.3B]. Results obtained revealed that both 
anti-Ad5 and Ad12 E1B-55K antibodies [Fig. 3.3, Ai and Bi, respectively], co-
immunoprecipitated p53 [Fig. 3.3, Aii and Bii, respectively], Consistent with previous 
observations Ad5 E1B-55K interacted more avidly with p53 than Ad12 E1B-55K [Fig. 3.3, Aii 
and Bii]. Taken together, these data demonstrate that Ad5 and Ad12 E1B-55K are functional 
in the Flp-In T-Rex U2OS cell lines and can be used to study E1B-55K function in isolation.   
 
Figure 3.3: Ad5 and Ad12 E1B-55K associate with p53 in Flp-In T-Rex U2OS cell lines. 
Ad5 and Ad12 E1B-55K were immunoprecipiated with anti-E1B-55K mAbs from 2 mg of 
U2OS cell lysate, which had been collected 24 h post-treatment +/- 0.1μg/ml doxycycline (A, 
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Ad5 E1B-55K; B, Ad12 E1B-55K). Immunocomplexes were isolated on protein-G Sepharose, 
subjected to SDS-PAGE, and p53 and Ad E1B-55K detected by WB analysis using the 
appropriate antibodies. The data shown is representative of 2 independent experiments. 
 
3.2.2.3. Characterization of Ad5 and Ad12 E1B-55K cell lines: recruitment of p53 to 
aggresomes in Ad5 E1B-55K Flp-In T-Rex U2OS cell lines  
It is clear that E1B-55K is a potent repressor of p53 proapoptotic activities (Zhao, et al. 2007). 
In Ad5-infected cells, E1B-55K co-operates with the E4orf6 oncoprotein to stimulate the 
ubiquitin-dependent degradation of p53 (Querido, et al. 2001). It has been determined that in 
Ad5-transformed cells however, that E1B-55K associates with p53 at p53-responsive 
promoters (Yew, et al. 1994), or associates with p53 in cytoplasmic aggresomal structures, 
which localize near the MTOC outside the nucleus, to inactivate p53 function (Zhao and Liao, 
2003; Blanchette, et al. 2013). To investigate whether Ad5 E1B-55K and p53 associated at 
aggresomes in the Flp-In T-Rex U2OS cell lines, we assessed the localization status of p53 and 
Ad5 E1B-55K by indirect immunofluorescence as described [section 2.3.9]. Consistent with 
previous observations Ad5 E1B-55K expression localized in the cytoplasm in a diffuse manner,  
or localized to discrete aggresome-like structures in the cytoplasm [panel i, Fig. 3.4B]. 
Consistent with this localization pattern p53 was found to be localized to the cytoplasm, or 
localized to cytoplasmic aggresomes [panel ii, Fig. 3.4B], where they appeared to co-localize 







Figure 3.4: Co-localization of p53 with Ad5 E1B-55K in cytoplasmic aggresomes in Ad5 
E1B-55K Flp-In T-Rex U2OS cells. Cells were plated on glass slides then fixed in 4% (w/v) 
paraformaldehyde and permeabilized in ice-cold acetone (Materials and Methods section 
2.3.9), 24 h post +/- 0.1μg/ml doxycycline treatment. Cells were then incubated with an anti-
Ad5 E1B-55K mAb antibody (2A6; green), an anti-p53 pAb (red) and counter-stained with 
anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 secondary antibodies, respectively 
for both non-induced (A) and Dox-treated cells (B).  Slides were then mounted in Vectashield 
containing DAPI.  Images were visualised using a Nikon Y-FL epi-fluorescence microscope. 
The data shown is representative of 2 independent experiments. Upper panel scale bar = 20m; 
lower panel scale bar = 10m. 
 
3.2.2.4. Characterization of Ad5 and Ad12 E1B-55K cell lines: localization of Ad12E1B-
55K to cytoplasmic flecks in Flp-In T-Rex U2OS cell lines 
According to previous studies and the data presented above Ad12 E1B-55K association with 
p53 is weak relative to Ad5 E1B-55K (Yew and Berk, 1992); [Fig. 3.3]. It has also been 
reported that Ad12 E1B-55K does not co-localize with p53 at cytoplasmic aggresomes but, 
instead, associates and co-localizes with p53 in the nucleus (Zantema, et al. 1985), where it 
inhibits p53 functionality (Yew and Berk, 1992). More recently, it has reported that Ad12 E1B-
55K forms cytoplasmic bodies or ‘flecks’ that are morphologically distinct from the largely 
spherical aggresomal structures formed by Ad5 E1B-55K. Indeed, Ad12 E1B-55K cytoplasmic 
bodies are elongated and filamentous in nature that are not found in a juxtanuclear locations; 
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p53 does not localize to Ad12 E1B-55K-containing cytoplasmic bodies (Zhao and Liao, 2003). 
To determine if Ad12 E1B-55K similarly forms these cytoplasmic bodies in the Flp-In T-Rex 
U2OS cell lines the localization status of p53 and Ad12 E1B-55K were investigated by indirect 
immunofluorescence [section 2.3.9]. Consistent with previous studies Ad12 E1B-55K 
localized in the nucleus excluded from nucleoli and was also found as elongated, filamentous 
structures in the cytoplasm with diffuse cytoplasmic Ad12 E1B-55K also detected [panel i, Fig. 
3.5 B]. Consistent with previous reports we were unable to detect any p53 sequestration in the 
Ad12 E1B-55K-containing cytoplasmic bodies although there was diffuse p53 staining in the 
cytoplasm [panel ii, Fig. 3.5 B]. However, we did note that p53 levels were elevated particularly 
in the nucleus, where it co-localized with Ad12 E1B-55K, and like Ad12 E1B-55K was 
excluded from nucleoli [panel ii, Fig. 3.5 B].  Taken together, these data indicate that both Ad5 
and Ad12 E1B-55K cells modulate p53 localization as reported previously, indicating that, as 
both the Ad5 and Ad12 E1B-55K  Flp-In T-Rex U2OS cell lines modulate p53 as expected that 
they are likely to be good cell models for dissecting other functions of E1B-55K.  
 
Figure 3.5: Localization of Ad12 E1B-55K to cytoplasmic filamentous structures in Ad12 
E1B-55K Flp-In T-Rex U2OS cells. Cells were plated on glass slides then fixed in 4% (w/v) 
paraformaldehyde and permeabilized in ice-cold acetone (Materials and Methods section 
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2.3.9), 24 h post +/- 0.1μg/ml doxycycline treatment. Cells were then incubated with an anti-
Ad12 E1B-55K mAb antibody (XPH9 mAb; green), an anti-p53 pAb (red) and counter-stained 
with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 secondary antibodies, 
respectively.  Slides were then mounted in Vectashield containing DAPI. Images were 
visualised using a Nikon Y-FL epi-fluorescence microscope. The data shown is representative 
of 2 independent experiments. Scale bar = 10m. 
 
3.2.2.5. Characterization of Ad5 and Ad12 E1B-55K cell lines: effects of E1B-55K 
expression on the levels and post-translational modification status of cellular 
proteins 
It is becoming increasingly clear that E1B-55K has many functions in adenovirus-infected and 
adenovirus-transformed cells. For instance, Ad5 E1B-55K can engage with the ubiquitin-
proteasome system independently of E4orf6 and target the protein Daxx for CRL5 and 
proteasome-dependent degradation (Schreiner, et al. 2010). As well as being able to increase 
cellular levels of p53 through increased protein half-life, Ad5 E1B-55K also functions as p53-
directed SUMO1 E3 ligase and also possesses the ability to self-SUMOylate (Endter, et al. 
2001; Muller and Dobner, 2008; Pennella, et al. 2010). We thought therefore, it would be 
interesting to determine whether the expression of either Ad5 or Ad12 E1B-55K protein had 
the ability to promote an increase in other cellular proteins, promote the degradation of other 
cellular proteins or promote the SUMOylation of other cellular proteins. In this regard, we 
chose cellular proteins that are mostly known to be targeted by both Ad5 and Ad12 during 
infection and/or cellular transformation such as PTPRF/LAR and Epha2 that are targeted for 
proteasome-mediated degradation during infection (Fu, et al. 2017). We also chose to 
investigate the effects of E1B-55K expression upon the protein levels of TIF1γ, an E4orf3 and 
E4orf6-binding protein (Forrester, et al. 2012) and the pRB family of proteins, which are 
targeted by E1A (see Gallimore and Turnell, 2001).  
In agreement with previous reports and analyses presented in [Fig. 3.2], we found that both 
Ad5 and Ad12 E1B-55K stabilized p53 levels [panel x, Fig 3.6]. Consistent with previous 
studies we also determined that Ad5 E1B-55K, but not Ad12 E1B-55K, promoted the, 
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presumably, SUMOylation of p53 [panel x, Fig 3.6]. Moreover, we also found that Ad5 E1B-
55K was similarly, post-translationally modified, whereas Ad12 E1B-55K was not [panels xi 
and xii, Fig. 3.6]. Interestingly, although, TIF1γ has previously been reported to be 
SUMOylated by E4orf3 (Sohn and Hearing, 2016), it was not modified or degraded by Ad5 
E1B-55K or Ad12 E1B-55K, despite the known ability of both Ad5 and Ad12 E1B-55K to 
interact with TIF1γ [panel vi, Fig. 3.6]; (Forrester, et al. 2012). Interestingly, we found that the 
protein tyrosine phosphatase receptor type F (PTPRF/LAR) level was reduced 48h post-
induction of both Ad5 and Ad12 E1B-55K relative to non-induced cells, suggesting that E1B-
55K might target PTPRF/LAR for proteasome degradation, independent of E4orf6 expression 
[panel i, Fig. 3.6]. Epha2 levels were somewhat reduced 48h post-induction of Ad12 E1B-55K 
but not following Ad5 E1B-55K induction [panel v, Fig 3.6].  It was interesting to note that 
Ad5/Ad12 E1B-55K expression appeared to have different effects on the pRB family of 
proteins such that p107 was unaffected by Ad5/Ad12 E1B-55K expression [panel viii, Fig 3.6], 
p130 levels were variable but largely unchanged following Ad5/Ad12 E1B-55K induction 
[panel vii, Fig 3.6], whereas both Ad5 and Ad12 E1B-55K expression appeared to increase 
pRB levels quite substantially [panel ix, Fig 3.6]. The levels of the DDR protein MSH2 also 
appeared to increase following Ad5 and Ad12 E1B-55K expression [panel iii, Fig 3.6], whereas 
its binding partner, MSH6 was unaffected [panel ii, Fig 3.6]. 
These experiments suggest that AdE1B-55K might affect the protein levels of a number of 
cellular proteins directly, and independently of other early region proteins, though no clear 
cellular SUMOylation substrates were identified in addition to p53. These data do indicate 
however that the Ad5 and Ad12 E1B-55K Flp-In T-Rex U2OS cells could be a valuable 




Figure 3.6: Effects of Ad5 and Ad12 E1B-55K expression upon cellular proteins levels 
and post-translational modification status. The expression of Ad5 and Ad12 E1B-55K in 
Flp-In T-Rex U2OS-FRT cell lines was induced with 0.1μg/ml doxycycline. 24 h and 48 h 
post-induction cells were harvested and subjected to SDS-PAGE and WB analysis with the 





3.2.3. Generation of Ad5 and Ad12 E4orf3 Flp-In T-Rex U2OS-FRT-inducible cell lines 
In a similar manner to that described in section 3.2.2, to generate Ad5 and Ad12 E4orf3 Flp-In 
T-Rex U2OS-FRT-inducible cell lines we synthesized w.t. Ad5 and Ad12 E4orf3 genes with 
appropriate restriction sites by PCR (section 2.3.5) and cloned them into the pcDNA5- FRT 
TO vector containing a 3X FLAG-tag (see section 2.1.5). After transformation of bacteria and 
mini-preparation of plasmid DNA we performed DNA sequencing and used Chromas and the 
NCBI BLAST program to validate the sequence integrity of the clones isolated (sections 2.3.2- 
2.3.4). We used a vector that incorporated a 3X FLAG-tag at the N-terminus of adenovirus 
E4orf3 to aid the detection of adenovirus E4orf3 as an Ad12 E4orf3 antibody has yet to be 
generated. Sequencing revealed that we had successfully isolated w.t. Ad5 and Ad12 E4orf3 
3XFLAG-pcDNA5-FRT TO clones that possessed a KpnI site prior to the ATG and XhoI site 
after the stop codon [Fig. 3.7 A, B, C, and D respectively]. Sequencing also revealed that the 







Figure 3.7: Chromatograms demonstrating sequence integrity of Ad5 and A12 E4orf3 
3XFLAG pcDNA5-FRT TO clones at the 5’ and 3’ ends. (A) Illustrates the 5` end of the 
Ad5 sequence showing the KpnI cloning site and the start codon (ATG); (B) Illustrates the 3` 
end of the Ad5 sequence showing the stop codon (TAA) and the XhoI cloning site. (C) 
Illustrates the 5` end of the Ad12 sequence showing the KpnI cloning site and the start codon 
(ATG); (D) Illustrates the 3` end of the Ad12 sequence showing the stop codon (TAA) and the 
XhoI cloning site. 
 
3.2.3.1. Generation and characterization of Ad5 E4orf3 and Ad12 E4orf3 Flp-In T-Rex 
U2OS inducible cell lines  
Once we had verified the validity of our Ad5 and Ad12 3X FLAG-Ad5/12 E4orf3 pcDNA5-
FRT TO clones, we next generated the Ad5 and Ad12 3X FLAG-Ad5/12 E4orf3 TET-
inducible clonal U2OS cell lines, as described [see Materials and Methods, section 2.1.5]. To 
evaluate the expression of E4orf3 in the clonal cell lines, cell lysates were prepared 24h and 
48h post-induction after which proteins were quantified, separated on SDS-PAGE and analysed 
by WB. Our WB analyses with an anti-FLAG mAb determined that both Ad5 and Ad12 E4orf3 
cell lines expressed FLAG-tagged versions of these viral proteins in a Dox-dependent manner 
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in all of the Flp-In T-Rex U2OS-FRT-cell lines investigated [panel i, Fig. 3.8 A and B, 
respectively], although it was noted that some cell lines (e.g. Ad12 E4orf3 #6) also expressed 
E4orf3, albeit at lower levels, in the absence of Dox [Fig. 3.8B]. These cell lines were then 
used to probe the function of Ad5 and Ad12 E4orf3. 
 
Figure 3.8: Validation of 3X FLAG Ad5 and Ad12 E4orf3 Flp-In T-Rex U2OS cell lines. 
The expression of FLAG-tagged Ad5 and Ad12 E4orf3 in Flp-In T-Rex U2OS-FRT cell lines 
was induced with 0.1μg/ml doxycycline. 24h and 48h post-induction cells were harvested and 
subjected to SDS-PAGE and WB analysis with the appropriate antibodies. # represents clone 
number.  The data shown is representative of 3 independent induction experiments.  
 
3.2.3.2. Characterization of Ad5 and Ad12 E4orf3 cell lines: effects of E4orf3 expression 
on the levels of cellular E4orf3-regulated proteins 
Ad5 E4orf3 has reported to associate with, or regulate numerous cellular proteins including 
DNA-PKcs, and its regulatory proteins Ku86 and Ku70 (Boyer, et al. 1999), whilst published 
work form our laboratory and others has indicated that TIF1γ is subject to Ad5/Ad12 E4orf3-
dependent SUMOylation and STUbl-dependent degradation (Forrester, et al. 2012; Sohn and 
Hearing, 2012;  Sohn and Hearing, 2016). Other work from our laboratory has suggested that 
the cellular protein Timeless is degraded in an Ad12 E4orf3-dependent manner but is not 
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degraded by Ad5 E4orf3 (Patel, PhD thesis 2013, University of Birmingham), whilst work 
from the O’Shea laboratory has indicated that Ad5 E4orf3 is a negative regulator of p53 
transcriptional activity (Soria, et al. 2010). In order to validate the functionality of Ad5 and 
Ad12 E4orf3 in the clonal FlpIn cell lines we performed WB analyses to examine the effects 
of both Ad5 and Ad12 E4orf3 expression upon the cellular levels of TIF1, DNA-PK and p53 
proteins which are known to be regulated by E4orf3. 
Consistent with the data presented in Figure 3.8 the addition of Dox induced the expression of 
FLAG-tagged Ad5 E4orf3, though the levels of FLAG-tagged Ad5 E4orf3 attained in the #3 
cell line were low compared with the levels of FLAG-tagged Ad5 E4orf3 achieved in #7 and 
#9 [panel vi, Fig. 3.9A]. Our WB data did reveal however that the induction of FLAG-tagged 
Ad5 E4orf3 in #7 and #9 cell lines resulted in low level post-translational modification of 
TIF1, which is most likely to be SUMOylation or ubiquitylation [panel i, Fig. 3.9A]. Further 
WB analyses revealed that FLAG-tagged Ad5 E4orf3 did not affect the expression levels, nor 
post-translational modification status, of Timeless, p53, Ku86, or Ku70 [panels ii-v, Fig 3.9A], 
which is consistent with published findings, although it was not previously known whether 
Ku86 or Ku70 were substrates for Ad5 E4orf3-dependent SUMOylation (Boyer, et al. 1999; 
Soria, et al. 2010; Patel, PhD thesis 2013, University of Birmingham). The results with FLAG-
tagged Ad12 E4orf3 were, however, much more encouraging as more obvious cellular effects 
were seen when FLAG-tagged Ad12 E4orf3 expression was induced by Dox treatment [Fig. 
3.9B]. Our WB analyses revealed that TIF1γ was post-translationally-modified, presumably by 
SUMOylation and ubiquitylation, and then degraded upon the induction of FLAG-tagged Ad12 
E4orf3 [Panel i, Fig 3.9B]. Consistent with previous observations from the Turnell laboratory 
(Patel, PhD thesis, University of Birmingham, 2013), our data also demonstrated that Timeless 
levels were reduced 48h post-induction of FLAG-tagged Ad12 E4orf3 [Panel ii, Fig. 3.9B]. 
Like the Ad5 E4orf3 studies WB revealed that neither p53, Ku86 nor Ku70 levels, nor PTM 
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status was affected by either FLAG-tagged Ad12 E4orf3 expression [Panel iii-v Fig. 3.9B]. 
Taken together, these data suggest that we have generated cell lines that express FLAG-tagged 
Ad5 and Ad12 E4orf3 proteins in a Dox-dependent manner. These FLAG-tagged E4orf3 
proteins retain the known enzymic activity of E4orf3, namely the ability to promote the PTM 
of TIF1, suggesting that these cell lines can be used for further functional studies.  
 
Figure 3.9: Effects of Ad5 and Ad12 E4orf3 expression upon cellular proteins levels and 
post-translational modification status. The expression of FLAG-tagged Ad5 and Ad12 
E4orf3 in Flp-In T-Rex U2OS-FRT cell lines was induced with 0.1μg/ml doxycycline. Cells 
were harvested 24 h and 48 h post-induction and subjected to SDS-PAGE and WB analysis 




3.2.3.3. Characterization of Ad5 and Ad12 E4orf3 cell lines: E4orf3-dependent 
recruitment of TIF1γ to PML-containing nuclear tracks 
Adenovirus promotes the spatial and dynamic reorganization of cellular structures during 
infection in order to facilitate viral replication and block antiviral signalling pathways. 
Adenovirus E4orf3 plays an important role in the reorganization of PML-containing nuclear 
bodies to track-like structures (Araujo, et al. 2005; Forrester, et al. 2012). Adenovirus E4orf3 
also promotes the recruitment of the MRN complex, TIF1α and TIF1γ to nuclear tracks during 
infection to inhibit their antiviral functions through sequestration and then degradation (Araujo, 
et al. 2005; Forrester, et al. 2012). In order to evaluate further the function of the Ad5 and Ad12 
E4orf3 Flp-In cell lines we investigated the ability of FLAG-tagged Ad5 and Ad12 E4orf3 to 
promote the recruitment of TIF1γ to nuclear tracks by immunofluorescence [section 2.3.9.]. In 
non-induced cells TIF1γ was distributed evenly throughout the nucleus and there was no 
obvious expression of Ad5 or Ad12 E4orf3 [Fig. 3.10 A and B]. Following induction of E4orf3 
expression both Ad5 and Ad12 E4orf3 were seen as distinct nuclear foci and nuclear tracks 
[Fig. 3.10 A and B]. In agreement with the known functions of E4orf3, TIF1γ was reorganized 
to these structures [Fig. 3.10 A and B], indicating that the E4orf3 Flp-In cell lines are a good 









Figure 3.10: Ad5 and Ad12 E4orf3-dependent recruitment of TIF1γ to nuclear tracks. 
Cells were fixed in 4% (w/v) paraformaldehyde and permeabilized in ice-cold acetone 
(Materials and Methods section 2.3.9), 24 h post +/- 0.1μg/ml doxycycline treatment. Cells 
were then incubated with an anti-FLAG mAb antibody (green) to stain Ad5/Ad12 E4orf3, an 
anti-TIF1 pAb (red) and counter-stained with anti-mouse Alexa Fluor 488 and anti-rabbit 
Alexa Fluor 594 secondary antibodies, respectively. Slides were then mounted in Vectashield 
containing DAPI (blue). Images were visualised using a Nikon Y-FL epi-fluorescence 






 3.2.3.4. Characterization of Ad5 and Ad12 E4orf3 cell lines: E4orf3-dependent 
recruitment of SUMO-1 and SUMO-2 to PML-containing nuclear tracks  
The importance of SUMOylated proteins in the DDR is widely recognised, whereby the SUMO 
conjugation machinery localizes at DNA damage sites to control the SUMOylation of proteins 
that participate in DNA damage response and repair (Sarangi and Zhao, 2015). It is now 
established that Ad5 E4orf3, at least, is a SUMO E3-ligase and promotes the recruitment of 
MRN complex components to nuclear tracks and their SUMOylation (Sohn and Hearing,  
2012; Sohn and Hearing, 2016). In this regard, in vitro SUMOylation assays revealed that Ad5 
E4orf3 utilised SUMO-2 more readily than SUMO-1 in the conjugation reaction (Sohn and 
Hearing, 2012). To establish whether the FLAG-Ad5 and Ad12 E4orf3 Flp-In T-Rex cells are 
a good model to study E4orf3-dependent modulation of SUMOylation, we investigated 
whether SUMO-1 and/or SUMO-2 were recruited to Ad5 and Ad12 E4orf3-containing nuclear 
tracks [Fig. 3.11]. Immunofluorescence microscopy revealed that SUMO-1 and SUMO-2 were 
efficiently reorganized to nuclear tracks with Ad5 E4orf3 [Fig. 3.11A], whilst Ad12 E4orf3 
appeared to preferentially re-organise SUMO-1 to nuclear tracks, but not SUMO-2 [Fig. 
3.11B]. Taken together, these data indicate that the adenovirus E4orf3 Flp-In cell lines are a 
good model system to investigate the relationship between E4orf3 and cellular SUMOylation. 
Moreover, these data establish that Ad12 E4orf3 preferentially utilises SUMO-1, and not 






Figure 3.11: Ad5 and Ad12 E4orf3-dependent recruitment of SUMO-1 and SUMO-2 to 
nuclear tracks. Cells were fixed in 4% (w/v) paraformaldehyde and permeabilized in ice-cold 
acetone (Materials and Methods section 2.3.9), 24 h post +/- 0.1μg/ml doxycycline treatment. 
Cells were then incubated with anti-SUMO-1/SUMO-2 mAbs (green) and an anti-FLAG pAb 
antibody (red) to stain Ad5/Ad12 E4orf3, and counter-stained with anti-mouse Alexa Fluor 
488 and anti-rabbit Alexa Fluor 594 secondary antibodies, respectively. Slides were then 
mounted in Vectashield containing DAPI (blue). Images were visualised using a Nikon Y-FL 
epi-fluorescence microscope. The data shown is representative of 2 independent experiments. 




3.2.3.5. Characterization of Ad5 and Ad12 E4orf3 cell lines: effects of E4orf3 expression 
on the levels and post-translational modification status of cellular proteins 
Given the known ability of adenovirus E4orf3 to promote the SUMOylation of MRN 
components (Sohn and Hearing, 2012), and the degradation TIF1γ (Forrester, et al. 2012) we 
decided to investigate by WB analsyes whether adenovirus E4orf3 induced the SUMOylation 
and/or degradation of cellular proteins known to be targeted by adenovirus during infection as 
we did for E1B-55K [see section 3.2.2.5]. Our WB results revealed that, despite good 
expression of the FLAG-tagged Ad5 and Ad12 E4orf3 proteins [panel ix, Fig. 3.12], none of 
the cellular proteins investigated were altered in either their expression level, or their post-
translational modification status [Fig. 3.12]. As such, the pRB tumor suppressor and its family 
members, p107 and p130 were not affected by E4orf3 expression [panels vi-viii, Fig. 3.12]. 
Similarly, no change was observed in the expression level, or the post-translational 
modification status of LAR-PTPRF, MSH6, MSH2, TOP2B or Epha2 in response to either Ad5 
or Ad12 E4orf3 expression [panels i-v, Fig. 3.12]. Despite these findings it is likely given the 
effects of E4orf3 expression on TIF1 levels and PTM status [Fig. 3.9], that these cell lines 





Figure 3.12: Effects of Ad5 and Ad12 E4orf3 expression upon cellular proteins levels and 
post-translational modification status. The expression of Ad5 and Ad12 E4orf3 in Flp-In T-
Rex U2OS-FRT cell lines was induced with 0.1μg/ml doxycycline. 24 h and 48 h post-
induction cells were harvested and subjected to SDS-PAGE and WB analysis with the 
appropriate antibodies. The data shown is representative of 3 independent experiments. 
 
3.2.4 Generation of Ad5 and Ad12 E4orf6 Flp-In T-Rex U2OS-FRT-inducible cell lines 
As outlined earlier that E1B-55K and E4orf3 cooperate with E4orf6 during adenovirus 
infection, thus we next decided to generate Ad5 and Ad12 E4orf6 Flp-In T-Rex U2OS-FRT-
inducible cell lines. As such, we synthesized w.t. Ad5 and Ad12 E4orf6 genes with appropriate 
restriction sites and an N-terminal HA-tag by PCR (section 2.3.5) and cloned them into the 
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pcDNA5- FRT TO vector (see section 2.1.5). After transformation of bacteria and mini-
preparation of plasmid DNA we performed DNA sequencing and used Chromas and the NCBI 
BLAST program to validate the sequence integrity of the clones isolated (sections 2.3.2- 2.3.4). 
Sequencing revealed that we had successfully isolated w.t. Ad5 and Ad12 E4orf6 pcDNA5-
FRT TO clones that possessed a BamHI site prior to the ATG and XhoI site after the HA-Tag 
and TGA stop codon [Fig.3.13 A, B, C, and D respectively]. Sequencing also revealed that the 











Figure 3.13: Chromatograms demonstrating sequence integrity of Ad5 and A12 E4orf6 
pcDNA5-FRT TO clones at 5’ and 3’ ends. (A) Illustrates the 5` end of the Ad5 sequence 
showing the BamHI cloning site and the start codon (ATG); (B) Illustrates the 3` end of the 
Ad5 sequence showing the incorporation of the HA-tag, the TGA stop codon and the XhoI 
cloning site. (C) Illustrates the 5` end of the Ad12 sequence showing the BamHI cloning site 
and the start codon (ATG); (D) Illustrates the 3` end of the Ad12 sequence showing the the 
incorporation of the HA-tag, the TGA stop codon and the XhoI cloning site. 
 
3.2.4.1. Generation and characterization of Ad5 E4orf6 and Ad12 E4orf6 Flp-In T-Rex 
U2OS inducible cell lines  
Once we had verified the validity of our Ad5 and Ad12 HA-tagged Ad5/12 E4orf6 pcDNA5-
FRT TO clones, we next generated the Ad5 and Ad12 HA-tagged-Ad5/12 E4orf6 TET-
inducible clonal U2OS cell lines, as described [see Materials and Methods, section 2.1.5] and 
tested their expression following doxycycline treatment by WB. Our WB data indicated that 
we had isolated Flp-In T-Rex U2OS cell lines that expressed both Ad5 and Ad12 HA-tagged 
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E4orf6 [panel iii, Fig. 3.14 A and B], although the protein levels of E4orf6 were highly variable 
and some cells did not express any detectable HA-tagged E4orf6 [panel iii, Fig. 3.14 A and B]. 
Consistent with previous work from our laboratory (Blackford, et al. 2010) Ad12 E4orf6 
promoted the degradation of TopBP1, whilst Ad5 E4orf6 did not [panel i, Fig. 3.14 A and B]. 
Reassuringly, those cell lines that did not express detectable levels of HA-tagged Ad12 E4orf6 
did not promote the degradation of TopBP1 [panel iii, Fig. 3.14 B]. The expression of either 
Ad5 or Ad12 HA-tagged E4orf6 had a modest effect upon the levels of p53 [panel ii, Fig. 3.14], 
though p53 did appear to be stabilized in some of the cell lines studied [e.g. Ad5 clones 2, 4, 
6, 7 and 12- panel ii, Fig. 3.14A; Ad12 clones 2, 5, 7, 11 and 12- panel ii, Fig. 3.14B]. Taken 
together, these data indicated that we had successfully isolated both Ad5 and Ad12 E4orf6 Flp-




Figure 3.14: Validation of Ad5 and Ad12 E4orf6 Flp-In T-Rex U2OS cell lines. The 
expression of HA-tagged Ad5 and Ad12 E4orf6 in Flp-In T-Rex U2OS cell lines was induced 
with 0.1μg/ml doxycycline. 24h post-induction cells were harvested and subjected to SDS-
PAGE and WB analysis with the appropriate antibodies. # represents clone number.  The data 
shown is representative of 2 independent induction experiments. 
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3.2.4.2. Characterization of Ad5 and Ad12 E4orf6 cell lines: cellular localization of  
E4orf6  
E4orf6 is a multifunctional protein that promotes viral DNA replication, particularly, the 
control of nuclear export of late viral mRNAs to the cytoplasm and the repression of cellular 
mRNA export from the nucleus (Halbert, et al. 1985; Bridge and Ketner, 1990). As such it not 
only regulates viral mRNA export, but it has been reported that E4orf6 also shuttles between 
the nucleus and cytoplasm in order to target E1B-55K to the nucleus (Goodrum, et al. 1996). 
In order to determine the cellular localization of HA-tagged E4orf6 we performed indirect 
immunofluoresence [Fig. 3.15 A and B].  Microscopy revealed that both Ad5 and Ad12 E4orf6 
were predominantly nuclear where they formed many punctate foci, suggesting that they 
localized to specific sites, or structures in the nucleus [Fig. 3.15 A and B].  These data indicate 










Figure 3.15: Ad5 and Ad12 E4orf6 localize to intranuclear foci in Flp-In T-Rex U2OS cell 
lines. Cells were fixed in 4% (w/v) paraformaldehyde and permeabilized in ice-cold acetone 
(Materials and Methods section 2.3.9), 24 h post +/- 0.1μg/ml doxycycline treatment. Cells 
were then incubated with an anti-HA pAb (red) and counter-stained with an anti-rabbit Alexa 
Fluor 594 secondary antibody. Slides were then mounted in Vectashield containing DAPI 
(blue). Images were visualised using a Nikon Y-FL epi-fluorescence microscope. The data 





3.2.4.3. Characterization of Ad5 and Ad12 E4orf6 cell lines: E4orf6 association with p53 
It is well known that the p53 tumour suppressor is stabilized following E1A expression (Lowe 
and Ruley, 1993), which left unchecked would be a major obstacle for adenovirus replication. 
However, E1B-55K and E4orf6 cooperate during infection to promote the degradation, and 
hence inactivation of p53 (Querido, et al. 1997). It has been shown that both E1B-55K (Sarnow, 
et al. 1982) and E4orf6 interact with p53 independently (Dobner, et al. 1996) to inhibit p53-
mediated transcriptional activation. To determine whether HA-tagged Ad5 and Ad12 E4orf6 
associate with p53 in the Ad5 and Ad12 E4orf6 in the Flp-In T-Rex U2OS cells we 
immunoprecipiated HA-tagged E4orf6 with an anti-HA pAb and performed WB analysis for 
both E4orf6 (HA) and p53 [sections 2.2.4 and 2.2.5]. WB results revealed that the 
immunoprecipitation was successful and that HA-tagged E4orf6 was immunoprecipitated from 
both Ad5 and Ad12 E4orf6 Flp-In T-Rex U2OS cells [panel Ai and Bi, Fig. 3.16], although the 
Ad5 E4orf6 cell line used did express some HA-tagged E4orf6 in the absence of doxycycline 
treatment [panel Ai, Fig. 3.16]. WB analyses of p53 revealed that both immunoprecipitation of 
both Ad5 and Ad12 E4orf6 resulted in the co-precipitation of p53 [panel Aii and Bii, Fig. 3.16], 
although it appeared that Ad12 E4orf6 associated more avidly with p53 than Ad5 E4orf6 [panel 
Aii and Bii, Fig. 3.16]. The small amount of co-precipitated p53 in the Ad5 E4orf6 cell line 
presumably reflects the leaky expression of HA-tagged Ad5 E4orf6 in these cells [panel Ai, 
Fig. 3.16]. These results indicate that HA-tagged E4orf6 associates with p53 in both Ad5 and 
Ad12 E4orf6 cell-lines, indicating that the HA-tagged E4orf6 species have retained their ability 
to interact with a known binding partner and could be used to study E4orf6 interactions with 





Figure 3.16: HA-tagged Ad5 and Ad12 E4orf6 associate with p53 in Flp-In T-Rex U2OS 
cell lines. HA-tagged Ad5 and Ad12 E4orf6 were immunoprecipiated with an anti-HA pAb 
from U2OS cell lysate, which had been collected 24 h post-treatment +/- 0.1μg/ml doxycycline 
(A, Ad5 E4orf6; B, Ad12 E4orf6). Immunocomplexes were isolated on protein-G Sepharose, 
subjected to SDS-PAGE, and p53 and adenovirus E4orf6 detected by WB analysis using the 
appropriate antibodies. The data shown is representative of 3 independent experiments. 
 
3.2.3.4. Characterization of Ad5 and Ad12 E4orf6 cell lines: effects of E4orf6 expression 
on the levels of cellular proteins 
Genome integrity is important for cell survival and as such, cells utilize different pathways to 
detect and fix DNA damage (Jackson and Bartek, 2009). As viral infection activates the host 
cell DDR pathway cellular proteins that participate in these pathways also inhibit viral 
replication (Chaurushiya and Weitzman, 2009). Previous work from our laboratory has 
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established that Ad12 E4orf6 inhibits the ATR pathway through its ability to target the ATR 
activator, TopBP1 for degradation (Blackford, et al. 2010). We therefore investigated whether 
adenovirus E4orf6 could target RAD51, which is involved in homologous recombination 
repair, and Ku86, which is involved in NHEJ repair for degradation. We also investigated 
whether PTPRF/LAR or Epha2, which are known to be targeted for degradation during Ad5 
infection (Fu, et al. 2017) are targeted for degradation by E4orf6. In agreement with previous 
studies and those reported earlier (Blackford, et al. 2010), WB analyses revealed that TopBP1 
was targeted for degradation by Ad12 E4orf6 but not Ad5 E4orf6 [panel i, Fig. 3.17 A and B]. 
The levels of RAD51, PTPRF/LAR and Ku86 were highly variable but there was no obvious 
positive correlation between adenovirus E4orf6 expression and the levels of these proteins 
[panels ii, iii, and v Fig. 3.17 A and B]. Epha2 was consistently reduced in levels following 
Ad5 E4orf6 expression, but not Ad12 E4orf6 expression [panel, iv Fig. 3.17 A and B]. Perhaps 
the most interesting finding from this study was that Ad5 E4orf6 itself appeared to be post-
translationally modified as noted by the observed higher molecular weight smear on the WB 
for Ad5 E4orf6 [panel vi, Fig. 3.17 A]. Ad12 E4orf6 appeared however, to be only modestly 
post-translationally modified [panel vi, Fig. 3.17 B]. These data suggest that Ad5 E4 orf6 is 






Figure 3.17: Effects of Ad5 and Ad12 E4orf6 expression upon cellular proteins levels and 
post-translational modification status. The expression of HA-tagged Ad5 and Ad12 E4orf6 
in Flp-In T-Rex U2OS-FRT cell lines was induced with 0.1μg/ml Dox. 24 h and 48 h post-
induction cells were harvested and subjected to SDS-PAGE and WB analysis with the 





It is well established that adenovirus early region proteins E1B-55K, E4orf3 and E4orf6 
cooperate during infection to promote viral replication (Weitzman, 2005). It is also appreciated 
that they cooperate in the transformation of primary cells (Nevels, et al. 2001). Studies with 
deletion viruses that fail to express one or more of these proteins has highlighted the important 
cooperative relationship between these proteins (Forrester, et al. 2012). Other studies however, 
have determined that these proteins can also function, independently both during infection 
(Pennella, et al. 2010; Blackford, et al. 2010) and transformation (Nevels, et al. 2001), see 
Introduction, sections 1.2 and 1.4). Moreover, these studies have indicated that there are subtle 
differences in the functions of Ad5 and Ad12 proteins. These differences have yet to be studied 
in detail, however. The principle aim of the study presented in this chapter was to generate cell 
line models that could be used to study the function of Ad5 and Ad12 E1B-55K, E4orf3 and 
E4orf6 in isolation, in the absence of viral infection and the presence of other viral proteins. It 
was hoped that these cell models would help identify new functions of these proteins and 
highlight similarities and differences between the two widely studied virus types, Ad5 and 
Ad12. 
3.3.2. Generation and characterization of Ad5 and Ad12 E1B-55K Flp -In T-Rex  
U2OS- Inducible cell lines.  
Results presented in this chapter indicate that we were able to isolate successfully, clonal cell 
U2OS cell lines that expressed both Ad5 and Ad12 E1B-55K in a Dox-dependent manner [Fig. 
3.2 A and B]. It was noted however that there were obvious variations the levels of Ad5 and 
Ad12 proteins expressed following Dox treatment [Fig. 3.2 A and B]. It is not clear why this 
is the case. It has been suggested that these cells have one integration site, though it is possible 
that they possess more than one integration site, which might explain the variance in 
expression. Consistent with previous studies we observed that low levels of higher molecular 
weight forms of Ad5 E1B-55K were observed by WB [Panel ii, Fig. 3.2 Ai-Aii], which are 
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presumed to be SUMOylated E1B-55K (Endter, et al. 2001). The target residue for 
SUMOylation within Ad5 E1B-55K is K104 which lies within a ψKxE consensus motif which 
is important for Ad5 E1B-55K mediated transformation (Endter, et al. 2001). It has been 
reported that Ad12 E1B-55K has a KxE, but however lacks the aliphatic amino acid residue, 
ψ, which is required for SUMO-1 conjugation (Rodriguez, et al. 2001). It has been proposed 
that Ad5 E1B-55K SUMOylation promotes the nuclear retention of Ad5 E1B-55K, such that 
mutation of the K acceptor, K104, to arginine results in the accumulation of E1B-55K in 
cytoplasmic aggregates (Kindsmuller, et al, 2007). Consistent with other studies, we also 
confirmed that Ad5 and Ad12 E1B-55K expression elicited the marked stabilization of p53 
levels in most cases [Fig. 3.2]. The explanation for high protein abundance of p53 in adenovirus 
E1B-55K expressing cells is two-fold- the direct association between E1B-55K and p53 masks 
the Mdm2-binding site on p53, and adenovirus E1B-55K inhibits p53 transcription of the 
Mdm2 gene (Li, et al. 2011). This accumulation of p53 is not normally evident in w.t. 
adenovirus-infected cells, due to the concerted action of E1B-55K and E4orf6 in the 
degradation of p53 (Querido, et al. 2001).  
Ad5 E1B-55K has also been established to function as a SUMO-ligase and promote the mono-
SUMOylation of p53, its association with PML nuclear bodies and its export to the cytoplasm 
(Muller and Dobner, 2008; Pennella, et al. 2010). In this regard, we determined that induction 
of Ad5 E1B-55K, but not Ad12 E1B-55K, expression, induced the PTM of p53. Interestingly, 
p53 is the only known protein to be SUMOylated by Ad5 E1B-55K. It would be valuable to 
perform proteome-wide MS-based screens to identify other cellular proteins targeted for Ad5 
E1B-55K-dependent SUMOylation. Ron Hay’s group have described an antibody method to 
isolate SUMOylated proteins from cells that express a mutant SUMO protein that possesses a 
K residue before the C-terminal diG motif that conjugates to acceptor K residues on substrates 
(Tammsalu, et al. 2015). Upon digestion with the Lys-C proteinase a diG-K specific antibody 
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can be used to isolate SUMOylated proteins that can be subjected to MS identification. Adrian 
Whitehouse’s group have developed FLAG-tagged and GFP-tagged affimers that recognize 
SUMO-1 and SUMO-2, specifically and could similarly be used to purify SUMOylated 
proteins from cell lysates for MS identification (Hughes, et al. 2017). The identification of 
other cellular proteins SUMOylated by E1B-55K would further our understanding of this 
protein and its relationship to the host cell. Interestingly, studies presented here suggested that 
pRB was stabilized following adenovirusE1B-55K expression, although the antibody used 
could not detect any obvious PTM [Fig. 3.6]. pRB, as well as p53, has been shown to be 
SUMOylated by a Kaposi’s sarcoma -associated herpesvirus (KSHV) SUMO E3 ligase 
(KbZIP; Chang, et al. 2010). Given this finding it will be important to establish whether E1B-
55K can SUMOylate pRB.  
Our studies with the Ad5 and Ad12 E1B-55K Flp-In cells also determined that both proteins 
retained the capacity to interact with p53, in vivo [Fig. 3.3]. As such, these cell lines could be 
used to study the interactomes of Ad5 and Ad12 E1B-55K by IP coupled to MS. Although our 
laboratory has performed such studies [Forrester, PhD thesis, University of Birmingham, 
2012], this was a long time ago, and the capability of the current generation of mass 
spectrometers are far more sensitive than previous models. We also used immunofluorescence 
to determine that Ad5 E1B-55K is recruited to cytoplasmic, aggresomal structures upon 
induction of Ad5 E1B-55K expression [Fig. 3.4]. This sequestration of p53 is known to inhibit 
the nuclear transcription functions of p53. Our immunofluorescence studies also revealed that 
Ad12 E1B-55K was mostly retained in the nucleus but also formed elongated, filamentous 
structure that were located at variable distances from the nucleus. This distribution of Ad12 
E1B-55K has been observed previously (Gallimore, et al. 1997). Interestingly, E1B-55K from 
the highly oncogenic Ad12 does not translocate p53 to the aggresome [Fig. 3.5 A and B]. This 
is most likely due to the absence of a nuclear export signal (NES) in Ad12 E1B-55K that is 
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present in Ad5 E1B-55K (Liao, et al. 1999; Krätzer, et al. 2000). How and why Ad12 E1B-
55K is transported into the cytoplasm is not currently known. It will be important in the future 
to establish, which residues are important for nuclear export and whether cellular proteins 
associate with Ad12 E1B-55K in the cytoplasmic filaments. In this regard, it would be 
interesting to see if we could purify cytoplasmic E1B-55K containing filaments and then 
subject them to MS characterization. 
Significantly, our laboratory has already used the Ad5 and Ad12 E1B-55K cells generated here 
to investigate the relationship between adenovirusE1B-55K and SMARCAL1 (Nazeer, et al. 
2019). These cell lines were used, specifically, to establish that both Ad5 and Ad12 E1B-55K 
promoted cellular DNA replication stalling and the inhibition of cellular DNA replication in 
order to promote viral DNA replication. We are therefore hopeful that these cells can be used 
in the future to perform the experiments outlined above. 
 
3.3.3. Generation and characterization of Ad5 and Ad12 E4orf3 Flp -In T-Rex U2OS- 
Inducible cell lines.  
During the course of this study we were also able to generate both Ad5 and Ad12 E4orf3 Flp-
In T-Rex U2OS cell lines that expressed FLAG-tagged Ad5 and Ad12 E4orf3 following 
treatment with Dox [Fig. 3.8]. As Ad5 E4orf3 has been found to function as an E3 SUMO 
ligase that stimulates the SUMOylation of the Mre11 and Nbs1 DDR proteins, the TFII-I 
transcription factor and the TIF1γ transcriptional repressor (Sohn and Hearing, 2016), we 
investigated whether Ad5 and Ad12 E4orf3 possessed the ability to induce the SUMOylation 
of TIF1γ in the Ad5 and Ad12 E4orf3 Flp -In T-Rex U2OS cell lines. Interestingly, all Ad12 
E4orf3 clones isolated possessed the ability to post-translationally modify TIF1γ and promote 
its degradation [Fig. 3.9B]. We presume that this reflects the known ability of Ad5 E4orf3 to 
induce the SUMOylation of TIF1γ and the subsequent recruitment of a STUbL to promote the 
ubiquitin-dependent degradation of TIF1γ (Sohn and Hearing, 2016). Relative to Ad12 E4orf6, 
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Ad5 E4orf3 was not as efficient at promoting TIF1γ SUMOylation and degradation. The 
reasons for these differences are not immediately apparent but might reflect inherent 
differences in the catalytic activities of the two proteins. Consistent with previous studies, these 
studies suggested that Timeless was also degraded by Ad12 E4orf3, though a role for PTM of 
Timeless in this process was not identified [Fig. 3.9B; Patel, PhD thesis, University of 
Birmingham 2013]. As for E1B-55K (section 3.3.2.) it would be valuable to use the proteome-
wide screens discussed previously to identify those cellular proteins targeted for SUMOylation 
by Ad5 and Ad12 E4orf3. Given that adenovirus E4orf3 expression often results in the 
degradation of cellular proteins it would also be valuable to use these cell lines to perform 
SILAC (Stable Isotope Labeling by/with Amino acids in Cell culture) type experiments to 
identify those proteins targeted for degradation by E4orf3. 
Our studies also established that both Ad5 and Ad12 E4orf3 formed nuclear tracks in E4orf3 
Flp -In T-Rex U2OS cell lines in a Dox-dependent manner, and were able to recruit TIF1γ to 
these structures [Fig 3.10]. It has been established previously that SUMOylation is not required 
for recruitment to these structures, but that SUMOylation occurs at nuclear tracks (Sohn and 
Hearing, 2019). Indeed, another TRIM family TIF1α (TRIM24), has been reported to be 
relocalized to nuclear tracks by E4orf3 but is not SUMOylated (Sohn and Hearing,  2016). 
Consistent with the studies of Patrick Hearing’s laboratory our study established that Ad5 
E4orf3 localized with SUMO-1 and SUMO-2 at nuclear tracks [Fig 3.11A]. Interestingly 
however, Ad12 E4orf3 only localized with SUMO-1 at nuclear tracks, and not SUMO-2, 
suggesting that Ad12 E4orf3 is a SUMO-1-specific E3 ligase [Fig 3.11B]. This is not 
unprecedented, as Ad5 E1B-55K also functions as SUMO-1-specific E3 ligase (Pennella, et al. 
2010). It would therefore be interesting to perform in vitro E3 SUMO-ligase reactions with 




Another known function of the Ad5 E4orf3 protein is the epigenetic silencing of p53 
transcriptional activity, such that Ad5 E4orf3 expression results in histone H3 K9 
trimethylation at p53-responsive promoters (Soria, et al. 2010). It would be interesting to see 
if Ad12 E4orf3 utilizes a similar mechanism to inhibit p53 function. Taken together, our initial 
studies with Ad5 and Ad12 E4orf3 have established that adenovirusE4orf3 is functional in the 
FlpIn cell lines generated and can be used to investigate AdE4orf3 function in more detail. Our 
studies have also highlighted important functional differences between Ad5 and Ad12 E4orf3 
proteins that can be explored in more detail in future studies. 
3.3.4. Generation and characterization of Ad5 and Ad12 E4orf6 Flp -In T-Rex U2OS- 
Inducible cell lines.  
Work presented in this chapter indicates that we successfully generated clonal FlpIn U2OS cell 
lines that expressed E4orf6 in a Dox-dependent manner [Fig 3.14]. Consistent with previous 
studies we were able to demonstrate that Ad12 E4orf6, but not Ad5 E4orf6, promoted the 
degradation of TopBP1 [Fig 3.14; Blackford, et al. 2010], indicating that Ad12 HA-tagged 
E4orf6, is functional in this system. WB analyses indicated that Ad5E4orf6, but not Ad12 
E4orf6 had undergone PTM [Fig 3.17]. PTM of Ad5 E4orf6 has not been described during 
infection or transfection, possibly because the levels of Ad5 E4orf6 during infection, or 
transfection were not as high as those observed in our inducible sytsem. Despite this, this 
observation might be important in explaining Ad5 E4orf6 function and will be considered in 
the next chapter. 
Co-IP studies confirmed that Ad5 E4orf6 interacted with p53, albeit weakly, whilst Ad12 
E4orf6 associated with p53 more avidly [Fig 3.16]. This is an important finding as it has not 
been recognised previously that Ad12 E4orf6 interacts with p53 and suggests that Ad12 E4orf6 
similarly inhibits p53 transcriptional activity. Ad5 E4orf6 has been shown to bind to p53 within 
its C-terminal regulatory domain and disrupt the interaction between TAFII31, a component of 
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transcription factor IID (TFIID) and the N-terminal activation domain of p53, which 
consequently blocks p53-mediated transcriptional activation (Dobner, et al. 1996). Early 
studies from Phillip Branton’s laboratory established that Ad5 E4orf6 interacted with cellular 
CRL5, whilst work from our laboratory determined that Ad12 E4orf6 interacted with CRL2 
(Querido, et al. 2001; Blackford, et al. 2010). The role of adenovirusE4orf6 in targeting cellular 
proteins for degradation by the UPS will be considered in more detail in the following chapter. 
Given that we have identified that Ad5 and Ad12 E4orf6 associate with p53 in the FlpIn U2OS 
cell lines, it would be interesting to perform IP-MS studies to identify other cellular proteins 
that associate with Ad5 and/or Ad12 E4orf6, in vivo. Such studies would be important towards 
a better understanding of how adenovirus E4orf6 proteins function in isolation in the cell. 
Immunofluorescence studies presented here demonstrated that both Ad5 and Ad12 E4orf6 were 
nuclear in their distribution, where they were visible as punctate foci [Fig. 3.15]. It will be 
important, in the future to establish whether these foci represent discrete intranuclear structures 
such as nucleoli, PML bodies, Cajal bodies etc, as this might give important insight into E4orf6 
function. 
Taken together, the work presented in this chapter has been important towards establishing a 
resource that we can study the function of Ad5 and Ad12 E1B-55K, E4orf3 and E4orf6 in 
isolation. Data presented in this chapter has highlighted important differences between Ad5 
and Ad12 proteins and given some new insights into the potential function of these proteins. 


















Investigating the molecular functions of 
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4.1. Introduction  
According to a large number of studies the adenovirus E4orf6 protein is a highly versatile 
protein that can work in isolation, or cooperation with E1B-55K and/or E4orf3 to perform 
multiple cellular functions in order to maximise adenovirus replication (Täuber and Dobner, 
2001). Adenovirus E4orf6 regulates host cell shut-off, in cooperation with E1B-55K, 
principally by regulating the selective transport of viral mRNAs from the nucleus to the 
cytoplasm as well as targeting for degradation a number of cellular proteins that possess anti-
viral activities (Dobbelstein, et al. 1997). Indeed, our laboratory recently identified 
SMARCAL1 as a cellular substrate for CRLs targeted by adenovirus E1B-55K/E4orf6 during 
infection (Nazeer, et al. 2019). As such, Ad5 E4orf6 interacts specifically with Cullin 5-
containing ubiquitin ligase complexes, whereas Ad12 E4orf6 interacts specifically with Cullin 
2-containing ubiquitin ligase complexes to promote the ubiquitin-dependent and proteasome-
mediated degradation of cellular targets (Cheng, et al. 2013).  
It is generally accepted that E1B-55K functions as a substrate receptor and E4orf6 serves to 
recruit the CRL in this process. However, there are exceptions to this rule. For instance, Ad5 
E1B-55K can promote the degradation of Daxx independently of E4orf6 (Schreiner, et al. 
2010), whereas, Ad12 E4orf6, but not Ad5 E4orf6, can function independently to suppress the 
ATR signalling pathway by targeting its activator, TopBP1, for proteasomal degradation 
(Blackford, et al. 2010). These studies illustrate that adenovirus types have evolved differently, 
such that although homologous proteins from different types retain many of the same functions, 
functional differences do exist between homologous proteins, particularly for the E1B-55K and 
E4orf6 proteins (Forrester, et al. 2012; Blanchette, et al. 2013). As we have made Flp-In T-
REx -inducible U2OS cell lines for Ad5 and Ad12 E1B-55K, E4orf3 and E4orf6 (Chapter 3), 
it was our intention to investigate functional differences between homologous Ad5 and Ad12 
proteins. As we have previously studied differences in the functional ability of Ad5 and Ad12 
E4orf6 to promote the degradation of TopBP1 for proteasomal degradation, we decided to 
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prioritise our studies with adenovirus E4orf6 to see if we could find other functional differences 
between these two proteins. These studies are presented in this Chapter. 
4.2. Results  
4.2.1. Post-translational modification of the Ad5 E4orf6 protein 
It has long been known that adenovirus early region proteins E1A and E1B-55K exist as 
phosphorylated species (Tremblay, et al. 1988; Blackford and Grand, 2009), whilst more recent 
studies have indicated that Ad5, but not Ad12, E1B-55K functions as a SUMO E3-ligase for 
p53 and can also PTM, namely autoSUMOylation, or E1B-dependent SUMOylation (see 
Introduction, section 1.2.2; Endter, et al. 2001; Blackford and Grand, 2009). Although E4orf6 
cooperates with both E1B-55K and E4orf3, it is not known whether E4orf6 possesses distinct 
enzymic activities or is subject to regulation through PTM. Interestingly, results presented in 
the last chapter suggested that Ad5 E4orf6 was subjected to PTM, whilst Ad12 E4orf6 was not 
[cf Fig. 3.17 A and B]. Given these findings we decided to identify and characterise the PTM 
status of Ad5 E4orf6. 
 
4.2.2. Investigating the potential O-linked glycosylation of the Ad5 E4orf6 protein 
4.2.2.1. Analysis of the Ad5 and Ad12 E4orf6 protein sequences for O-linked 
glycosylation 
One of the well-studied PTMs is glycosylation where a sugar moiety (Glycan) is attached to 
proteins to modify their structure and function. Glycosylated proteins are classified into five 
distinct types: N-linked glycans, C-linked glycans, O-linked glycans, glypiation and 
phosphoglycans (Ali, et al. 2019). O-linked glycosylation-the attachment of glycans to 
hydroxyl groups of Ser and Thr residues in proteins passaging through the golgi to form 
complex branched oligosaccharide structures, have pivotal roles in different cellular processes 
(Karve and Cheema, 2011). Interestingly, viruses utilize the host-cell glycosylation machinery 
to glycosylate their surface proteins to enhance infectivity. Prominent examples include Ebola 
virus, HIV-1 and influenza virus (Bagdonaite and Wandall, 2018; Watanabe, et al. 2019). In 
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addition to these enveloped viruses, non-enveloped viruses such as adenoviruses utilize sialic 
acid-containing oligosaccharides as cell surface receptors (Stencel-Baerenwald, et al. 2014).  
 
Inspection of predicted O-linked glycosylation sites in Ad5 and Ad12 E4orf6 using the 
NetOGlyc 4.0 - prediction software revealed major differences in the potential O-linked 
glycosylation of these two proteins [Fig. 4.1]. Indeed, analysis of these proteins revealed that 
there are ten potential O-linked glycosylation sites in Ad5 E4orf6, all located in the N-terminal 
region of the protein, whereas Ad12 E4orf6 was shown not to possess any potential O-linked 
glycosylation sites in the whole protein [Fig. 4.1]. Indeed, it was particularly striking that the 
N-terminal region of Ad5 E4orf6 possessed multiple Ser and Thr residues, whereas Ad12 
E4orf6 did not. These analyses suggested the possibility that Ad5 E4orf6 might be modified 




Figure 4.1:Potential O-linked glycosylation sites in Ad5 E4orf6 and Ad12 E4orf6 protein. 
The NetOGlyc 4.0 - prediction program was used to identify potential O-linked glycosylation 
sites in Ad5 E4orf6 and Ad12 E4orf6 amino acids sequence. (A) Ad5 E4orf6 (B) Ad12 E4orf6. 
start/end relate to amino acid residue. The probability-based score of O-linked glycosylation is 
listed under score and the likelihood of that site being glycosylated is listed under comment. 
 
4.2.2. Investigating whether Ad5 E4orf6 is modified by O-linked glycosylation  
The first step in protein O-linked glycosylation is the transfer of GlcNAc from UDP-GlcNAc 
to the Ser and Thr residues of substrate proteins, which is catalysed by the O-linked N-
acetylglucosamine (O-GlcNAc) transferase, OGT. An inhibitor of OGT has been developed, 
OSMI-1 (OGT small molecule inhibitor) which prevents the ability of OGT to catalyse the 
transfer of GlcNAc from UDP-GlcNAc to Ser and Thr residues such that complex 
glycosylation of target proteins is inhibited (Ortiz-Meoz, et al. 2015).  Taking advantage of the 
ability of OSMI-1 to inhibit O-linked glycosylation, we investigated whether OSMI-1 could 




A) Ad5 E4orf6  
B) Ad12 E4orf6  
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OSMI treatment upon the PTM status of the Ad5 E4orf6 protein [Fig. 4.2]. These data indicated 
that it was unlikely that the PTMs observed on Ad5 E4orf6 were due to O-linked glycosylation. 
 
Figure 4.2: The OGT inhibitor, OSMI-1 does not affect the PTM status of the Ad5 E4orf6 
protein. HA-tagged Ad5 E4orf6 expression was induced in a Flp-In T-REx U2OS-FRT cell 
line following treatment with 0.1 μg/ml doxycycline. Cells were simultaneously treated with 
different concentrations of the OGT inhibitor, OSMI-1, or equivalent amounts of DMSO 
vehicle. At 24 h post-treatment cells were harvested and subjected to SDS-PAGE and WB 
analysis with an anti-HA antibody. The data shown is representative of 3 independent 
experiments. 
 
4.2.3 Investigating whether the Ad5 E4orf6 protein is subject to ubiquitylation 
Given the known role of Ad5 E4or6 in the proteasomal-mediated degradation of cellular 
proteins and its ability to interact with CRL5 we next investigated whether the higher molecular 
weight Ad5 E4orf6 species were ubiquitylated forms. In the first instance therefore, we decided 
to investigate whether, the peptide-aldehyde proteasome inhibitor, MG132 (carbobenzoxyl-L-
leucyl-L-leucyl-L-leucine), which inhibits the chemotryspin-like peptidase activities of the 20S 
proteasome β5-subunit (Goldberg, 2012), affected the cellular levels of Ad5 E4orf6. Low 
exposure WBs revealed that the unmodified Ad5 E4orf6 species was increased substantially in 
the presence of MG132 [cf lanes 3 and 4, as well as 7 and 8, Fig. 4.3]. Similarly, the higher 
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molecular weight forms of Ad5 E4orf6 were also increased dramatically following treatment 
with MG132 [cf lanes 3 and 4, as well as 7 and 8, Fig. 4.3]. These data suggest that Ad5 E4orf6 
is targeted for degradation through the 26S proteasome and that the higher molecular weight 
forms of Ad5 E4orf6 are ubiquitylated species. 
 
 
Figure 4.3: Effect of the proteasome inhibitor, MG132 on the PTM status of HA-tagged 
Ad5 E4orf6. Flp-In T-REx U2OS Ad5 HA-tagged-E4orf6 cells were treated +/- 0.1µg/ml 
doxycycline in the presence or absence of 1μM MG132. Cell lysates were harvested at 24 h 
and 48 h post-treatment and subject to WB analysis with anti-HA antibodies. The data shown 
is representative of 3 independent experiments. 
 
4.2.4. Effects of the NAE inhibitor, MLN4924 on Ad5 E4orf6 expression 
Given that the Ad5 E4orf6 protein associates with CRL5 via Elongins B and C and, potentially 
the Cullin itself (Querido, et al. 2001; Gilson, et al. 2014), it is possible that CRL5 itself, 
through direct interaction, promotes Ad5 E4orf6 ubiquitylation. MLN4924 is a small molecule 
inhibitor of the NEDD8-activating enzyme (NAE), which inhibits the NEDDylation and 
consequent activation of the CRL complex (Soucy, et al. 2009; Nawrocki, et al. 2012). Indeed, 
MLN treatment of Ad-infected cells is known to inhibit the Ad-mediated degradation of a 
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number of cellular proteins (Blackford, et al. 2010; Nazeer, et al. 2019). To investigate whether 
CRL5 was responsible for Ad5 E4orf6 ubiquitylation, we investigated whether MLN4924 
affected Ad5 E4orf6 protein levels and/or Ad5 E4orf6 PTM status. WB analysis revealed that 
MLN4924 treatment increased the levels of the non-modified Ad5 E4orf6 species [first panel, 
Fig 4.4]. Longer exposures suggested that MLN4924 treatment also increased the overall levels 
of ubiquitylated Ad5 E4orf6 species but only very slightly [second panel, Fig. 4.4]. Given the 
increase in the overall levels of the unmodified Ad5 E4orf6 protein it is unlikely that there was 
an actual increase in the overall level of Ad5 E4orf6 ubiquitylation in the presence of 
MLN4924. These data suggest that CRL5 might also be responsible for regulating the stability 
of the Ad5 E4orf6 protein. 
 
Figure 4.4: Effect of the NAE inhibitor, MLN4924 on the levels of unmodified HA-tagged 
Ad5 E4orf6 and the PTM status of HA-tagged Ad5 E4orf6. Flp-In T-REx U2OS Ad5 HA-
tagged-E4orf6 cells were treated +/- 0.1µg/ml doxycycline in the presence or absence of 3 μM 
MLN4924. Cell lysates were harvested at 24 h post-treatment and subject to WB analysis with 
anti-HA antibodies. The data shown is representative of 3 independent experiments. 
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4.2.5. Cellular localization of ubiquitylated Ad5 E4orf6 species 
As discussed earlier Ad5 E4orf6 is a nucleo-cytoplasmic shuttle protein that participates in the 
transport of viral mRNAs from the nucleus to the cytoplasm (see section 1.2.4.2). As such, Ad5 
E4orf6 exists as both nuclear and cytoplasmic species. It also known that the 26S proteasome 
exists as both nuclear and cytoplasmic species (Turnell, et al. 2000). We therefore considered 
it important to investigate whether Ad5 E4orf6 was ubiquitylated and targeted for degradation 
in the nucleus or the cytoplasm. To investigate the site of Ad5 E4orf6 ubiquitylation and 
degradation we performed subcellular fractionation from to isolate cytoplasmic, 
nucleoplasmic, chromatin-associated and chromatin preparations from Flp-In T-REx Ad5 HA-
tagged-E4orf6 U2OS cells. WB analyses revealed that Ad5 E4orf6 was predominantly located 
in the cytoplasm, although it was also found in the nucleoplasm, and chromatin-associated and 
chromatin fractions [panel i, Fig. 4.5]. These analyses also revealed that ubiquitylated Ad5 
E4orf6 species were found exclusively in the cytoplasm [panel i, Fig. 4.5], suggesting that 
Ad5E4orf6 is subject to CRL5-dependent ubiquitylation and 26S proteasome degradation in 




Figure 4.5: Ad5 E4orf6 ubiquitylated species exist exclusively in the cytoplasm. Flp-In T-
REx Ad5 HA-tagged-E4orf6 U2OS cells were treated +/- 0.1µg/ml doxycycline. Cell 
fractionation was performed 24 h post-treatment and subject to WB analysis with anti-HA 
antibodies [panel i], or anti-histone H3 antibodies [panel ii]. The data shown is representative 
of 3 independent experiments. 
 
4.2.6 Generation and characterization of K95R and K171R Ad5 E4orf6 mutants 
4.2.6.1. Inspection of the Ad5 E4orf6 primary sequence 
It is generally accepted that lysine is the canonical ubiquitin acceptor site, though non-
canonical acceptor sites have also been described (e.g. N-terminal amine groups of proteins, 
serine and threonine hydroxyl groups, cysteine thiol groups); (McDowell, et al. 2013). In order 
to establish the ubiquitin acceptor sites in Ad5 E4orf6 we first inspected the Ad5 E4orf6 
primary sequence and established that Ad5 E4orf6 only possesses two lysine residues in its 
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entire sequence, K95 and K171 [Fig. 4.6], whilst multiple alignment of adenovirus E4orf6 
sequences from different adenovirus groups revealed that K95 is only weakly conserved 
between adenovirus types (only Ad5 and Ad12), although a number of adenovirus types did 
have arginine at this site but K171 was much more well conserved between adenovirus types 
[Fig. 4.6].  
 
Figure 4.6: Analysis of Ad5 E4orf6 sequence and the conservation of K ubiquitin acceptor 
sites between different adenovirus types. Adenovirus E4orf6 species from multiple 
adenovirus groups were aligned using the multiple alignment program, CLUSTAL W. 




4.2.6.2. Generation of Ad5 E4orf6 lysine mutants 
In order to establish whether K95 and/or K171 of Ad5 E4orf6 served as K acceptors for 
ubiquitin we decided to perform site-directed mutagenesis using the Q5 site-directed 
mutagenesis kit using the primers detailed using pcDNA5-FRT-Ad5 E4orf6 as a template (see 
Material and Methods section 2.3.8). In this regard we made replaced lysine with arginine in 
an attempt to conserve Ad5 E4orf6 secondary and tertiary structure. Initially, therefore we 
made K95R and K171R single mutants and confirmed sequence identity and mutation by 
Sanger sequencing of the entire gene. For clarity only the sequence where the mutation was 
incorporated is shown [Fig. 4.7].  
 
 
Figure 4.7: Generation of K95R and K171R Ad5 E4orf6 mutants. Chromas images of 
single mutants showing the K95R mutation and the K171R mutation where lysine (AAG) is 
mutated to arginine (AGG).  
 
4.2.6.3. Investigating the effects of K95R and K171R mutation on Ad5 E4orf6 
ubiquitylation status 
To investigate the requirement for both K95 and K171 as ubiquitin acceptors we transiently 
transfected w.t. pcDNA5 FRT Ad5 E4orf6 and pcDNA5 FRT Ad5 E4orf6 mutants into U2OS 
cells that did not express a TET repressor such that the genes would be expressed in the absence 
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of doxycycline treatment. We took this approach as we anticipated that we would be able to 
get more similar expression of w.t. Ad5 E4orf6 and its mutants by transient expression rather 
than by generating Flp-In T-REx-inducible U2OS cell lines. Indeed, WB analyses revealed that 
the expression levels of unmodified HA-tagged Ad5 E4orf6 species were very similar for w.t., 
K95R and K171R species [Fig. 4.8]. More interestingly, it appeared that mutation of either 
potential K acceptor reduced the PTM of HA-tagged Ad5 E4orf6, suggestive that both of these 
residues were subjected to polyubiquitylation. It did appear, however that mutation of K171 
was the major site for PTM, as mutation of K171 had more of a detrimental effect upon PTM 
than did mutation of K95 [Fig. 4.8]. Taken together these data indicate that both K95 and K171 
are likely subjected to polyubiquitylation upon the expression of Ad5 E4orf6. 
 
Figure 4.8: Investigating a role for K95 and K171 as ubiquitin acceptor residues in Ad5 
E4orf6. U2OS cells were transfected transiently with either w.t. pcDNA5 FRT Ad5 E4orf6, 
pcDNA5 FRT K95R Ad5 E4orf6 or pcDNA5 FRT K171R Ad5 E4orf6 expression plasmids. 
Cell lysates were harvested at 24 h post-treatment and subject to WB analysis with anti-HA 




4.2.7. Targeting of the Ubiquitin-Proteasome System by Ad12 E4orf6 
Although Ad12 E4orf6 was not a major substrate for ubiquitylation we wished to investigate 
its function in more detail. Previous studies from our laboratory have established that Ad12 
E4orf6 can promote the CRL2-dependent degradation of the ATR activator, TopBP1, 
independently of E1B-55K (Blackford, et al. 2010). Given this finding we wondered whether 
Ad12 E4orf6 could target other cellular proteins for degradation independently of E1B-55K. 
Indeed, this was the primary reason we made the Tet-inducible Ad12 HA-tagged-E4orf6 U2OS 
cells described in Chapter 3. Consistent with our earlier studies induction of Ad12 E4orf6, but 
not Ad5 E4orf6, promoted the degradation of TopBP1 (see Figure 3.14). To investigate 
whether Ad12 E4orf6 targeted other cellular proteins for degradation independently of E1B-
55K we adopted a mass spectrometric approach. This approach was taken in an attempt to 
define, in a non-biased way, global changes in the total levels of nuclear protein levels 
following Ad12 E4orf6 expression. We chose to focus on nuclear proteins as most proteins 
targeted by adenovirus for degradation are nuclear (e.g. p53, TopBP1, Mre11, DNA-ligase IV) 
and to simplify the dataset. To quantify nuclear proteins +/- Ad12 E4orf6 we chose to use the 
dimethyl, post-trypsinization, labelling approach, where those peptides isolated from + Ad12 
E4orf6 cells were labelled with ‘heavy’ formaldehyde (2H-CH20), whereas those peptides 
isolated from - Ad12 E4orf6 cells were labelled with ‘light’ formaldehyde (1H-CH20). This 
labelling strategy would produce peptides that would possess an N-terminal dimethyl label 
containing 2H or 1H that would produce a mass difference between identical peptide sequences 
of 2 mass units that could be detected by high resolution mass spectrometers. Data for each 
peptide pair identified from each protein would then be compared to produce a heavy:light 
peptide ratio, which relates to their relative abundance. This technique requires that both the 
heavy and the light forms of the peptide are found to provide a ratio, such that in circumstances 
where Ad12 E4orf6 expression induces a complete loss of a protein, these proteins will not be 
identified as being reduced upon Ad12 E4orf6 expression. Other issues, such as incomplete 
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dimethylation labelling could affect peptide quantification, though on the plus side this 
technique is much cheaper than similar methods such as SILAC.  
4.2.7.1. Identification of cellular proteins that are reduced in levels following Ad12 
E4orf6 expression 
For these experiments we chose #8 of the Ad12 E4orf6 U2OS FlpIn cells which expressed 
Ad12 E4orf6 to high levels and also targeted TopBP1 for degradation [Fig. 3.14]. Nuclear cell 
lysates +/- Ad12 E4orf6 were isolated and processed for MS analysis as described (see sections 
2.2.11 and 2.2.12). They were then subject to mass spectrometry using an Impact TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany) and analysed by WARP-LC (Bruker) and 
ProteinScape 2.1 (Bruker Daltonics), to obtain ratios of ‘Heavy’ to ‘Light’ peptides and a 
quantitative readout of the effect of Ad12 E4orf6 expression on the absolute levels of nuclear 
proteins from U2OS cells; data is presented as a waterfall plot for simplicity [Fig. 4.9]. In two 
separate experiments we identified 256 different proteins where we isolated one or more 
peptides to allow for the effect of Ad12 E4orf6 on cellular protein levels to be determined.   
 
 
Figure 4.9: Effect of Ad12 E4orf6 expression on nuclear protein levels. Nuclear lysates 
from +/- Ad12 E4orf6 cells were isolated and prepared for quantitative analysis by mass 
spectrometry (sections 2.2.11-2.2.13). Combined data from two separate experiments is shown. 





Table 4.1: Effect of Ad12 E4orf6 expression on nuclear protein levels. Table illustrating 
those nuclear proteins whose levels reduced the most following the expression of Ad12 HA-
tagged E4orf6. The number of peptides identified from each protein is indicated, as is the 
overall Mowse score, which is a statistical score for how well the experimental data matches 
the database sequence. The score shown for each protein is the sum of scores for individual 
peptides. 
 
Close inspection of the data revealed that all of the core histone proteins (H2A, H2B, H3 and 
H4) which comprise the histone octamer were reduced substantially upon Ad12 E4orf6 
expression, as was the histone linker protein, histone H1 [Table 4.1]. In some instances 
different histone isoforms were also identified as being reduced, such as histone H1.1 and H1.2 
and histone H2A type 2-B and 1-H [Table 4.1]. Importantly, multiple different peptides were 
identified from each histone species giving a high degree of confidence that the observed 
reduction in the levels of these proteins is real representation of what is happening in the cell. 
A number of 60S and 40S ribosomal proteins were also observed as being reduced following 
Ad12 E4orf6 expression though typically only 3 or 4 peptides were identified and quantified 
from each of these proteins, and the overall confidence score was lower than those observed 
for the histones, though is still high enough to suspect these changes were real [Table 4.1]. 
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Unfortunately, although we have previously shown we did not observe the known Ad12 E4orf6 
target, TopBP1 in this mass spectrometric screen. This is likely due to one of two reasons. 
Either all of the TopBP1 was degraded in the Ad12 E4orf6 expressing cells such that no ‘heavy’ 
TopBP1 peptides were detected in that sample, or, alternatively that the nuclear levels of 
TopBP1 were not as abundant as those that were detected by mass spectrometry. An 
interactomic map of those proteins identified as, potentially, being targeted by Ad12 E4orf6 is 
















Figure 4.10: Effect of Ad12 E4orf6 expression on nuclear protein levels. Protein-Protein 
interaction network for those 25 proteins whose levels are reduced the most following Ad12 
E4orf6 expression. The figure was generated using the Protein-Protein Interaction Networks 
programme, String-db (https://string-db.org/). 
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In a number of cases peptides were only detected in one or the other experiment. In total we 
identified 389 different proteins that where only identified in one of the two experiments. The 
effects of Ad12 E4orf6 expression on cellular proteins were determined and are presented as a 
waterfall plot below [Fig. 4.11]. 
 
Figure 4.11: Effect of Ad12 E4orf6 expression on nuclear protein levels. Nuclear lysates 
from +/- Ad12 E4orf6 cells were isolated and prepared for quantitative analysis by mass 
spectrometry (sections 2.2.11-2.2.13). Data is combined from two experiments - proteins 
displayed were detected in just one of the two experiments. The log2 fold change is shown. 
 
Inspection of the data revealed that those proteins whose levels were reduced there was, 
typically, only one or two peptides identified which reduces confidence in what was observed 
was a reflection of what happens in response to Ad12 E4orf6 expression [Table 4.2]. This is 
reflected in the calculated Mowse scores. A few interesting proteins were detected including 
the recombination-repair protein, RAD51 and the Ras-related proteins, CDC42 and RhoA. The 




 Table 4.2: Effect of Ad12 E4orf6 expression on nuclear protein levels. Table illustrating 
those nuclear proteins which were detected in only one of the two experiments and whose 
levels were reduced the most following the expression of Ad12 E4orf6. The number of peptides 
identified from each protein is indicated, as is the overall Mowse score (see Table 4.1 for more 
details). 
 
Taken together these experiments reveal that we have identified a number of cellular proteins 
that are down-regulated following Ad12 E4orf6 expression. In the first instance it was 
important to validate these findings by WB using, particular drug treatments to establish 
whether, or not, these changes in cellular protein levels were due to Ad12 E4orf6’s ability to 
engage with the UPS. 
 
4.2.7.2. Effect of Ad12 E4orf6 expression upon cellular histone levels: WB analyses 
Our analyses identified two classes of nuclear proteins that appeared to be reduced following 
Ad12 E4orf6 expression: histones, which comprise the major protein component of the 
nucleosome, and ribosomal proteins that are synthesized and assembled in nucleoli before 
being translocated to the cytoplasm. Given that there is a large cytoplasmic component of 
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ribosomal proteins which our analyses did not investigate, we decided to focus our attention 
on the relationship between Ad12 E4orf6 expression and the levels of histones. Firstly, we 
decided to investigate by WB the effects of Ad12 E4orf6 expression on cellular histone levels 
using a number of individual Ad12 HA-tagged-E4orf6 U2OS FlpIn cell clones to establish 
whether the ability of Ad12 E4orf6 to reduce cellular histones was a common phenomenon. 
Given that we only observed between 10 and 60% reduction in nuclear histone levels by MS 
analyses after 24h post-induction we decided to extend the induction time to 48 h to maximize 
any Ad12 E4orf6 affects. WB analyses revealed that, in addition to the known Ad12 E4orf6 
target TopBP1, the total cellular levels of histone H3 and histone H2A were also reduced 
appreciably following Ad12 HA-tagged-E4orf6 expression [Fig. 4.12]. Taken together these 
data validate the MS findings that histones are reduced in an Ad12 E4orf6-dependent manner 
 
 
Figure 4.12: Effect of Ad12 E4orf6 expression on histone H3 and H2A protein levels. 
Whole cell lysates from Ad12 HA-tagged-E4orf6 U2OS FlpIn cells treated +/- 0.1 μg/ml 
doxycycline were harvested 48 h post-treatment and subjected to SDS-PAGE and WB analysis 
with the appropriate antibodies. # represents clone number.  The data shown is representative 
of 3 independent experiments. 
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Given that Ad5 E4orf6 lacks the ability to promote the degradation of TopBP1 (Blackford, et 
al. 2010) we next investigated whether Ad5 E4orf6 could promote the cellular loss of histones. 
WB analyses revealed that Ad5 E4orf6 was unable to promote a reduction in the levels of 
TopBP1, histone H3 or histone H2A indicating that the ability of Ad12 E4orf6 to target cellular 
histones is not conserved in Ad5 E4orf6 [Fig. 4.13].  
 
Figure 4.13: Effect of Ad5 E4orf6 expression on histone H3 and H2A protein levels. 
Whole cell lysates from Ad5 HA-tagged-E4orf6 U2OS FlpIn cells treated +/- 0.1 μg/ml 
doxycycline were harvested at 24 and 48 h post-treatment and subjected to SDS-PAGE and 
WB analysis with the appropriate antibodies. The data shown is representative of 3 independent 
experiments. 
 
4.2.7.3. Role of CRLs and the 26S proteasome in the Ad12 E4orf6-dependent 
modulation of cellular histone levels  
Given the role of CRLs and the 26S proteasome in the Ad-mediated degradation of cellular 
protein substrates (see section 1.3.2.1) we next decided to investigate whether they were 
similarly responsible for the Ad12 E4orf6-induced reduction in the levels of cellular histones. 
To do this we incubated Ad12 HA-tagged-E4orf6 U2OS cells in the absence or presence of the 
CRL inhibitor, MLN4924 (as described in section 4.2.4), or the irreversible 26S proteasome 
inhibitor, Lactacystin (Pasquini, et al. 2003). Consistent with previous work from our 
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laboratory induction of Ad12 E4orf6 expression promoted the CRL and 26S proteasome-
mediated degradation of TopBP1 [panel i, Fig. 4.14]. Interestingly, the CRL inhibitor, MLN-
4924 and the 26S proteasome inhibitor also limited the Ad12E4orf6-dependent reduction in 
both histone H3 and H2A protein levels which was more evident at 48 h post-treatment [panels 
ii and iii, respectively, Fig. 4.14]. These data suggest that Ad12 E4orf6 interacts with CRL2 in 
cells to target core histone proteins, H3 and H2A for 26S proteasome-dependent degradation. 
 
Figure 4.14: Requirement for CRLs and the 26S proteasome in the Ad12 E4orf6-
dependent modulation of histone H3 and H2A protein levels. Whole cell lysates from Ad12 
HA-tagged-E4orf6 U2OS FlpIn cells treated +/- 0.1μg/ml doxycycline in the absence or 
presence of 3M MLN-4924 or 1 M Lactacystin were harvested at 24 and 48 h post-treatment 
and subjected to SDS-PAGE and WB analysis with the appropriate antibodies. The data shown 
is representative of 3 independent experiments. 
 
4.2.7.4. Effect of Ad12 E4orf6 expression on core histone protein expression 
The WB analyses presented in Figures 4.12 and 4.13 indicate that Ad12 E4orf6, but not Ad5 
E4orf6, expression promotes the loss of histones H2A and H3. To see if other core histones 
were also affected by Ad12 E4orf6 expression we decided to analyze core histone expression 
by SDS-PAGE following the acidic extraction of histones from Flp-In T-REx -U2OS 
adenovirus E4orf6 cells; acid extraction of histones is a well characterized technique for the 
isolation of histones (see section 2.2.7 for details). Consistent with the WB data coomassie blue 
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staining of SDS-PAGE gels revealed that Ad12 E4orf6 expression reduced the protein levels 
of all core histones, whereas Ad5 E4orf6 did not [Fig. 4.15]. Unfortunately, although the 
proteins were run on a 14% (w/v) acrylamide gel we could not separate H2A and H2B. These 
data indicate that Ad12 E4orf6, specifically modulates the protein levels of all core histones.  
 
Figure 4.15: Ad12 E4orf6-dependent modulation of core histone protein levels. Ad5 and 
Ad12 HA-tagged-E4orf6 U2OS FlpIn cells were treated +/- 0.1μg/ml doxycycline for 24h. 
Histones were isolated by acid extraction (see section 2.2.7), separated by SDS-PAGE and 
stained with coomassie brilliant blue stain. The gel shown is representative of 3 independent 
experiments. The histogram represents the mean of all histone data (i.e. H3+ H2A/H2B + H4) 
from 3 independent experiments +/- S.D using ImageJ for densitometry. A two-tailed, paired 
student T-test indicated that there was no significant difference between Ad5 E4orf6 +/- 
doxycycline samples (p=0.74), whereas a two-tailed, paired student T-test indicated that there 
was a significant difference between Ad12 E4orf6 +/- doxycycline samples (* p=0.009). 
 
4.2.7.5. Ad12 E4orf6 interacts with core histones in vitro 
As we have shown that Ad12 E4orf6 promotes the degradation of core histones H3 and H2A 
[Fig. 4.12] and potentially all core components of the histone octamer [H3-H4 and H2A-H2B 
dimers; Fig. 4.15] and targets them for degradation in a CRL and 26S proteasome-dependent 
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manner we decided to investigate whether Ad12 E4orf6 could interact with core histones 
directly. To do this we first cloned the Ad12 E4orf6 gene into the bacterial GST expression 
vector, pGEX-4T-1 (using the primers listed in section 2.3.4), and then expressed and purified 
GST-Ad12 E4orf6 from the protease-deficient bacterial strain, BL21 as described in section 
2.2.8. We then performed a GST pull-down by mixing either GST or GST-Ad12 E4orf6 with 
calf histones (Fraction VII; Sigma-Aldrich) that comprise all the core histones and also the 
linker histone, H1 (see section 2.2.9). Following SDS-PAGE and transfer to nitrocellulose 
filters, proteins were stained with ponceau S to visualise GST proteins and any associated 
histones. Protein staining revealed that GST alone did not associate with core histones but GST-
Ad12 E4orf6 did [cf lanes 3 and 4, Fig. 4.16]. Staining also revealed that Ad12 E4orf6 did not 
associate, particularly with histone H1 [Fig 4.16]. These data indicate that AdE4orf6 has the 
capacity to interact directly with core histones in vitro. 
 
Figure 4.16: GST-Ad12 E4orf6 associates with histones in vitro. 5 µg of GST and GST-
Ad12 E4orf6 were incubated in the absence or presence of 5 µg calf thymus histone fraction 
VII by end-to-end mixing for 2 h at 4°C. GST proteins and associated proteins were then 
captured upon glutathione agarose by end-to-end mixing for an additional 2 h at 4°C. 
Glutathione-agarose associated proteins were separated by SDS-PAGE, transferred to 
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nitrocellulose and stained with ponceau-S to visualise binding. The first image shows the actual 
staining observed. The contrast of the second image has been altered so that the difference in 
histone binding between GST and GST-Ad12 E4orf6 is more clearly visible. The data shown 
is representative of 3 independent experiments. 
 
4.2.7.6. Investigating the ability of Ad12 E4orf6 complexes to ubiquitylate core histones 
in vitro 
As Ad5 E4orf6 has previously been shown to associate with CRL5 to ubiquitylate p53 in vitro 
ubiquitylation assays (Querido, et al. 2001), we decided to adopt a similar approach to see if 
Ad12E4orf6 complexes immunoprecipitated from HA-Ad12 E4orf6 U2OS cells could 
promote the ubiquitylation of core histones in vitro. To do this we immunoprecipitated Ad12 
E4orf6 from HA-Ad12 E4orf6 U2OS cells [section 2.2.5] and incubated immunoprecipitates 
with histone fraction VII (Sigma-Aldrich) in the presence of an E1-activating enzyme, the 
promiscuous E2-conjugating enzyme-UbcH5a, ubiquitin and an ATP regeneration mix. After 
the reactions had been performed they were separated upon SDS-PAGE and analysed by WB 
for H2A and H3 ubiquitylation. WB revealed that histone H2A was not post-translationally 
modified to any great extent, although a feint higher molecular weight band was observed [Fig. 
4.17]. WBs revealed that histone H3 was modified but there was no obvious difference between 
the levels of modification between the IgG control and the anti-HA immunoprecipitates. This 
experiment was only performed once in duplicate and thus requires optimisation but it suggests 
that under the experimental conditions used Ad12 E4orf6 immunocomplexes do not possess 




Figure 4.17: Histone-directed in vitro ubiquitylation assay. HA-Ad12 E4orf6 was 
immunoprecipitated from Flp-In T-REx Ad12 HA-tagged-E4orf6 U2OS cells with anti-HA 
antibodies, 12CA5 and 16B12, or a mouse IgG control onto Protein G sepharose beads. 
Immunoprecipitates were incubated with  an E1-activating enzyme, an E2-conjugating 
enzyme-UbcH5a, ubiquitin and an ATP regeneration mix in the presence of 1g core histones 
(histone fraction VII; Sigma-Aldrich) for 1 h at 37°C. Samples were then separated on SDS-
PAGE and subject to WB analysis with anti- H2A and anti-H3antibodies. Arrows indicate 
potential ubiquitylated versions of H2A and H3. Images taken from one experiment performed 
in duplicate. 
 
4.2.7.7. Investigating the effects of w.t. Ad5 and w.t. Ad12 infection upon cellular 
histone levels  
As we have shown that Ad12 E4orf6, in isolation, promotes the degradation of all core histones 
we wished to investigate whether the levels of core histones were also reduced during infection 
with w.t. Ad12 or w.t. Ad5. WB anlyses revealed that the levels of cellular histone proteins, 
histone H2A and histone H3, were reduced considerably after infection with either w.t. Ad5 or 
w.t. Ad12 [panels i and ii, Fig. 4.18]. The Ad12 data is consistent with the Ad12 E4orf6 data 
presented earlier [Fig. 4.12], whilst the Ad5 data is inconsistent with the Ad5 E4orf6 data 
presented earlier [Fig. 4.13]. The reasons for these discrepancies will be considered in the 
discussion of this chapter. Consistent with previous studies both Ad5 and Ad12 promoted the 
degradation of p53 [panel iii, Fig. 4.18], whilst only Ad12 promoted the degradation TopBP1 
[panel iv, Fig. 4.18]. Taken together these data suggest that adenoviruses from diverse groups 
149 
 
have the conserved ability to promote the reduction of cellular histone expression during 
infection.  
 
Figure 4.18: Effects of w.t. Ad5 and w.t. Ad12 infection on cellular histone levels. A549 
cells were mock-infected or infected with w.t. Ad5 or Ad12 at an m.o.i of 10 p.f.u./cell. Cells 
were harvested and subjected to WB analysis at the indicated times post-infection using 
antibodies raised against the proteins indicated. β-actin was used as a loading control. 
Representative of 3 independent experiments. 
 
4.2.7.8. Effects of w.t. Ad5 and w.t. Ad12 on core histone protein expression 
As w.t. Ad5 infection reduced the amount of cellular histone H3 and histone H2A we next 
decided to investigate whether Ad5 and Ad12 similarly reduced the levels of the other core 
proteins. We therefore infected A549 cells with these viruses, as described above and 
performed acidic extraction of basic proteins after 24h post-infection. The isolated proteins 
were then separated by SDS-PAGE and stained with coomassie blue. Consistent with the WB 
studies, protein staining revealed that all core histones were reduced following both w.t. Ad5 
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and w.t. Ad12 infection [Fig. 4.19]. These data are consistent with those presented in [Fig. 
4.18] and confirm that a reduction in cellular histone levels is a common feature of both Ad5 
and Ad12 infection. 
 
Figure 4.19: Effects of w.t. Ad5 and w.t. Ad12 infection on core histone protein levels. 
A549 cells were mock-infected or infected with w.t. Ad5 or Ad12 at an m.o.i of 10 p.f.u./cell. 
Histones were isolated 24 h post-infection by acid extraction (see section 2.2.7), separated by 
SDS-PAGE and stained with coomassie brilliant blue stain. The data shown is from one 
experiment, and representative of one other independent experiment. 
 
4.2.8 Effect of Ad5 E4orf6 and Ad12 E4orf6 expression on chromosomal aberrations  
4.2.8.1 Metaphase spreads for Ad5 and Ad12 E4orf6 Flp-In T-Rex U2OS cell lines 
It is well known that in order to maintain genomic integrity host cells trigger cellular defence 
pathways (Blackford and Jackson, 2017; see section introduction, section 1.4), but, in mitosis, 
there is no DNA damage repair (Rieder and Cole, 1998), such that DNA lesions are stabilised 
and undergo repair in the following G1 phase (Lee, et al. 2016). However, DNA lesions are 
marked for repair during mitosis such that phosphorylation of histone H2AX marks sites of 
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DNA damage and recruits the DDR and scaffold protein, MDC1 to these sites (Giunta and 
Jackson, 2011). Recently, it was found that MDC1 associates with TopBP1 to tether DSBs 
during mitosis until repair factors are reactivated in G1 phase (Leimbacher, et al. 2019). 
Disruption of MDC1-TopBP1 association in mitosis is responsible for increased chromosomal 
aberrations during cell cycle (Leimbacher, et al. 2019). We have shown that TopBP1 is targeted 
for degradation following the expression of Ad12 E4orf6 but, not Ad5 E4orf6 (see section 
3.2.3.4), which is consistent with published results from our laboratory (Blackford, et al. 2010). 
Given this relationship between Ad12 E4orf6 and TopBP1 we hypothesized that, the loss of 
TopBP1 following Ad12 E4orf6, but not Ad5 E4orf6, expression would increase the number 
of chromosomal aberrations during mitosis. To test this possibility we investigated the effects 
of Ad5 and Ad12 E4orf6 expression upon chromosomal aberrations in mitosis by performing 
metaphase-spread analyses (Materials and Methods, section 2.3.10). Metaphases were viewed 
using a Zeiss Axioscop light-microscope; images were captured using Axiovision software. 
We then quantified the number of chromosomal aberrations observed in each metaphase: i.e. 
chromosome and chromatid breaks and gaps were scored. 
Our analyses revealed that chromosomal aberrations were observed in all experimental 
conditions [Fig. 4.20, A and B], however, we observed more chromosomal aberrations, 
particularly chromosome breaks, following the expression of Ad12 E4orf6, relative to Ad5 
E4orf6, though significant increases in chromosomal aberrations were observed following the 
induction of both Ad5 E4orf6 and Ad12 E4orf6 [Fig. 4.20]. These results are consistent with 
our hypothesis that the Ad12 E4orf6-dependent degradation of TopBP1 destabilises MDC1 at 
chromosome and chromatid breaks and gaps, leading to higher levels of chromosomal 
aberrations in the presence of Ad12 E4orf6, although for completeness we do need to establish 
that Dox-treatment alone does not cause chromosomal damage. It is possible that Ad5 E4orf6 
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destabilises MDC1 via other mechanisms than TopBP1 degradation to cause chromosomal 
aberrations (Leimbacher, et al. 2019).  
 
 
Figure 4.20: Effects of Ad5 E4orf6 and Ad12 E4orf6 expression on chromosomal 
aberrations in mitosis. The Ad5 and Ad12 E4orf6 Flp-In T-Rex U2OS-FRT cell lines were 
induced with 0.1μg/ml doxycycline. 24h post induction cells were treated with 0.2μg/ml 
colcemid 4 hr prior to harvesting. Metaphase spreads were then isolated as described in the 
Materials and Methods, section 2.3.10). 30 individual metaphases for each experimental 
condition were viewed under a Zeiss Axioscop light-microscope at 100x magnification and 
images captured using Axiovision software. The data are represented as mean +/- S.D. two-
tailed, unpaired t test (n=3); *P<0.02, **P<0.003. Red triangles indicate chromososmal 






Several studies have identified a number of cellular substrates that are targeted for ubiquitin-
mediated proteolysis in an E4orf6 and E1B-55K CRL-dependent manner (Stracker, et al. 2002; 
Baker, et al. 2007). Importantly, the E4orf6 protein from all human adenovirus types (A-G) are 
characterised by their ability to associate with cellular CRLs (Gilson, et al. 2016). As such, 
E4orf6 from different adenovirus species (mast-, at- and avi- adenoviruses) all possess 
conserved Elongin B and C boxes and Cul boxes that allow E4orf6 to associate with specific 
CRLs (Gilson, et al. 2016). Work from our laboratory has also shown that Ad12E4orf6, at least, 
also has the ability to recruit TopBP1 for degradation (Blackford, et al. 2010). E1B-55K and 
E4orf6 help adenoviruses exploit ubiquitylation during infection to shape the cellular proteome 
in order to enhance productive infection (Dybas, et al. 2018). The generation of Ad5 and Ad12 
E4orf6 U2OS FRT-TREX cell lines (Chapter 3), has afforded us the opportunity to study 
E4orf6 function in isolation, particularly to investigate the role of E4orf6 in cellular 
degradation programmes independent of E1B-55K and the possibility that E4orf6 undergoes 
PTMs. These possibilities were considered in this chapter. 
4.3.2. Ad5 E4orf6 is post-translationally modified by ubiquitylation  
There is much evidence to indicate that adenovirus proteins are modified by different PTMs, 
such as phosphorylation and SUMOylation, which help promote viral replication and 
pathogenesis (Dybas, et al. 2018). Work presented in this chapter identified that Ad5 E4orf6 
but not, Ad12 E4orf6 was post-translationally modified, which has not been described 
previously [Fig. 3.17]. As Ad12 E4orf6 did not undergo PTM, we inspected the E4orf6 protein 
sequences from Ad5 and Ad12 and determined that Ad5 had 10 potential O-glycosylation sites, 
whilst Ad12 E4orf6 did not have any [Fig. 4.1]. Given that some viruses exploit glycosylation 
(Baker, et al. 2007; Bagdonaite and Wandall, 2018; Watanabe, et al. 2019), we investigated the 
effect of the OGT inhibitor, OSMI-1, on Ad5 E4orf6 PTM but it did not reduce its PTM 
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suggesting that the PTM observed on Ad5 E4orf6 was not O-glycosylation [Fig 4.2]. We next 
investigated whether manipulation of the UPS affected the PTM of Ad5 E4orf6. Significantly 
the proteasome inhibitor, MG132, elevated the level of both unmodified Ad5 E4orf6 and the 
PTM forms of Ad5 E4orf6, suggesting that the PTM on Ad5 E4orf6 was likely to be 
ubiquitylation [cf lanes 3 and 4, as well as 7 and 8, Fig. 4.3]. Studies with the NAE inhibitor 
were suggestive that the ubiquitylation of Ad5 E4orf6 was dependent upon cellular CRLs [Fig. 
4.4] and that Ad5 E4orf6 ubiquitylated species were found in the cytoplasm [panel i, Fig 4.5]. 
We next mutated K95 and K171 in isolation to ablate ubiquitin K acceptor function, which 
reduced appreciably Ad5 E4orf6 PTM suggesting both of these K residues were acceptor sites 
for ubiquitylation though K171 was the preferred site of ubiquitylation [Fig. 4.8], which 
interestingly is the most well conserved K residue in E4orf6 from multiple species [Fig. 4.6], 
suggesting that E4orf6 ubiquitylation might be conserved between species.  
The engagement of E1B-55K and E4orf6 with the cellular UPS to inactivate antiviral pathways 
during infection is well established (e.g. Querido, et al. 2001; Harada, et al. 2002; Blanchette, 
et al. 2004). Although viral early proteins have been shown to undergo PTM the data presented 
here is the first to suggest that a viral early protein is modified by ubiquitin, although co-IP-
WB studies with HA-tagged ubiquitin, or anti-ubiquitin antibodies needs to be performed to 
establish definitively that the PTM observed is ubiquitylation. Moreover, it will also be 
important to investigate whether Ad5 E4orf6 is subject to PTM during infection with w.t. Ad5 
or following cellular transformation. Although Ad5 E4orf6 function during infection has been 
extensively studied no publication has commented specifically on Ad5 E4orf6 PTM. Careful 
analysis of published work suggests that Ad5 E4orf6 is subject to PTM during infection (e.g. 
Fig 1B, (Schmid, et al. 2011), which interestingly appears to be increased following ablation 
of E4orf6’s nuclear export signal (Fig 1B, (Schmid, et al. 2011), though this was not mentioned 
in the text. In consideration of our data that indicates that ubiquitylated Ad5 E4orf6 is 
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cytoplasmic [Fig 4.5], the data published by Schmid and colleagues might suggest that E4orf6 
is ubiquitylated in the nucleus and then transported to the cytoplasm. Cellular transformation 
of baby rat kidney (BRK) cells with E1A, E1B-55K and E4orf6 also suggests that Ad5 E4orf6 
might undergo PTM (Fig. 2B, Nevels, et al. 2001), though again this was not discussed in the 
paper. 
The cellular consequence of Ad5 E4orf6 ubiquitylation needs to be considered in more detail. 
Initially, it would be worthwhile to establish that proteasome and NAE inhibitors increase the 
stability of Ad5 E4orf6, by measuring their effect upon Ad5 E4orf6 protein levels over a time-
course in the presence of the protein synthesis inhibitor, cycloheximide. Functionally, it could 
be envisaged that by engaging with CRLs, Ad5 E4orf6 effectively controls its own destruction- 
and the activity of cellular CRLs against adenovirus targeted substrates, during infection in a 
temporally-coordinated manner. As such, it would be interesting to establish, using the 
Ad5E4orf6 KR mutants, whether Ad5 E4orf6 degradation is required for the E1B-55K/E4orf6 
and CRL-dependent degradation of substrates, like p53 or Mre11, or whether enhanced 
stability of the KR E4orf6 mutants enhances the degradation of adenovirus substrates. As 
ubiquitylated Ad5 E4orf6 is found in the cytoplasm and that the E1B-55K/E4orf6-CRL is 
required for the transport of viral mRNA into the cytoplasm, it would also be interesting to 
establish, using the KR E4orf6 mutants, whether the transport of viral transcripts from the 
nucleus to cytoplasm is dependent on Ad5 E4orf6 ubiquitylation. This could be achieved by 
qPCR detection of viral transcripts in the cytoplasm using mutant KR-E4orf6 adenoviruses. 
Given that E4orf6 also possesses transforming capability in the presence of E1A and E1B-55K 
it would be also interesting to see whether ablation of Ad5 E4orf6 ubiquitylation sites by 
mutation also affects the ability of E4orf6 to participate in the cellular transformation of Rat 
embryo fibroblasts or BRKs with E1A and E1B-55K. Finally, it would be interesting to 
establish whether E4orf6 ubiquitylation was conserved between different adenovirus types and 
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if so, whether ablation of E4orf6 ubiquitylation from these adenovirus types affected its 
biological functions. 
Although many viruses encode proteins that modulate cellular CRL activity (e.g. HPV, SV40, 
EBV, KSHV, HSV1, HIV-1, HepB; reviewed by (Mahon, et al. 2014) there is little published 
information to indicate that the viral protein is also a substrate for the CRL to which it 
associates. The only possible exception is HPV E7 which associates with CRL2 to promote the 
degradation of pRB (Huh, et al. 2007). Although the Huh paper does not investigate E7 
ubiquitylation by CRL2, an earlier publication indicated that a Cullin 1 and Skp2- containing 
CRL could ubiquitylate E7 in an in vitro E3 ligase assay (Oh, et al. 2004). Experiments with 
proteasome inhibitors suggested that ubiquitylated E7 was transported to intranuclear bodies 
for proteasomal degradation (Oh, et al. 2004), though further studies have not considered 
whether HPV E7 association with CRL2 is responsible for regulating HPV E7 stability.  
4.3.3. Identification of core histone proteins as targets for CRL-dependent degradation 
following Ad12 E4orf6 expression 
Previous studies from our laboratory indicated that Ad12 E4orf6, in the absence of E1B-55K 
expression, targeted TopBP1 for degradation in a CRL2- dependent manner (Blackford, et al. 
2010). Here, we used a quantitative mass spectrometric approach using ‘heavy’ and ‘light’ 
formaldehyde to label peptides retrieved from cell lystaes +/- Ad12 E4orf6 expression, in order 
to identify other cellular proteins targeted for degradation by Ad12 E4orf6 (section 4.2.7). 
Using this approach we identified 256 different proteins from 2 independent experiments that 
were labelled with both ‘heavy’ and ‘light’ formaldehyde such that we could quantify the 
effects of Ad12 E4orf6 expression on their levels. Given that we only identified 256 cellular 
proteins it is perhaps not surprising that we did not identify TopBP1 in our analyses and 
identified, more abundant cellular proteins using this approach. Interestingly, however, we 
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identified core histone proteins as major targets for CRL and proteasome-mediated degradation 
following Ad12 E4orf6 expression [Table 4.1; Figs. 4.12-4.15].  
DNA is packaged inside the nucleus of the cell in chromatin. Approximately 146 DNA base 
pairs wrap around an octamer of core histone proteins (2 copies each of H3-H4 and H2A-H2B 
dimers) to form the nucleosome, the basic unit of chromatin (Mirza, et al. 1982). The function 
of the core histones goes beyond simple packaging of the DNA and histone PTM by 
acetylation, methylation, ubiquitylation, phosphorylation etc (modulated by histone writers and 
erasers), through histone readers regulates cellular gene expression, DNA replication and DNA 
repair. Core histones also have the capacity to modulate viral gene expression and DNA 
replication, as either proviral or antiviral agents (Sterner and Berger, 2000; Kobiyama, et al. 
2010). Indeed, Ad5 E1A interacts with the histone acetyltransferases CBP/p300 to modulate 
H3K18 acetylation, and moreover, regulates cellular transcription programmes during 
infection through interaction with both CBP/p300 and pRB (Horwitz, et al. 2008). Indeed, 
although E1A does not interact with core histones directly it has long been known to interact 
with histone writers, erasers and readers during infection to modulate histone function (Turnell 
and Gallimore, 2001). Moreover, most, if not all, viruses similarly encode proteins that interact 
with cellular chromatin writers, erasers and readers to regulate cellular transcription 
programmes to support viral replication (Wei and Zhou, 2010).  
Consistent with the ability of Ad12 E4orf6 to target core histones for degradation, we showed 
by GST pull-down assay that Ad12 E4orf6 interacts with core histones directly [Fig. 4.16]. 
These data are consistent with our earlier studies that determined that Ad12 E4orf6 also 
interacted with CRL2 substrate TopBP1 directly (Blackford, et al. 2010). Although many viral 
genomes, including adenovirus, become ‘chromatinized’ during infection and many viral 
proteins (e.g. adenovirus protein VII) also act as histone mimics to package viral DNA (see 
section 1.1.4) , to date there aren’t many viruses whose proteins are known to associate directly 
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with core histones to modulate their activity or levels. The Dengue virus capsid protein 
DENVC accumulates in the nucleus, where it associates with all core histones as heterodimers 
in order to disrupt and inhibit normal histone function (Colpitts, et al. 2011), whilst LANA 
from KSHV (Barbera, et al. 2006) and IE1 from CMV (Mücke, et al. 2014) bind directly to 
histones to an acidic pocket on the nucleosome surface to modulate higher order chromatin 
organization. The EBV BKRF4 tegument protein also binds to histone H2A-H2B and H3-H4 
dimers, through a different mechanism to LANA and IE1, to inhibit DDR signalling during 
EBV infection (Ho, et al. 2018). As such, it will be important to establish where Ad12 E4orf6 
binds to core histones and whether this is modulated by histone PTM. 
Work presented here indicated that although Ad5 E4orf6 could not promote the degradation of 
core histones directly, infection with w.t. Ad5, like w.t. Ad12, promoted the loss of cellular 
core histones [Figs. 4.18 and 4.19]. This might suggest that E4orf6 cooperates with E1B-55K 
during infection to promote histone degradation, and further studies should investigate this 
possibility and the role played by CRLs in this process. Work by Jane Flint over 35 years ago 
determined that histone gene expression was reduced following Ad2 infection of HeLa cells 
(Flint, et al. 1984) though the cellular protein levels of core histones were not investigated in 
that study, or in any study since. It is possible therefore during infection that histone levels are 
controlled at the level of transcription and translation. Interestingly, it has recently been shown 
that DNA damage promotes the proteasomal-mediated degradation of core histones by 20-40% 
(Hauer, et al. 2017). It might be that although adenovirus inhibits a number of DDR pathways 
during infection it is possible that other DDR pathways in Ad-infected cells are activated, 
which promote core histone loss.  
The question arises why adenovirus promotes the loss of cellular core histones during infection. 
It is most likely that adenoviruses modulate cellular transcription programmes and DNA 
replication programmes through the loss of core histones. It is possible that loss of histones 
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leads to an open chromatin configuration that promotes gene expression. It would be extremely 
interesting, given our findings to characterise whether histone loss is selective at the level of 
gene promoters and gene regions at the genomic level and correlates with cellular gene 
expression levels. It is also possible that core histone loss helps the virus to inhibit cellular 
DNA replication which requires histone deposition on newly synthesized DNA. These studies 
will help establish why adenoviruses selectively promote the loss of core histones during 
infection. 
4.3.4. Chromosomal aberrations following Ad5 and Ad12 E4orf6 expression 
Here we determined that the expression of both Ad5 E4orf6 and Ad12 E4orf6 induced 
chromosomal aberrations, particularly chromosomal breaks [Fig. 4.20, A and B]. The Ad12 
studies are in good agreement with the finding that loss of TopBP1 affects MDC1 stabilization 
of chromosome breaks and gaps during mitosis (Leimbacher, et al. 2019). How Ad5 E4orf6 
promotes chromosomal aberrations in this circumstance is not immediately clear as it does not 
promote TopBP1 degradation, though it might disrupt MDC1 function via other pathways 
(Leimbacher, et al. 2019). These findings are consistent with very early studies that indicate 
that adenovirus 12 infection resulted in chromosomal aberrations (zur Hausen, 1967; 
McDougall, 1970; Zur Hausen, 1976). Such chromosomal disruption might be important in 
how adenovirus can promote chromosomal and genomic instability that leads to cellular 
transformation by a ‘hit and run’ mechanism (Nevels, et al. 2001), and might explain why 
persistent adenovirus infection of lymphocytes has been linked with childhood acute 
lymphoblastic leukaemia (Gustafsson, et al. 2007).  
Collectively, the studies detailed in this Chapter have provided insights into the molecular 
functions of Ad5 and Ad12 E4orf6 proteins which have important ramifications for 






























5.1. Introduction  
Adenovirus viral replication centres are structural entities in the nucleus that coordinate viral 
transcription, viral DNA replication, viral particle assembly and packaging (Charman, et al. 
2019). Previous work in our laboratory attempted to identify proteins that are recruited to VRCs 
through interaction with the RPA complex, a cellular protein complex known to be recruited 
to VRCs (Qashqari, PhD thesis, University of Birmingham, 2017). Of those proteins identified, 
the FACT chaperone complex, comprising SPT16 and SSRP1, Pur and Pur transcriptional 
regulators and the RNA-binding protein, RBM14 were all identified as cellular proteins that 
are recruite to VRCs during infection and are thus considered worthy of further investigation. 
The FACT complex has been considered in detail in the introduction (section 1.1.5.1), so here, 
we will consider Pur, Pur and RBM14.  
Purα, Purβ and Purγ are members of the Pur protein family that are characterized by their high 
affinity for purine-rich elements (Lezon-Geyda, et al. 2001; Gupta, et al. 2007; Johnson, et al. 
2013). Pur proteins function in diverse aspects of cell growth and differentiation by regulating 
both transcription, translation and the modulation of apoptosis (Gupta, et al. 2007). Purα and 
Purβ have been reported to dysregulated in acute myelogenous leukemia and brain tumours 
(Lezon-Geyda, et al. 2001; Johnson, et al. 2013). In addition, both Purα and Purβ have been 
suggested to participate in cellular senescence (Mulnix, et al. 2014). Purα has been shown to 
be required for human polyomavirus 2 gene expression and viral replication (Sariyer, et al. 
2016). RNA binding motif protein 14 (RBM14) belongs to the family of RNA binding proteins. 
RBM14 is a multifunctional protein that is involved in transcription, splicing, DNA repair and 
genome integrity (Li, et al. 2019; Jang, et al. 2020). Influenza A virus has been shown to utilise 
RBM14 for its replication cycle and the NS1 protein actively reorganises RBM14 to the 
nucleolus for this purpose (Beyleveld, et al. 2018). The EBV non-coding RNA, EBER2 also 
interacts with RBM14 to modulate LMP2 oncogene expression (Lee, et al. 2016).  
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The aim of the work presented in this chapter was to take forward previous findings that 
suggested the FACT complex, Pur, Pur and RBM14 were recruited to VRCs during 
adenovirus infection. As such, we investigated whether these proteins were: recruited to VRCs 
during infection; targeted for degradation during infection; and/or possessed anti-viral or pro-
viral activities during infection. Findings from these studies are described here. 
5.2. Results 
5.2.1. The protein levels of SPT16, SSRP1, Pur and RBM14 are not altered following 
adenovirus infection. 
Previous studies from our laboratory had indicated that in addition to SMARCAL1 (Nazeer, et 
al. 2019), FACT complex components-SPT16 and SSRP1, nucleotide binding proteins-Pur 
and Pur and RNA binding protein-RBM14 all associated with RPA complex component, 
RPA1, following GFP-RPA1 pulldown from both Ad5 and Ad12 infected GFP-RPA1 U2OS 
cells, but not GFP U2OS cells (Qashqari, University of Birmingham PhD thesis 2017). Given 
that other studies from our laboratory have indicated that SMARCAL1 was targeted in an E1B-
55K/E4orf6- and cullin RING ligase-dependent manner for proteasomal degradation during 
both Ad5 and Ad12 infection we decided to investigate whether SPT16, SSRP1, Pur or 
RBM14 were similarly targeted for degradation following adenovirus infection. 
To test this possibility A549 cells were either mock-infected or infected with w.t. Ad5 or w.t. 
Ad12 and subjected to WB. WB analyses showed that consistent with previous observations 
anti-viral proteins p53 and SMARCAL1 were targeted for degradation following both Ad5 and 
Ad12 infection [panels i and ii, Fig. 5.1 A and B, respectively]. Interestingly, however, those 
proteins that had previously been shown to associate with RPA1 during infection-SSRP1, 
SPT16, Pur and RBM14 were not targeted for degradation during either Ad5 or Ad12 
infection [panels iii-vi, Fig. 5.1 A and B]. Furthermore, the WB data suggested that SSRP1, 
SPT16, Pur and RBM14 were not subjected to PTM following adenovirus infection. Taken 
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together, these data indicate that SSRP1, SPT16, Pur and RBM14 are not typical anti-viral 
cellular proteins that undergo degradation during infection. However, at this stage it is not 
possible to discern these proteins possess pro- or anti- viral activities.   
 
Figure 5.1: The protein levels of SPT16, SSRP1, PURβ and RBM14 are not altered 
following Ad5 or Ad12 infection. A549 cells were mock-infected or infected with w.t. Ad5 
or w.t. Ad12 at an m.o.i of 10 p.f.u./cell. Cells were harvested at the indicated times and 
subjected to SDS-PAGE and WB using the appropriate antibodies. The data shown is 
representative of 3 independent experiments. 
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5.2.2. Validation of SPT16, SSRP1, PUR and RBM14 association with RPA1 following 
adenovirus infection 
Our laboratory previously used GFP-U2OS and GFP-RPA1 U2OS cell lines in combination 
with MS to identify proteins that associated with RPA1 in both uninfected cells and in cells 
following Ad5 or Ad12 infection (Qashqari, University of Birmingham PhD thesis 2017). As 
none of the candidate proteins investigated here were shown to be degraded after adenovirus 
infection, as would be expected for most anti-viral cellular proteins, we next decided to 
establish whether these proteins did, indeed, associate with RPA1 in uninfected cells or in cells 
following Ad5 infection. To do this, we either mock-infected or infected GFP-U2OS and GFP-
RPA1 cells with w.t Ad5 and subjected cell lystaes to GFP pulldown with GFP-Trap beads 
(Materials and Methods, section 2.2.10). Isolated proteins were then separated by SDS-PAGE 
and subjected to WB analysis to establish whether or not, these cellular proteins associated 
with RPA1.  
WB analysis confirmed that GFP and GFP-RPA1 were expressed to similar levels [panel i, Fig. 
5.2] and useful conclusions could be drawn about the ability of the proteins studied to bind to 
RPA. Consistent with our MS studies our GFP pulldown experiments revealed that, like 
SMARCAL1, SSRP1 and SPT16 were both recruited to RPA1 following Ad5 infection [cf 
panels iii and iv with panel ii, Fig. 5.2]. The RNA-binding protein, RBM14, although it did 
bind RPA1 specifically, its ability to associate with RPA1 was not altered by Ad5 infection 
[panel v, Fig. 5.2]. Interestingly however, Pur, which had previously been shown to bind 
RPA1 following adenovirus infection did not bind to RPA1, either in uninfected cells or Ad5-
infected cells [panel vi, Fig. 5.2]. Taken together, these data help establish that FACT 
components, SPT16 and SSRP1 associate with RPA1 selectively after Ad5 infection and that 





Figure 5.2: GFP-Pulldown demonstrating FACT and RBM14 association with RPA1 in 
Ad5-infected cells. GFP-U2OS and GFP-RPA1-U2OS cells were either mock-infected, or 
infected with Ad5 at an m.o.i of 10 p.f.u./cell. 24h post infection cells were harvested and 
subjected to GFP pulldown utilizing GFP-Trap beads (Materials and Methods, section 2.2.10). 
Isolated proteins were then separated by SDS-PAGE, and subjected to WB analysis. The data 
shown is representative of 3 independent experiments. 
  
5.2.3. Recruitment of SPT16 to VRCs with RPA following w.t Ad5 and Ad12 infection 
Previous studies from our laboratory have determined that the FACT complex component, 
SSRP1, associates with RPA2 at VRCs (Qashqari, University of Birmingham PhD thesis 
2017). As we had not established previously whether SPT16 was also recruited to VRCs during 
infection we next sought to establish whether this was the case or not. We therefore co-stained 
the cells with an anti-rabbit SPT16 antibody and a mouse anti-RPA2 antibody and appropriate 
fluorophore-conjugated secondary antibodies to visualise these proteins by 
immunofluorescence. These studies revealed that RPA2 was pan-nuclear in mock-infected 
cells, whilst in Ad5 and Ad12 -infected cells it was reorganised to VRCs. Interestingly, 
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however, SPT16 existed as discrete intranuclear foci in both mock-infected, and Ad5 and Ad12 
-infected cells [Fig. 5.3]. Consistent with the GFP pull-down studies [Fig. 5.2] it appeared that 
RPA2 and SPT16 did not co-localize in mock-infected cells but did co-localize in both Ad5 
and Ad12 -infected cells [Fig. 5.3]. These data suggest that as RPA2 is a marker for VRCs that 
VRCs might originate at intranuclear sites occupied by SPT16. 
 
Figure 5.3: Co-localization of SPT16 with RPA32 to VRCs during w.t Ad5 and w.t. Ad12 
infection. Cells were plated on glass slides then fixed in 4% (w/v) paraformaldehyde and 
permeabilized in ice-cold acetone. 24 h post-infection cells were incubated with an anti-SPT16 
antibody (red), an anti-RPA32 antibody (green) and counter-stained with anti-mouse Alexa 
Fluor 488 and anti-rabbit Alexa Fluor 594 secondary antibodies. Slides were then mounted in 
Vectashield containing DAPI. Images were visualised using a whole-field Nikon Y-FL epi-
fluorescence microscope. The data shown is representative of 2 independent experiments. Scale 
bar = 20m. 
 
5.2.4. Recruitment of RBM14 to VRCs during Ad5 and Ad12 infection 
We next investigated whether RBM14 was similarly recruited to VRCs or nuclear tracks during 
adenovirus infection. We therefore infected A549 cells with w.t. Ad5 or a recombinant Ad12 
virus, where the E4orf3 gene had been replaced with HA-tagged E4orf3 to facilitate its 
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detection and analysed their recruitment to nuclear tracks by imunofluoresence [section 2.3.9.]. 
Immunofluorescent staining revealed that RBM14 was mostly cytoplasmic in mock-infected 
cells, whereas in both w.t. Ad5 and Ad12-infected cells it was reorganized to discrete 
intranuclear sites that co-localized to some extent with E4orf3, although not exclusively [Fig. 
5.4]. These data suggest that RBM14 is likely recruited to both VRCs and nuclear tracks during 
both Ad5 and Ad12 infection.  
 
Figure 5.4: Recruitment of RBM14 to VRCs during w.t Ad5 and w.t. Ad12 infection. Cells 
were plated on glass slides then fixed in 4% (w/v) paraformaldehyde and permeabilized in ice-
cold acetone (see section 2.4.5). 24 h post-infection cells were incubated with an anti-RBM14 
antibody (red), or an anti-Ad5E4orf3 antibody (green), or an anti-HA antibody (HA-Ad12 
E4orf3, green) and counter-stained with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa 
Fluor 594 secondary antibodies. Slides were then mounted in Vectashield containing DAPI. 
Images were visualised using a whole-field Nikon Y-FL epi-fluorescence microscope. The data 
shown is representative of 2 independent experiments. Scale bar = 10m. 
 
5.2.5. Pur is not recruited to VRCs during Ad5 and Ad12 infection 
We next wished to investigate whether Purβ was also recruited to VRCs during adenovirus 
infection. Unfortunately, the commercially available Purβ antibody was not suitable for 
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immunofluorescence studies We therefore decided to construct a GFP-tagged Purβ construct 
as we knew that GFP-tagged RPA1 was recruited to VRCs successfully following adenovirus 
infection (Nazeer, et al. 2019). To do this we first amplified and cloned Purβ into the GFP 
vector, pEGFP-C3 (see Materials and Methods section 2.3.4) and validated sequence integrity 
by Sanger sequencing and a combination of Chromas and the NCBI BLAST program [Fig. 
5.5]. Sequencing results indicated that we had successfully generated full-length w.t. GFP-Purβ 
plasmid [Fig. 5.5 and data not shown]. 
 
Figure 5.5: Sanger sequencing indicating the integrity of 5’ and 3’ the pEGFP-C3- Purβ 
construct. (A) Illustrates the 3` end of the GFP sequence showing the XhoI cloning site and 
the start codon of the Purβ gene (ATG); (B) Illustrates the 3` end of the Purβ gene sequence 
showing the stop codon (TGA) and the BamHI cloning site. 
 
To generate a GFP-Pur RPE− stable cell line we transfected the pEGFP-Pur plasmid into 
RPE-1 cells and isolated by selection [section 2.1.7]. Following the generation of these cells 













Clonal GFP-Pur RPE-1 cells were therefore infected with w.t. Ad5 or w.t. Ad12 and the 
cellular localisation of GFP-Pur in these clonal RPE-1 cells visualized using an EVOS 
fluorescent digital inverted microscope [Fig. 5.6]. In mock-infected cells GFP-Pur was almost 
predominantly cytoplasmic, with only a small amount of nuclear staining visible [Fig. 5.6]. The 
cellular localisation of GFP-Pur remained cytoplasmic throughout the time-course of 
infection up to 72 h and there was no obvious accumulation of GFP-Pur at intranuclear sites 
[Fig. 5.6 and data not shown]. Taken together, these data suggest Pur is not recruited to VRCs 
during either Ad5 or Ad12 infection. The reasons for these apparent discrepancies will be 
discussed in detail later. 
 
Figure 5.6: Purβ is not recruited to VRCs during w.t Ad5 or w.t. Ad12 infection. Cells 
were either mock-infected, or infected with w.t. Ad5 or w.t. Ad12. 24 h post-infection cells 
were visualized with an EVOS fluorescent digital inverted microscope, scale bar = 200µm  
showing both cells under phase-contrast and cell GFP expression. The data shown is 
representative of 2 independent experiments. 
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5.2.6. The FACT complex modulates adenovirus early region gene product expression 
Given that the FACT complex was shown to be present at VRCs in Ad-infected cells this 
suggests that SPT16 and SSRP1 might possess either pro-viral or anti-viral activity. As FACT 
possesses the ability to regulate transcription we decided to examine whether SPT16 and 
SSRP1 regulate adenovirus early region transcription programmes during infection. To do this 
we used RNA interference to knock down the expression of both SPT16 and SSRP1 in A549 
cells then infected cells with either w.t. Ad5, or a w.t. Ad12 species that expresses FLAG-
tagged E4orf3. Cell lysates were then subjected to SDS-PAGE and WB analyses for early 
region proteins. WB analyses revealed that we had successfully knocked-down the expression 
of both SPT16 and SSRP1 [panels v and vi, Fig. 5.7 A and B respectively]. Our results also 
suggested that, FACT complex knockdown affected differentially the expression of early 
region gene products E1B-55K, E2A and E4orf3 following both Ad5 and Ad12 infection. As 
such, FACT complex component knockdown reduced the expression of Ad5 E1B-55K, E2A 
and E4orf3, though E1A expression was not altered appreciably [panels i-iv, Fig. 5.7 A]. This 
was particularly evident for E2A and E4orf3 at all time-points and E1B-55K at later times of 
infection. The response in Ad12-infected cells was more complex: E1A and E1B-55K levels 
were elevated following the infection of knockdown cells, whereas E2A and E4orf3 levels were 
reduced [panels i-iv, Fig. 5.7 B]. Taken together, these data suggest that the FACT complex 





Figure 5.7: The FACT complex regulates adenovirus early region gene product 
expression. A549 cells were transfected with the indicated siRNAs for 48 h, before being 
mock-infected or infected with Ad5 (A) or Ad12 (B). Cells were harvested at the indicated 
times post-infection and subjected to SDS-PAGE and WB analysis using the appropriate 




5.3 Discussion  
5.3.1 Background 
As outlined in section 5.1 VRCs are discrete intranuclear structures where adenovirus genome 
transcription and replication occurs, as well as viral particle assembly and Charman, 
(Herrmann, et al. 2019). Although we know that both pro-viral and anti-viral cellular proteins 
are recruited to VRCs during infection we do not fully appreciate the extent to which cellular 
proteins participate in modulating viral genome replication at these sites. As such, we 
previously identified cellular proteins that were recruited to the cellular RPA complex at VRCs 
during adenovirus infection, which identified the FACT complex, RBM14, and Pur and Purβ 
(Qashqari, PhD thesis, University of Birmingham, 2017). Work detailed in this Chapter 
attempted to validate these findings and investigate their role in adenovirus replication. Whilst 
we confirmed that both the FACT complex and RBM14 were components of VRCs we could 
not confirm the recruitment of Purβ to VRCs. 
5.3.2. Investigating the role of the FACT complex during adenovirus infection 
Studies in this chapter established that FACT components, SPT16 and SSRP1 are not targeted 
for degradation during infection, suggesting that they do not participate in the host DDR 
response to viral infection [Fig. 5.1]. This is perhaps surprising as SPT16, at least, has been 
shown to interact with SMARCAL1 in both 293T and HeLa cells, and is therefore likely to 
participate in DDR signalling during cellular DNA replication (Bétous, et al. 2013). Indeed, 
previous studies from our laboratory have established that SMARCAL1 is targeted for 
degradation during infection (Nazeer, et al. 2019). The study detailed here established that both 
SPT16 and SSRP1 only associated with RPA, component, RPA1 during infection [Fig. 5.2] 
and that SPT16 co-localized with RPA component, RPA2 at VRCs during both Ad5 and Ad12 
infection [Fig. 5.3]. Interestingly, it appeared that RPA2 was recruited to SPT16 during 
infection such that VRCs formed at FACT-containing intranuclear loci [Fig. 5.3] and suggests 
that the FACT complex might be important in the nascent production of VRCs. This is an 
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interesting and perhaps, unexpected, finding. Previous studies looking at VRC formation for 
DNA viruses at least, suggests that VRCs from DNA viruses that form in the cytoplasm (e.g. 
Poxviridae family) originate at, or close to microtubule-organising centres (MTOCs), whilst 
DNA viruses that form VRCs in the nucleus (e.g. Adenoviridae family) originate adjacent to 
PML-containing nuclear bodies (PML-NBs; (Schmid, et al. 2014). Although PML-NBs are 
known to be involved in transcription and DNA replication amongst other functions, the FACT 
complex is not known to be a component of PML-NBs (Van Damme, et al. 2010), though 
whether they lie adjacent to PML-NBs has not been explored. Given our finding that SPT16 is 
a component of VRCs, it will be important in future studies to explore whether the nuclear foci 
occupied by the FACT complex lie close to PML-NBs. Moreover, given that E2A/DBP is a 
major component of VRCs (Pombo, et al. 1994), it would be interesting to study whether FACT 
knockdown affects E2A/DBP localisation during infection or affects viral DNA genome 
replication which could be assessed by qPCR. 
Although previous studies have indicated both pro-viral and anti-viral roles for the FACT 
complex in viral replication, there are no publications to date have reported that FACT is a 
component of VRCs. Our knockdown data suggests that FACT is pro-viral for both Ad5 and 
Ad12 and participates in viral early gene transcription [Fig. 5.7]. Other viruses similarly utilise 
the FACT complex to promote viral gene transcription. For instance, it has been reported that 
HSV-1 viral protein ICP22 binds to FACT directly, and recruits the FACT complex to the 
HSV-1 genome to facilitate viral gene transcription, such that an ICP22 mutant virus, is 
attenuated in its ability to synthesize most viral mRNAs during infection, relative to a w.t. virus 
(Pombo, et al. 1994). Additionally, the FACT complex is utilised by HCMV viral protein 
LANA to promote the transactivation of the major immediate early promoter (MIEP) to 
stimulate the expression of the IE genes, UL122 and UL123, such that small molecule anti-
cancer curaxins, which promote FACT ‘trapping’ on chromatin inhibits IE gene expression 
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(O'Connor, et al. 2016). Given these findings it would be interesting to see if curaxins also 
inhibit adenovirus early gene expression. Interestingly, FACT has also been reported to 
suppress viral gene transcription. For instance, depletion of FACT by RNAi enhances HIV- 
transcription initiation and elongation, and promotes viral latency; FACT associates with the 
HIV-1 Tat transactivator to suppress transcriptional activity at LTRs (Huang, et al. 2015). The 
FACT complex is also required to promote latent replication of KSHV, through the association 
of KSHV latency protein, LANA with SSRP1, such that knockdown of FACT reduces KSHV 
latent replication (Hu, et al. 2009). Given the known role of the FACT complex in transcription 
it will be important in the future to determine by Chromatin immunoprecipitation coupled with 
qPCR whether SPT16 or SSRP1 associate with viral gene promoters, viral gene sequences or 
viral genomes during Ad5 or Ad12 infection through interaction with viral early proteins such 
as the 13S E1A gene product which serves to transactivate viral early genes during adenovirus 
infection. 
5.3.3. Investigating the role of RBM14 during adenovirus infection 
Experiments presented here indicate that RBM14 protein levels do not change following either 
Ad5 or Ad12 infection suggesting that like the FACT complex, RBM14 is not involved in the 
DDR response to viral infection [Fig 5.1]. Other experiments established that RBM14 had the 
capacity to associate with the RPA complex component, RPA1, but unlike the FACT complex 
RBM14 associated with RPA1 in both uninfected and Ad-infected cells [Fig. 5.2]. We also 
established that RBM14 is likely recruited to VRCs as it did not co-localize to any great extent 
with E4orf3 [Fig. 5.4] during adenovirus infection though this needs to be confirmed by co-
staining with RPA2 or E2A/DBP. Like the FACT complexes a number of different viruses 
target RBM14 during infection. Interestingly, RBM14 has known pro-viral activities and 
facilitates Influenza A virus replication such that depletion of RBM14 inhibits viral mRNA 
production (Beyleveld, et al. 2018). In this regard, Influenza A viral protein NS1, relocates 
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RBM14 to nucleoli during infection through the biological requirement for this is not known 
(Beyleveld, et al. 2018). Given these findings it would be interesting to establish whether 
RBM14 is recruited to nucleoli during adenovirus infection by co-staining with a nucleolar 
protein, such as nucleophosmin, although RBM14 was not identified by an early proteomic 
screen as being recruited to the nucleolus during Ad5 infection (Lam, et al. 2010; Reyes, et al. 
2017). RBM14 also participates in viral gene expression programmes, such that it interacts 
with EBV protein, EBER2 at genomic terminal repeats to impair LMP2A transcription, such 
that knockdown of RBM14 enhances LMP2A transcription (Lee. et al, 2016; Salahuddin, et al. 
2019). It is perhaps not surprising given the known functions of RBM14 that it also regulates 
viral mRNA spicing during infection. It has been found that RBM14 associates with the HIV-
1 Rev protein to enhance the CRM1-dependent transport of unspliced viral transcripts to the 
cytoplasm, such that knockdown of RBM14 impaired Rev function (Budhiraja, et al. 2015). 
The RBM14 protein is characterized with RNA recognition motif (RRM), and is involved in 
diverse cellular process, including RNA export and stability, RNA splicing and transcription 
regulation (Iwasaki, et al. 2001). Given that adenovirus utilises splicing during infection to 
maximise its coding potential it would be interesting to see if RBM14 knockdown affected 
viral mRNA levels or splicing using a recently developed method of long-read direct RNA 
sequencing of polyadenylated adenovirus mRNA. It is interesting to note that, three viral 
proteins implicated in splicing, L4-33K, L4-22K, and E4-ORF4 all found in VRCs (Hidalgo 
and Gonzalez, 2019). As such it would be interesting to see if these adenoviral proteins 
associate with RBM14 during infection. 
Earlier studies from our laboratory also identified the Pur family proteins, Pur and Purβ as 
proteins that are potentially recruited to VRCs during adenovirus infection. We could not detect 
any association between Purβ and RPA however following adenovirus infection [Fig. 5.2]. We 
also made a cell-line that expressed GFP-Pur constitutively but unfortunately we did not 
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observe any recruitment to VRCs during adenovirus infection [Fig. 5.6]. It is clear that we need 
to re-visit these studies but future priorities are to investigate the function of the FACT complex 
and RBM14 at VRCs during adenovirus infection. Indeed, the data presented in this Chapter 
confirm that FACT and RBM14 are recruited to VRCs during infection and suggest that FACT 
participates in viral early gene transcription programmes, though more work needs to be done 






































It is now well accepted that adenovirus, like many other viruses, modulates host cell processes 
in order to promote viral replication. As such, adenoviruses utilise pro-viral host cellular factors 
that facilitate viral entry and viral transport, stimulate viral gene transcription and DNA 
replication, or promote viral packaging and virus exit from the cell. On the other hand 
adenovirus inactivates anti-viral host cell factors that limit these processes. It is well established 
that many anti-viral cellular factors participate in host cell DDR pathways or regulate some 
aspect of chromatin function. Adenovirus has therefore evolved to engage with the host cell 
UPS to promote the inactivation of such anti-viral host cell factors by ubiquitin-mediated 
proteolysis or SUMOylation (see sections 1.3 and 1.2.4.1). The viral early region proteins, 
E1B-55K, E4orf3 and E4orf6 function specifically during infection, either together or 
independently, to inactivate host cell anti-viral proteins. Consistent, with this notion, our 
laboratory has recently shown that E1B-55K and E4orf6 from both Ad5 and Ad12 inactivate 
host cell DNA replication by targeting the host cell DDR and replication protein, SMARCAL1 
for proteasome-mediated degradation during infection (Nazeer, et al. 2019). 
The work detailed in this thesis has been important in developing cell models to identify novel 
cellular anti-viral proteins targeted by Ad5 and Ad12 E1B-55K, E4orf3 and E4orf6 proteins in 
isolation. Consistent with previous work from our laboratory that identified TopBP1 as a target 
for Ad12 E4orf6 (Blackford, et al. 2010), we determined, using these cell models, that Ad12 
E4orf6, but not Ad5 E4orf6, engaged independently with a CRL to promote the ubiquitin-
mediated degradation of core histones. Most of the follow-on experiments for the findings 
described in this thesis have been described in the discussion sections of the relevant results 
chapters. Given the complex relationship between adenovirus and the host cell, however, I 
would like to discuss how we can utilise cell models and whole proteome and genome 
techniques to gain further insight into how adenovirus targets the UPS during infection, and 
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how adenovirus utilizes the UPS to modulate host cell DDR pathways and host cell chromatin 
during infection.  
6.2. Adenovirus regulation of the ubiquitin-proteasome system 
As adenovirus utilizes the UPS for multiple roles during infection it is important that we adopt 
whole proteome approaches in order to identify novel cellular targets. As such, we used a 
quantitative mass spectrometric approach that labelled isolated peptides with ‘heavy’ or ‘light’ 
formaldehyde to distinguish proteins isolated +/- Ad12 E4orf6 expression (section 4.2.7). 
Whilst we were able to use this technique to identify core histones as a novel target for 
adenovirus during infection [Fig. 4.10-4.15] our labelling approach and quantitative tandem 
MS analyses with a Bruker Impact mass spectrometer only identified 256 common cellular 
proteins from both experiments and an additional 389 proteins that were only identified in one 
of the two experiments [Fig. 4.10 and 4.11]. Given that the latest generation mass spectrometers 
typically identify and quantify 5000+ proteins from single experiments it will be important to 
use these newer mass spectrometers with more efficient protein/peptide labelling techniques in 
any future analyses to maximise data output. Indeed, one of our collaborators has used Tandem-
Mass-Tag (TMT) labelling of peptide N-termini allied with an Orbitrap Fusion Tribridmass 
spectrometer to quantify the levels of over 5900 proteins during Ad5 infection of A549 cells 
(Fu, et al. 2017). However, although our collaborators were able to identify over 5900 proteins 
quantitatively they only identified 20+ proteins that were reduced appreciably in expression 
after 24h and did not establish fully the role of the early region proteins in the degradation 
process, which is where our Tet-responsive cell lines have further utility in dissecting the 
contribution of each of these viral proteins in cellular protein degradation.  
As these viral proteins also cooperate to promote cellular protein degradation through the UPS 
it will be important to generate Ad5/Ad12 E1B-55K/E4orf3, E1B-55K/E4orf6, E4orf3/E4orf6, 
and E1B-55K/E4orf3/E4orf6 inducible cell lines and perform quantitative tandem mass 
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spectrometry to identify those proteins that require more than one viral protein for degradation. 
A current limitation to doing these experiments is the lack of commercially-available TREx 
plasmids that possess more than one promoter to drive the inducible expression of two or more 
exogenous proteins in one cell-line. However, as we noted in Chapter 3 (sections 3.2.2.1, 
3.2.3.1 and 3.2.4.1), the expression of viral proteins between cell lines was highly variable, 
suggesting that there might be more than one genomic site for plasmid recombination in the 
parental U2OS FlpIn cell line, such that we should use these cells to see if we can isolate cell 
lines that express more than one viral protein at a time. Otherwise, it will be important to 
construct TREx plasmids that can express multiple exogenous genes in a TET-responsive 
manner.  
As discussed in the Introduction (sections 1.2.2 and 1.2.4.1) and Chapter 3 (sections 3.3.2 and 
3.3.3), adenovirus E1B-55K and E4orf3 proteins modulate host cell SUMOylation pathways 
during infection. In the future the cell lines generated during this project should be used to 
investigate which cellular proteins are targeted by Ad5 E1B-55K and Ad5/Ad12 E4orf3 for 
SUMOylation or STUbL-targeted proteasome degradation in response to the expression of 
these viral proteins. As such we should utilize SUMO1 and SUMO2-specific affimers (Hughes, 
et al. 2017) coupled to quantitative tandem mass spectrometry to identify cellular proteins that 
are subject to SUMOylation and/or degradation in response to viral early gene product 
expression. Moreover, as Ad5 E4orf3 is known to SUMOylate Ad5 E1B-55K (Sohn and 
Hearing, 2019) it would be interesting to determine the dual effects of Ad5 E1B-55K/E4orf3 
expression on host cell protein SUMOylation STUbL-targeted proteasome degradation. 
Clearly, the identification of cellular proteins that are SUMOylated by Ad5 E1B-55K and/or 
E4orf3 would only be the first step in characterizing the effects of Ad-induced SUMOylation 
on cellular protein function. 
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6.3. Adenovirus regulation of chromatin 
We presented data in Chapter 4 to indicate that adenoviruses regulate histone protein levels 
during infection and that Ad12 E4orf6 targets, selectively, core histones for proteasome-
mediated degradation. The effects of adenovirus infection on cellular and viral transcription 
programmes are well established. It is known, for instance, that 13S E1A utilises TBP, the 
Mediator complex, CBP/p300 and the 26S proteasome to stimulate viral gene expression 
during infection (Berk, 2005; Rasti, et al. 2006), whilst 12S E1A regulates cellular transcription 
programmes through its ability to associate with CBP/p300 and pRB to modulate histone 
acetylation at the genome level and the selective association/dissociation of coactivator and 
repressor complexes with cellular and viral chromatin in order to regulate cellular and viral 
transcription programmes (Horwitz, et al. 2008; Ferrari, et al. 2014). Although not described 
here, it would be invaluable to generate both Ad5 and Ad12 12S E1A and 13S E1A TET-
inducible U2OS FlpIn cell lines to dissect further the contribution of these viral transcriptional 
regulators in viral and host cell transcription programmes through the modulation of histone 
readers, writers and erasers. Given our findings with FACT and RBM14 (Chapter 5), ChIP-seq 
should be used to establish how FACT and RBM14 association with cellular and viral genomes 
is affected by adenovirus infection and adenovirus early region gene product expression in all 
of the TET-inducible U2OS FlpIn cell lines. As such, it would be possible to determine the 
molecular mechanisms regulating FACT and RBM14 function during infection and the 
contribution of early region proteins in these processes. Indeed, as FACT is known to 
disassemble H2A-H2B histone dimers, it would be interesting to determine if the FACT 
complex contributes towards histone loss during infection. Moreover, as RBM14 is implicated 
in gene splicing it would also be interesting to use direct long read RNA-seq to see whether 
RBM14 ablation modulates adenovirus early region gene cellular splicing. Interestingly, 
although E1B-55K, E4orf3 and E4orf6 are all known to modulate p53 transcriptional activity 
(Yew and Berk, 1992; Dobner, et al. 1996;  Soria, et al. 2010), with the exception of E4orf3 
182 
 
(Soria, et al. 2010) the selective recruitment of E1B-55K or E4orf6 to the cellular genome at 
specific loci during infection has yet to be established. It would be possible to use the TET-
inducible U2OS FlpIn cell lines coupled with ChIP-seq and RNA-seq to determine whether 
these proteins associate more generally with cellular promoters or gene sequences, which 
would expand our current understanding of the general roles of E1B-55K and E4orf6 in 
transcription control. Given these few examples it is clear that there is still much to be learnt 
about the relationship between viral early gene products and the regulation of cellular 
chromatin. The TET-inducible U2OS FlpIn cell lines generated here will be important in 
dissecting this complex relationship.  
6.4 Adenovirus regulation of DNA damage response pathways 
It is well established that many proteins targeted for proteolytic degradation during infection 
are key players in the cellular DDR and are known to associate with early region gene products 
during infection (Weitzman and Ornelles, 2005). It would be interesting therefore to perform 
immunoprecipitation studies with these viral proteins using the TET-inducible U2OS FlpIn 
E1B-55K, E4orf3 and E4orf6 cell lines to identify novel cellular-interacting proteins that could 
function in the DDR (or other anti-viral pathways) and/or are targeted for degradation by the 
UPS during infection. To investigate whether novel E1B-55K, E4orf3 and E4orf6-interacting 
proteins function in the DDR we could use CRISPR or RNAi to ablate their cellular expression 
and subject cells to DNA-damaging stimuli (e.g. X-rays for DSBs; UV/HU for SSBs and 
replication stress) and look at the cellular DDR response (e.g. p53 stabilization, induction of 
H2AX phoshorylation, Chk1 and/or Chk2 phoshorylation, or the re-localization of 53BP1 or 
RAD51 to sites of DNA damage). In this context we could also establish how expression of 
the viral protein modulates the specific DDR pathway engaged by the interacting cellular 
protein. In support of this approach our laboratory has previously determined that the E1B-
55K-interacting protein (E1B-AP5/hnRNPUL1) functions in ATR signalling pathways in both 
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normal and infected cells (Blackford, et al. 2008). The Weitzman laboratory recently used 
iPOND to identify cellular proteins that were recruited or excluded from newly made viral 
DNA during Ad5 DNA replication in infected cells (Charman, et al. 2019). Interestingly, one 
of the proteins shown to be excluded from viral DNA was the DDR and replication protein, 
TIMELESS, which our laboratory has shown previously to be targeted for proteasomal 
degradation by Ad12, but not Ad5 (Patel, PhD thesis, The University of Birmingham, 2013), 
suggesting that Ad5 also inactivates TIMELESS function during infection. Other cellular 
proteins such as Claspin were also shown to be excluded from viral DNA during infection 
(Charman, et al. 2019). It would be interesting to establish whether proteins excluded from 
viral DNA are targeted for degradation during infection, and moreover, by using the TET-
inducible U2OS FlpIn cell lines generated here, establish whether they are targets for 
Ad5/Ad12 E1B-55K, E4orf3 and/or E4orf6. 
The ability of adenovirus to utilise the UPS to modulate chromatin and DDR during infection, 
and cellular transformation is now well-established. Research presented in this thesis shows 
that there is still lots to be learnt about adenovirus early gene product function, and their ability 
to modulate chromatin and DDR during infection through engagement with the UPS. It is clear 
that adenovirus can still be used as a molecular tool to investigate the DDR and chromatin in 
both normal and cancer cells and results arising from these studies will not only be important 
towards understanding the molecular basis of fundamental cellular processes but might be 
useful towards identifying potential cancer therapeutic targets or the design of oncolytic-
selective adenoviruses. Moreover, as most, if not all, viruses modulate UPS, DDR and 
chromatin function during infection, adenovirus continues to serve as a useful model system 
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